ID	Species	ncRNA	ncRNA type	Environmental factor (EF)	Phenotype	Sample	Condition of EF	Evidence	PubMed ID
1	Human	4631405K08Rik	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
2	Human	A2M-AS1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human neonatal cardiomyocytes	hypoxia/reoxygenation (H/R) treatment	LncRNA A2M-AS1 lessens the injury of cardiomyocytes caused by hypoxia and reoxygenation via regulating IL1R2.	33057899
3	Human	AC003092.1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	temozolomide (TMZ) treatment	lncRNA AC0030921 expression was significantly down- regulated in both U87TR and U251TR cells	30442884
4	Human	AC005523.2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
5	Human	AC005550.3	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	downregulated	30093949
6	Human	AC006050.3-003	lncRNA	cisplatin (DDP)	lung squamous cell carcinoma (LSQCC)	advanced lung squamous cell carcinoma patients	cisplatin treatment	downregulated	25250788
7	Human	AC006262.5	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
8	Human	AC007283.5	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
9	Human	AC007952.1.1-3:1	lncRNA	nigericin	pancreatic cancer (PC)	PANC-4 cells	nigericin treatment	downregulated	32850392
10	Human	AC013451.2	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
11	Human	AC015849.2	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
12	Human	AC023115.3	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	human glioblastoma cells	cisplatin treatment	upregulated	28499919
13	Human	AC026904.1	lncRNA	TGF-¦Â	breast cancer	MCF-7 cells	TGF-¦Â treatment	"TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis"	29774079
14	Human	AC068039.4	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	pulmonary artery smooth muscle cells (PASMCs)	hypoxia treatment	"Consistent with microarray analysis, quantitative PCR verified that AC068039.4 was obviously upregulated in hypoxia-induced PASMCs."	33026218
15	Human	AC068580.3	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
16	Human	AC078883.3	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"lung tissues, A549 and H460 cells"	?cisplatin treatment	?the low expression of lncRNA-AC0788833 contributed to the development of chemoresistance against cisplatin	31111480
17	Human	AC092620.3	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	Cr(VI)-treated 16HBE cells	Cr(VI) exposure	dysregulated	30476843
18	Human	AC092620.3	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	16HBE cells	hexavalent chromium [Cr(VI)] treatment	upregulated	30476843
19	Human	AC105052.4	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
20	Human	AC133485	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	downregulated	31514003
21	Human	AC145676.2.1-6	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	whole blood samples	Mycobacterium tuberculosis (MTB) infection	downregulated	31028876
22	Human	ADAMTS9-AS2	lncRNA	tamoxifen (TAM)	breast cancer	Human MCF-7 cells	Tamoxifen (TAM) treatment	downregulated	30840279
23	Human	ADAMTS9-AS2	lncRNA	cisplatin (DDP)	gastric cancer (GC)	SGC7901 cells; BGC823C cells	cisplatin treatment	downregulated	32516127
24	Human	ADAMTS9-AS2	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"GBM cell lines (T98G, U118)"	temozolomide (TMZ) treatment	upregulated	31632968
25	Human	AF085935	lncRNA	chrysin	hepatocellular carcinoma (HCC)	HepG2 cells	chrysin treatment	chrysin against HCC through the suppression of the GPC3/SULF2 axis along with the downregulated of lncRNA-AF085935 expression.	33076548
26	Human	AF085935	lncRNA	epigallocatechin-3-gallate (EGCG) and metformin	hepatocellular carcinoma (HCC)	HepG2 cells	epigallocatechin-3-gallate (EGCG) and metformin treatment	downregulated	30710234
27	Human	AF086415	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
28	Human	AF086415	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	downregulated	24379026
29	Human	AF131217.1	lncRNA	laminar shear stress	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Laminar shear stress induce	upregulated	30905197
30	Human	AF131217.1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30905197
31	Human	AF147447	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	tumor tissues	H. pylori treatment	downregulated	27835575
32	Human	AFAP1-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	upregulated	32020881
33	Human	AFAP1-AS1	lncRNA	oridonin	epithelial-mesenchymal transition (EMT)	?BxPC-3 and PANC-1 cells	oridonin treatment	"the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice."	31314060
34	Human	AFAP1-AS1	lncRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	BxPC-3 cells; HPAC cells	cucurbitacin B (CuB) treatment	CuB inhibits proliferation of PC cells by downregulating AFAP1-AS1 expression.	30206930
35	Human	AFAP1-AS1	lncRNA	cucurbitacin B (CuB)	pancreatic cancer (PC)	"Human PC cell lines, ASPC©\1, BxPC©\3, HPAC, MiaPaCa©\2"	cucurbitacin B (CuB) treatment	CuB-induced high miR-146b-5p expression and inhibited the expression of AFAP1-AS1.	30206930
36	Human	AFAP1-AS1	lncRNA	oridonin	pancreatic cancer (PC)	BxPC-3 and PANC-1 cells	oridonin treatment	"the combination of oridonin and siAFAP1-AS1 inhibited pancreatic cancer cell proliferation, induced apoptosis, arrested cell cycle progression, prevented the migration, regulated EMT-related protein expression in BxPC-3 and PANC-1 cells, and inhibited pancreatic cancer cell tumorigenicity and EMT in nude mice."	31314060
37	Human	AGAP2-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	upregulated	30157918
38	Human	AIRN	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
39	Human	AK001796	lncRNA	resveratrol	lung cancer	lung cancer tissues	resveratrol (RS) treatment	reduced lncRNA AK001796 level potentially impaired the inhibitory effect of resveratrol on cell proliferation	25888808
40	Human	AK021021	lncRNA	baicalin (BAI)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	baicalin (BAI) treatment	upregulated	26885187
41	Human	AK027294	lncRNA	glycyrrhiza glabra	nasopharyngeal carcinoma (NPC)	C666-1 cells	glycyrrhiza glabra treatment	downregulated of AK027294 contributes to the anti-cancer function of G. glabra.	31589096
42	Human	AK027294	lncRNA	glycyrrhiza glabra	nasopharyngeal carcinoma (NPC)	C666-1 cells	Glycyrrhiza glabra treatment	AK027294 had a strongest downregulated upon G. glabra treatment.	31589096
43	Human	AK056098	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
44	Human	AK056098	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
45	Human	AK056155	lncRNA	TGF-¦Â1	loeys-Dietz syndrome (LDS)	peripheral blood circulating endothelial cells	TGF-¦Â1 treatment	upregulated	26617788
46	Human	AK058003	lncRNA	hypoxia	gastric cancer (GC)	GC cell lines	hypoxia-induced GC treatment	upregulated	25499222
47	Human	AK077216	lncRNA	high glucose (HG)	diabetic retinopathy (DR)		high glucose treatment	AK077216 is downregulated in diabetic retinopathy and inhibited the apoptosis of ARPE-19 cells by downregulating miR-383.	31391356
48	Human	AK092074	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
49	Human	AK094457	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (hVSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"LncRNA AK094457 downregulated by shRNA-AK094457-1 have inhibiting effects on proliferation, migration, ROS level and inflammation level in OX-LDL induced vascular smooth muscle cells (VSMCs)."	31632534
50	Human	AK094457	lncRNA	angiotensin II (Ang II)	hypertension	human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	The expression of the lncRNA AK094457 in the angiotensin II (Ang II) treatment groups were higher than the control group.	32027625
51	Human	AK094629	lncRNA	IL-1¦Â	temporomandibular joint osteoarthritis	synovial-derived mesenchymal stem cells (SMSCs)	IL-1¦Â treatment	IL-1¦Â upregulated the expression of AK094629 in the SMSCs in vitro.	32468015
52	Human	AK095147	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
53	Human	AK095147	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	downregulated	24379026
54	Human	AK294004	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
55	Human	AK294004	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
56	Human	AK309872	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
57	Human	AL049437	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	32057949
58	Human	AL645940.1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
59	Human	ALT1	lncRNA	hypoxia	regulation of cell cycle	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	upregulated	28977802
60	Human	ANCR	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"MCF10A,MDA-MB-231,MCF7,T47D,BT549,HEK293T"	TGF-¦Â1 down-regulates ANCR treatment	downregulated	28978036
61	Human	ANPODRT	lncRNA	tert-butyl hydroperoxide (TBHP)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	?tert-butyl hydroperoxide (TBHP) treatment	We found that ANPODRT was downregulated in degenerative NP tissues and in NP cells treated with tert-butyl hydroperoxide	33603950
62	Human	ANRIL	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	lipopolysaccharide (LPS) treatment	The upregulation of ANRIL can reduce the expression of microRNA-199a and increases the number of apoptotic cells	32069473
63	Human	ANRIL	lncRNA	human T-cell leukemia virus type 1 (HTLV-1)	adult T-cell leukemia (ATL)	ATL cells	human T-cell leukemia virus type 1 (HTLV-1) infection	The expression level of the lncRNA ANRIL was elevated in HTLV-1-infected cell lines and clinical ATL samples.	30258009
64	Human	ANRIL	lncRNA	tanshinone IIA (Tan IIA)	age-related nuclear cataract	H2O2 treated human lens epithelial cell line SRA01/04	Tanshinone IIA treatment	upregulated	30701534
65	Human	ANRIL	lncRNA	IL-13	allergic rhinitis (AR)	Human nasal epithelial cells (HNECs)	IL-13 treatment	"The expression levels of ANRIL and JAK2 were also upregulated in IL-13-induced HNECs, while the expression levels of miR-15a-5p were downregulated."	33325534
66	Human	ANRIL	lncRNA	oxygen glucose deprivation (OGD)	angiogenesis	Human umbilical vein endothelial cells (HUVECs)	oxygen glucose deprivation (OGD) treatment	OGD remarkably decreased lncRNA-ANRIL expression level.	32400082
67	Human	ANRIL	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aorta vascular smooth muscle cells (HA-VSMCs); human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ANRIL promoted AS progression by sponging miR-399-5p and regulating RAS/RAF/ERK signal pathway.	32141564
68	Human	ANRIL	lncRNA	H2O2	cataract	HLECs	H2O2 treatment	lncRNA ANRIL attenuated H2O2-induced cell injury in HELCs via up-regulating miR-21 via the activation of AMPK and ¦Â-catenin.	32310822
69	Human	ANRIL	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	kidney tissues	high glucose (HG) treatment	ANRIL and TXNIP were elevated in DN kidney tissues and HG-treated HK-2 cells while miR-497 was reduced.?miR-497 mimics inhibited caspase-1-dependent pyroptosis while co-overexpression of TXNIP blocked its effects in HG-treated HK-2 cells.	33160992
70	Human	ANRIL	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial cell cells (HK-2)	high glucose (HG) treatment	ANRIL promotes pyroptosis and kidney injury in DN via acting as miR-497 sponge to disinhibit TXNIP expression.	33160992
71	Human	ANRIL	lncRNA	Rhein-8-O-¦Â-D-glucopyranoside (Rg)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	Rhein-8-O-¦Â-D-glucopyranoside (Rg) treatment	Rg attenuated HG-induced apoptosis of HMCs by regulating the lincRNA ANRIL/let-7a/TGF-¦Â1/Smad signaling pathway	32256771
72	Human	ANRIL	lncRNA	high glucose (HG)	diabetic wound healing	Human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	downregulated	30565672
73	Human	ANRIL	lncRNA	H2O2	glaucoma	human trabecular meshwork (TM) cells	"For the stimulation with H2 O2 , the cells were cultured in Trabecular Meshwork Cell Medium (TMCM) containing 50-400 ¦ÌM H2O2 (Sigma-Aldrich, St. Louis, MO, USA) for 24 h after they reached 80-85% confluence."	H2O2-induced decrease of cell viability and the increases in apoptosis and ROS generation were significantly attenuated by lncRNA ANRIL overexpression	31081068
74	Human	ANRIL	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
75	Human	ANRIL	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	ANRIL knockdown inhibited the development of DDP resistance by upregulating miR-98.	32705261
76	Human	ANRIL	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	U2-OS and Saos-2 osteosarcoma cell lines	cisplatin (DPP) treatment	ANRIL-silenced cells were more sensitive to cisplatin: apoptotic ratio was increased and cleaved caspase-3 level was upregulated.	30777616
77	Human	ANRIL	lncRNA	hypoxia	osteosarcoma (OS)	osteosarcoma cells (MNNG and U2OS)	hypoxia treatment	upregulated	28588425
78	Human	ANRIL	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells	cisplatin treatment	upregulated	31189742
79	Human	ANRIL	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
80	Human	ANRIL	lncRNA	propofol (PPF)	papillary thyroid cancer (PTC)	Human PTC cell lines TPC-1 and IHH-4	Propofol treatment	downregulated	30703346
81	Human	ANRIL	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	downregulated	31974617
82	Human	ANRIL	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	downregulated	31974617
83	Human	ANRIL	lncRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	fetal human cells (FHCs)	lipopolysaccharide (LPS) treatment	upregulated	30477744
84	Human	ANRIL	lncRNA	ursolic acid (UA)	uric acid nephropathy (UAN)	HK-2?cells	uric acid treatment	Uric acid increased the expression levels of ANRIL in HK-2 cells	30347231
85	Human	ANRIL	lncRNA	high glucose (HG)	wound healing	human dermal lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"ANRIL was downregulated, whereas miR-181a was upregulated in high glucose (HG)-induced LECs."	30565672
86	Human	ANRIL	lncRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells	irradiation treatment	Irradiation significantly decreased cell viability and ANRIL expression in a dose-dependent manner.	33529508
87	Human	AP000769.1-2:10	lncRNA	celecoxib	lung squamous cell carcinoma (LSQCC)	The human LSQCC cell line SK-MES-1	celecoxib treatment	downregulated	29512696
88	Human	APAP2-AS1	lncRNA	trastuzumab	breast cancer	HER2-positive SKBR-3 and BT474 cells	Trastuzumab treatment	upregulated	30910994
89	Human	APPAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	APPAT showed significant reduction in ox-LDL treated human VSMCs in vitro.	29372117
90	Human	ARAP1-AS2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	32969198
91	Human	ARAP1-AS2	lncRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	HK-2 cells	high glucose (HG) treatment	upregulated	31975379
92	Human	Arid2-IR	lncRNA	advanced glycation end product (AGE)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	advanced glycation end product (AGE) treatment	upregulated	31912402
93	Human	ARSR	lncRNA	oxaliplatin	colorectal cancer (CRC)	SW480 cells; SW620 cells	oxaliplatin (OXA) treatment	upregulated of lncARSR promoted OXA resistance in CRC.	32558022
94	Human	ARSR	lncRNA	atorvastatin	hypercholesterolemia	peripheral blood samples	atorvastatin treatment	Atorvastatin increased the expression of lncRNAs ARSR after treatment.	33198086
95	Human	ARSR	lncRNA	fatty acid	nonalcoholic fatty liver disease (NAFLD)	human hepatocarcinoma cell line (HepG2)	fatty acid treatment	upregulated	29555473
96	Human	ARSR	lncRNA	high fatty acid	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	high fatty acid treatment	upregulated	32169080
97	Human	AT102202	lncRNA	epigallocatechin-3-gallate (EGCG)	cholesterol metabolism	"human hepatoblastoma cell line, HepG2"	epigallocatechin-3-gallate (EGCG) treatment	upregulated	25563320
98	Human	ATB	lncRNA	TGF-¦Â1	atherosclerosis (AS)	human umbilical vein endothelial cell (HUVEC) line	TGF-¦Â1 treatment	upregulated	30942415
99	Human	ATB	lncRNA	angiotensin II (Ang II)	endothelial cell injury	human umbilical vein endothelial cell (HUVECs)	angiotensin II (Ang II) treatment	Ang II treatment downregulated the lncRNA-ATB level in HUVECs.	32581029
100	Human	ATB	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells	TGF-¦Â1 induces EMT process and elevates treatment	upregulated	29113749
101	Human	ATB	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	A549 cells; Beas-2B cells	TGF-¦Â1 treatment	TGF-¦Â1 induces EMT process and elevates lncRNA-ATB levels in pulmonary epithelial cells	30010033
102	Human	ATB	lncRNA	TGF-¦Â	glioblastoma multiforme (GBM)	LN-18 and U251 cells	TGF-¦Â treatment	upregulated	31140621
103	Human	ATB	lncRNA	hepatitis B virus (HBV)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cell lines	hepatitis B virus (HBV) infection	upregulated	31746419
104	Human	ATB	lncRNA	astragaloside IV (AS-IV)	hepatocellular carcinoma (HCC)	SMMC-7721 cells	astragaloside (AS-IV) treatment	downregulated	29331759
105	Human	ATB	lncRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	hepatoma cells	SMMC-7721 continuously with TGF-¦Â for 21 days treatment	different experssion	24768205
106	Human	ATB	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	HBx treatment	HBx-induced autophagy could upregulate the expression of TGF-¦Â and lncRNA-ATB.	31746419
107	Human	ATB	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human ATDC5 cells	lipopolysaccharide (LPS) treatment	"lncRNA-ATB expression was downregulated in LPS-injured cells, and lncRNA-ATB overexpression significantly alleviated LPS-induced inflammatory injury in ATDC5 cells."	30771739
108	Human	ATB	lncRNA	TGF-¦Â1	renal fibrosis	human kidney 2 (HK-2) cells	TGF-?1 treatment	LncRNA-ATB was highly expressed in TGF-?1 induced HK-2 cells	32447340
109	Human	ATXN8OS	lncRNA	ginsenoside Rg3	breast cancer	MCF-7 breast cancer cells	ginsenoside Rg3 treatment	"Here, a lncRNA (ATXN8OS) was found to be downregulated via Rg3-mediated promoter hypermethylation in MCF-7 breast cancer cells."	33477683
110	Human	AU015836	lncRNA	glyoxylate	kidney damage and kidney stones	HK-2 cells	glyoxylate	upregulated	29160413
111	Human	AV310809	lncRNA	TGF-¦Â1	peritoneal fibrosis	human peritoneal mesothelial cells (HPMCs)	TGF-¦Â1 treatment	upregulated	30935692
112	Human	AWPPH	lncRNA	bone morphogenetic protein 2 (BMP2)	non-traumatic osteonecrosis of femoral head (ONFH)	human MSCs from bone marrow (hMSC-BM)	bone morphogenetic protein 2 (BMP2) treatment	BMP-2 significantly upregulated the expression of lncRNA AWPPH in a dose-dependent manner.	31853285
113	Human	AWPPH	lncRNA	bone morphogenetic protein 2 (BMP2)	osteogenesis	Human MSCs from bone marrow (hMSC-BM)	bone morphogenetic protein 2 (BMP2) treatment	"BMP-2 treatment significantly increased the expression level of AWPPH in human MSCs from bone marrow (hMSC-BM). AWPPH overexpression promoted, while AWPPH short hairpin RNA silencing inhibited the expression of Runx2 expression in hMSC-BM cells."	31853285
114	Human	AWPPH	lncRNA	carboplatin (CBP)	triple negative breast cancer (TNBC)	o human TNBC cell lines MDA©\MB©\231 and BT©\ 20	carboplatin (CBP) treatment	LncRNA AWPPH overexpression led to promoted cancer cells proliferation and improved cancer cell viability under carboplatin treatment.	31033015
115	Human	AX747207	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	upregulated	29749447
116	Human	AX800134	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	blood; liver tissues	hepatitis B virus (HBV) infection	AX800134 was upregulated in HBV-positive HCC compared with HBV-negative HCC.	29789998
117	Human	BACE1	lncRNA	anisomycin	ovarian cancer (OC)	human ovarian cancer stem cells (OCSCs)	anisomycin treatment	upregulated	26783004
118	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	"The BACE1-AS level was found to be upregulated in serum samples of AD patients, brain tissues of AD transgenic (Tg) mice and A¦Â1-42-treated SH-SY5Y cells."	33197504
119	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	BACE1-AS Promotes Autophagy-Mediated Neuronal Damage Through The miR-214-3p/ATG5 Signalling Axis In Alzheimer's Disease.	33197504
120	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	HPN; SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	31898085
121	Human	BACE1-AS	lncRNA	berberine (BBR)	Alzheimer's disease (AD)	HPN; SK-N-SH cells	berberine (BBR) treatment	downregulated	31898085
122	Human	BACE1-AS	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	senile plaque (SP) AD SH-SY5Y cell	synthetic amyloid ¦Â-protein( A¦Â1-42) treatment	up-regulate	24970022
123	Human	BACE1-AS	lncRNA	HIV-1 transactivator of transcription (Tat) protein	HIV-associated neurocognitive disorders (HAND)	human primary astrocytes (HPAs)	HIV-1 transactivator of transcription (Tat) protein treatment	HIV-1 Tat-mediated astrocytic amyloidosis involves the HIF-1¦Á/lncRNA BACE1-AS axis.	32453744
124	Human	BANCR	lncRNA	IFN-¦Ã	age-related macular degeneration (AMD)	ARPE-19 cells	IFN-¦Ã treatment	IFN-¦Ã by itself increases BANCR expression in RPE cells.	29054724
125	Human	BANCR	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cell line ARPE-19	high-glucose (HG) treatment	"In vitro, high-glucose treatment failed to affect the expression of lncRNA BANCR in the human retinal pigment epithelial cell line ARPE-19. However, lncRNA BANCR overexpression inhibited the apoptosis of ARPE-19 cells under high-glucose conditions."	31007747
126	Human	BANCR	lncRNA	IFN-¦Ã	inflammation	ARPE-19 cells	IFN¦Ã treatment	upregulated	29054724
127	Human	BANCR	lncRNA	IFN-¦Â	myocardial injury	iPS cell-derived cardiomyocytes	IFN-¦Â treatment	BANCR promotes interferon-¦Â-induced cardiomyocyte apoptosis by targeting signal transducer and activator of transcription 1 in vitro.	33284897
128	Human	BANCR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
129	Human	BC005927	lncRNA	hypoxia	gastric cancer (GC)	SGC7901 cells; MKN45 cells; MKN28 cells	hypoxia treatment	"BC005927 was strongly induced by hypoxia in SGC7901 cells, MKN45 cells and MKN28 cells in a time- dependent method."	29383777
130	Human	BC064139	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
131	Human	BC200	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
132	Human	BC200	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
133	Human	BC200	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	H1299/DDP cells	cisplatin treatment	the IC50 in H1299/DDP cells transfected with si-BC200 was lower than in those transfected with si-NC.	30779077
134	Human	BC200	lncRNA	carboplatin (CBP)	ovarian cancer (OC)	SKOV3 and A2780 ovarian cancer cells	carboplatin (CBP) treatment	"it was observed that carboplatin induced BC200 expression in the cell lines, and that the inhibition of BC200 decreased the sensitivity of the cells to the drug"	26893717
135	Human	BCAR42	lncRNA	Yes-associated protein (YAP)	breast cancer	"human breast cancer cell lines MDA©\MB©\231, MDA©\MB©\468, and human embryonic kidney cell line HEK293T"	YAP treatment	upregulated	28963395
136	Human	BDLNR	lncRNA	baicalin (BAI)	cervical cancer (CC)	HeLa cells; SiHa cells	baicalin (BAI) treatment	BDLNR is downregulated by baicalein in a dose- and time-dependent manner in cervical cancer.	29175387
137	Human	BDLNR	lncRNA	baicalin (BAI)	cervical cancer (CC)	"HeLa, SiHa, ME-180 cells"	baicalin (BAI) treatment	upregulated	291753872
138	Human	BDNF-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial (RPE) cells	50 mM D-glucose	upregulated	28657668
139	Human	BDNF-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	"With treatment of 50?mM D-glucose, BDNF was markedly downregulated whereas BDNF-AS upregulated in ARPE-19 cells."	28657668
140	Human	BDNF-AS	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	32057951
141	Human	BDNF-AS	lncRNA	lithium (Li)	spinal cord injury (SCI)	SH-SY5Y cells	lithium treatment	Lithium treatment rescued the upregulation of BDNF-AS expression and downregulated of miR-9-5p expression induced by H2O2 in SH-SY5Y cells.	33464390
142	Human	BFAL1	lncRNA	enterotoxigenic bacteroides fragilis (ETBF)	colorectal cancer (CRC)	HCT-116 and DLD-1 cells	Enterotoxigenic Bacteroides fragilis (ETBF) infection	upregulated	31515468
143	Human	BLACAT1	lncRNA	ketamine	anesthesia-induced neural cytotoxicity	human induced pluripotent stem cells (hiPSCs)-derived neurons	"HiPSC-derived neurons were incubated with ketamine (MilliporeSigma, Shanghai, China) at various concentrations of 0, 0.001, 0.01, 0.1, 0.5, 1, 2 and 5 mM for 24 h."	"ketamine induced neuronal apoptosis, neurite degeneration, and upregulated BLACAT1 gene expression. Inversely, lentiviral-induced BLACAT1 downregulated rescued ketamine-induced neural cytotoxicity in hiPSCs-derived neurons. In addition, BLACAT1 downregulated was demonstrated to prevent ketamine-induced mitochondrial dysregulations by suppressing ROS and caspase 3/7 activities in hiPSCs-derived neurons."	31622594
144	Human	BLACAT1	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	SCC25 cell; FaDu cells	radiation treatment	BLACAT1 knockdown enhanced radioresistance of HNSCC cells via regulating PSEN1	31944856
145	Human	BLACAT1	lncRNA	afatinib	non-small cell lung cancer (NSCLC)	NSCLC cell lines Calu3 and H1975	afatinib treatment	BLACAT1 was upregulated in afatinib-resistant NSCLC cells.	31359792
146	Human	Blnc1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	upregulated	31632538
147	Human	BMP5	lncRNA	oestrogen (E2)	phallus development	urethral epithelium of male phalluses	oestrogen (E2) treatment	Lnc-ZBTB16 was downregulated by oestrogen treatment in male phalluses at day 50 post-partum (pp).	30598023
148	Human	C0100223	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
149	Human	C2dat1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	platelet-derived growth factor (PDGF)-BB treatment	C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with PDGF-bb	30474870
150	Human	C2dat1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	C2dat1 was higher in coronary artery disease (CAD) tissues than in normal arterial tissues and the C2dat1 expression level was upregulated in the proliferating VSMC after being treated with TNF-¦Á	30474870
151	Human	C3orf67-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	breast cancer	Ginsenoside Rh2-treated MCF-7 cancer cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31645124
152	Human	C3orf67-AS1	lncRNA	ginsenoside Rh2	breast cancer	MCF-7 cancer cells	Ginsenoside Rh2 treatment	downregulated	31645124
153	Human	C5orf66-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"gastric cardia adenocarcinoma (GCA) cell lines MGC-803, BGC-823, HGC-27, SGC-7901, NCI-N87"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29566283
154	Human	C7orf30-2	lncRNA	IFN-¦Ã and TNF-¦Á	atopic dermatitis (AD)	human keratinocytes (HaCaT cells)	IFN-¦Ã/TNF-¦Á treatment	upregulated	31181406
155	Human	C7orf30-2	lncRNA	quercetin	atopic dermatitis (AD)	IFN-¦Ã/TNF-¦Á-treated human keratinocytes (HaCaT cells)	Quercetin (Que) treatment	downregulated	31181406
156	Human	CA7-4	lncRNA	high glucose (HG)	autophagy	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	LncRNA CA7-4 that was induced by a high concentration of glucose. LncRNA CA7-4 facilitated endothelial autophagy and apoptosis as a competing endogenous RNA (ceRNA) by decoying miR877-3p and miR5680.	30957640
157	Human	CA7-4	lncRNA	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO)	vascular endothelial cells (VECs) autophagy and apoptosis	human vascular endothelial cells (VECs)	3-benzyl-5-([2-nitrophenoxy] methyl)-dihydrofuran-2(3H)-one (3BDO) treatment	3BDO restrained the upregulation of CA7-4 induced by high glucose in VECs.	30957640
158	Human	CAIF	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human CHON-001 cells	lipopolysaccharide (LPS) treatment	"CAIF overexpression inhibited the apoptosis of CHON-001 cells under LPS treatment, while miR-1246 overexpression attenuated the effects of CAIF overexpression."	31653823
159	Human	CASC15	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	CIHP-1 cells	high glucose (HG) treatment	CASC15 is upregulated in DCRF patients and promotes the apoptosis of podocytes by sponging miR-34c.	32053576
160	Human	CASC15	lncRNA	hypoxia	non-small cell lung cancer (NSCLC)	"NSCLC cell lines (A549, H1299, H1650, H1975, H520)"	hypoxia treatment	?Further analysis showed that hypoxia-induced CASC15 transactivation was mainly dependent on hypoxia-inducible factor 1¦Á (HIF-1¦Á) and hypoxia response elements (HREs) located in CASC15 promoter.	33407675
161	Human	CASC2	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	32323747
162	Human	CASC2	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	downregulated	29492259
163	Human	CASC2	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells and MDA-MB-231 cells	paclitaxel (PTX) treatment	upregulated	31352515
164	Human	CASC2	lncRNA	berberine (BBR)	colorectal cancer (CRC)	The human colorectal cancer cell lines HT29 and HCT116	berberine (BBR) treatment	"LncRNA CASC2 was upregulated in cells treated with berberine, and knockdown of lncRNA CASC2 reversed the berberine-induced apoptosis."	30681073
165	Human	CASC2	lncRNA	berberine (BBR)	colorectal cancer (CRC)	"Five human CRC cell lines (HT-29, HCT116, SW480, SW620 and LoVo)"	berberine (BBR) treatment	lncRNA CASC2 was upregulated by berberine treatment	31173223
166	Human	CASC2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	"CASC2 upregulation suppressed HG-induced proliferation, ECM accumulation and oxidative stress of HMCs through miR-133b /FOXP1 regulatory axis."	32016985
167	Human	CASC2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal mesangial cells (HRMCs)	high glucose (HG) treatment	"CASC2 could alleviate the degree and process of apoptosis, inflammation, and fibrosis in diabetic nephropathic models by regulating the miR-144/SOCS2 axis."	33227790
168	Human	CASC2	lncRNA	sanguinarine	epithelial ovarian cancer (EOC)	SKOV3 cells	sanguinarine treatment	upregulated	29571014
169	Human	CASC2	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	downregulated	30372881
170	Human	CASC2	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U257 cells; U87 cells	temozolomide (TMZ) treatment	downregulated	29136760
171	Human	CASC2	lncRNA	iodine-131 (131I)	papillary thyroid cancer (PTC)	TPC-1 cells; IHH-4 cells	Radioiodine (131I) treatment	CASC2 increases 131I sensitivity in PTC by sponging miR-155	33134385
172	Human	CASC2	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	CASC2 attenuated hypoxia-induced PASMC proliferation and migration by regulating the miR-222/ING5 axis to prevent vascular remodeling and the development of PAH.	32206065
173	Human	CASC7	lncRNA	corticosteroid	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	corticosteroid treatment	CASC7 increased corticosteroid sensitivity by inhibiting the PI3K/AKT signaling pathway via targeting miR-21.	31412983
174	Human	CASC7	lncRNA	dexamethasone (DEX)	corticosteroid resistance	Airway smooth muscle cells (ASMCs)	dexamethasone (DEX) treatment	Overexpression of CASC7 suppressed the PI3K/AKT signaling pathway and promoted the inhibition effects of dexamethasone on cell proliferation and cytokines secretion via targeting miR-21.	31412983
175	Human	CASC7	lncRNA	NaSH	spinal cord ischemia/reperfusion injury (SCII)	SH5Y-SY cells	NaSH treatment	NaSH preprocessing upregulated CasC7 and downregulated miR-30c in OGD/R-induced SH5Y-SY cells.	29571256
176	Human	CASC9	lncRNA	lipopolysaccharide (LPS)	lung injury	human small airway epithelial cells (HSAECs)	Lipopolysaccharide (LPS) treatment	CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis.	32221619
177	Human	CASC9	lncRNA	hypoxia	pancreatic cancer (PC)	"human pancreatic cancer cell lines (SW1990, PANC-1, BxPC-3, and MiaPaCa-2)"	hypoxia treatment	"Additionally, our findings showed that hypoxia induced the expression of CASC9 and enhanced the binding of HIF-1¦Á to its promoter."	33520364
178	Human	CCAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS administration reduced CCAT1 in tubular epithelial cells in vitro.	32243922
179	Human	CCAT1	lncRNA	radiation	breast cancer	MCF-7 cells; MDA-MB-231 cells	radiation treatment	Radiation treatment triggered a significant increase in CCAT1 and an obvious decrease in miR-148b	29024383
180	Human	CCAT1	lncRNA	X-rays	breast cancer	human breast cancer cell lines MCF-7 and MDA-MB-231	radiation treatment	upregulated	29024383
181	Human	CCAT1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	A2780; SKOV3	cisplatin treatment	CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.	32124583
182	Human	CCAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"HCT 116, SW1417, HT-29, and KM12 cell lines and NCM460 cell line"	5-fluorouracil (5-FU) treatment	the expression levels of CCAT1 were high in HCT 116/5-FU and HT-29/5-FU cell lines	31039730
183	Human	CCAT1	lncRNA	dandelion	gastric cancer (GC)	human GC cells	dandelion treatment	downregulated	28724210
184	Human	CCAT1	lncRNA	solasonine (SS)	hepatocellular carcinoma (HCC)	"HepG2 cells, QGY-7703 cells"	Solasonine (SS) treatment	downregulated	31681610
185	Human	CCAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	skin keratinocyte HaCaT cells	lipopolysaccharide (LPS) treatment	upregulated	31356903
186	Human	CCAT1	lncRNA	Sinomenine (SIN)	inflammation	skin keratinocyte HaCaT cells	sinomenine treatment	downregulated	31356903
187	Human	CCAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammatory bowel disease (IBD)	Human colorectal cancer cell line Caco-2	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30615124
188	Human	CCAT1	lncRNA	dexmedetomidine (DEX)	ischemia/reperfusion (I/R) injury	HL7702 cells	dexamethasone (DEX) treatment	Dex partially reversed the OGD-inhibited expression of lncRNA CCAT1.	29851220
189	Human	CCAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cell	cigarette smoke extract (CSE) treatment	upregulated	28184029
190	Human	CCAT1	lncRNA	baicalin (BAI)	melanoma	A375 and SK-MEL-28 cells	baicalin (BAI) treatment	downregulated	31778440
191	Human	CCAT1	lncRNA	oleic acid (OA)	nonalcoholic fatty liver disease (NAFLD)	L02 cells	oleic acid (OA) treatment	"CCAT1 increases LXR¦Á transcription by serving as a competing endogenous RNA for miR-613 in an LXRE-dependent manner, thereby promoting lipid droplet formation and NAFLD."	32413192
192	Human	CCAT1	lncRNA	hyperoside	non-small cell lung cancer (NSCLC)	H1975 cells	hyperoside treatment	downregulated	31894285
193	Human	CCAT1	lncRNA	hyperoside	non-small cell lung cancer (NSCLC)	The adenocarcinoma lung cancer cell line PC-9 and the T790M-positive NSCLC cell line NCI-H1975	Hyperoside treatment	downregulated	31894285
194	Human	CCAT1	lncRNA	paclitaxel (PTX)	paclitaxel (PTX) resistance	PC3-TXR cells; DU145-TXR cells	Paclitaxel (PTX) treatment	Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1	32089062
195	Human	CCAT2	lncRNA	X-rays	esophageal cancer (EC)	TE-3 cells; ECA109 cells	X-ray radiation treatment	lncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway	31789385
196	Human	CCAT2	lncRNA	calcitriol	ovarian cancer (OC)	SKOV3 cells; A2780 cells	calcitriol treatment	calcitriol inhibited CCAT2 expression in ovarian cancer cells.	32230936
197	Human	CCDC26	lncRNA	imatinib	gastrointestinal stromal tumor (GIST)	GIST-882 cells; GIST- T1 cells	imatinib treatment	downregulated	29423012
198	Human	CCNB1IP1-1:2	lncRNA	nigericin	pancreatic cancer (PC)	PANC-5 cells	nigericin treatment	upregulated	32850392
199	Human	Ccnd1	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
200	Human	CD160	lncRNA	hepatitis B virus (HBV)	hepatitis B virus (HBV) infection	CD8+ T cells	hepatitis B virus (HBV) infection	lncRNA-CD160 is positively associated with CD160 in CD8+ T cells with HBV infection.	32565950
201	Human	CD1D-2:1	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
202	Human	CDKN2B-AS	lncRNA	gemcitabine (GEM)	gemcitabine sensitivity	T24 cells	gemcitabine treatment	The expression of CDKN2B-AS gene in Gemcitabine-resistant T24/Gem cells was much higher than that in T24 cells.	29937935
203	Human	CDKN2B-AS1	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
204	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	"Knockdown of CDKN2B-AS1 suppressed proliferation, ECM accumulation and PI3K/AKT signaling by increasing miR-424-5p and decreasing HMGA2 in high glucose-treated HMGC cells."	31707340
205	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMC)	high glucose (HG) treatment	upregulated	31707340
206	Human	CDKN2B-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	Long non-coding RNA CDKN2B-AS1 regulates high glucose-induced human mesangial cell injury via regulating the miR-15b-5p/WNT2B axis	33298110
207	Human	CDKN2B-AS1	lncRNA	¦Â-Elemene	esophageal squamous cell carcinoma (ESCC)		¦Â-Elemene treatment	The chemotherapeutic drug ¦Â-elemene suppressed the proliferation of esophageal carcinoma ECA-109 cells by regulating the inhibition of hTERT expression by lncRNA CDKN2B-AS1	25646744
208	Human	CDKN2B-AS1	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
209	Human	CERNA1	lncRNA	"annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine)"	endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	"annexin A7 inhibitor, ABO (6-amino-2,3-dihydro-3-hydroxymethyl-1,4-benzoxazine) treatment"	upregulated	30911960
210	Human	CETP-3	lncRNA	medroxyprogesterone acetate (MPA)	endometrial cancer (EC)	Ishikawa cells (PRB+)	medroxyprogesterone acetate (MPA) treatment	upregulated	31718641
211	Human	CF129	lncRNA	hypoxia	pancreatic cancer (PC)	The PANC-1 and BxPC-3 cell lines	hypoxia induce	downregulated	31367258
212	Human	CHCHD4P4	lncRNA	glyoxylate	kidney damage and kidney stones	HK-2 cells	glyoxylate	upregulated	29160413
213	Human	CHRF	lncRNA	TGF-¦Â1	idiopathic pulmonary fibrosis (IPF)	A549 cells	TGF-¦Â1 treatment	CHRF and L1CAM expression were significantly upregulated and promoted the EMT process in A549 after treatment of TGF-¦Â1	33754922
214	Human	CHRF	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
215	Human	CILinc02	lncRNA	ibuprofen	osteoarthritis (OA)	cartilage tissues of osteoarthritis	Ibuprofen treatment	downregulated	30548658
216	Human	CILinc02	lncRNA	methylene blue (MB)	osteoarthritis (OA)	cartilage tissues of osteoarthritis	methylene blue treatment	downregulated	30548658
217	Human	CLDN10-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28316063
218	Human	CMPK2	lncRNA	IFN-¦Á	chronic hepatitis C virus (HCV) infection	primary human hepatocytes	IFN-¦Á treatment	upregulation	25122750
219	Human	COX2	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
220	Human	COX2	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (PASMCs)	hypoxia exposure	lincRNA-COX2 expression was upregulated in hypoxic PASMCs.	32803651
221	Human	COX2	lncRNA	lipopolysaccharide (LPS)	postoperative peritoneal adhesion (PPA)	The human peritoneal mesothelium cells (HPMCs)	lipopolysaccharide (LPS) treatment	"Suppression of Cox-2 ameliorated LPS induced HMPCs injury as cell viability was promoted, and cell apoptosis and the production of inflammatory factors were inhibited."	31885500
222	Human	CPS1-IT1	lncRNA	CoCl2	colorectal cancer (CRC)	LoVo and HCT116	CoCl2 treatment	downregulated	29017924
223	Human	CPS1-IT1	lncRNA	melatonin	hepatocellular carcinoma (HCC)	HepG2 cells;Huh7 cells	Melatonin treatment	downregulated	29137263
224	Human	CRAL	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901 cells	cisplatin treatment	downregulated	31885317
225	Human	CRART16	lncRNA	cetuximab	colorectal cancer (CRC)	Caco-2 cells	cetuximab treatment	lncRNA CRART16 was upregulated in Caco-2 CR cells.	32158358
226	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	"si-CRNDE-1 and miR-181a-5p mimic were able to reverse the promoting effects of LPS on production of NF-kB, TNF-a, IL-1b and IL-6 by THP-1 cells."	31604377
227	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32399391
228	Human	CRNDE	lncRNA	paclitaxel (PTX)	colorectal cancer (CRC)	SW480 cells; SW620 cells	Paclitaxel (PTX) treatment	?CRNDE Promotes Colorectal Carcinoma Cell Progression and Paclitaxel Resistance by Regulating miR-126-5p/ATAD2 Axis	32581554
229	Human	CRNDE	lncRNA	dextran sodium sulfate (DSS)	inflammatory bowel disease (IBD)	"human colonic epithelial cell lines (HT-29, LOVO, and Caco-2)"	dextran sulfate sodium (DSS) treatment	CRNDE in the colonic epithelial cell lines.	31251902
230	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	liver damage	L02 cells	lipopolysaccharide (LPS) treatment	LPS significantly suppressed CRNDE expression in L02 cells.	32031750
231	Human	CRNDE	lncRNA	cisplatin (DDP)	medulloblastoma	"Medulloblastoma cell lines D283, Daoy, D425, and D341"	cisplatin treatment	upregulated	31753063
232	Human	CRNDE	lncRNA	cisplatin (DDP)	medulloblastoma	Daoy; D341	cisplatin (DDP) treatment	upregulated	31753063
233	Human	CRNDE	lncRNA	palmitic acid (PA)	obesity	Human umbilical vein endothelial cells (HUVECs)	palmitic acid (PA) treatment	upregulated	31863035
234	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	LPS exposure induced cell injuries and increased CRNDE expression in WI-38 cells.	29864958
235	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	CRNDE expression was induced in LPS-induced MRC-5 cells.	32317619
236	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	Linkage of lncRNA CRNDE sponging miR-181a-5p with aggravated inflammation underlying sepsis.	31604377
237	Human	CRNDE	lncRNA	lipopolysaccharide (LPS)	sepsis-induced renal injury	HK-2 and HEK293 cells	lipopolysaccharide (LPS) treatment	CRNDE was markedly downregulated in sepsis models.	31877497
238	Human	CTA	lncRNA	doxorubicin (DOX)	osteosarcoma (OS)	"osteosarcoma cell lines Saos-2, U-2OS and MG-63"	doxorubicin treatment	upregulated	28415557
239	Human	CTB-60E11.4-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
240	Human	CTBP1-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA CTBP1-AS2 may serve a role in AS by inhibiting the proliferation and promoting the autophagy of VSMCs through ATG14 modulation via miR-195-5p.	32626936
241	Human	CTBP1-AS2	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	"CTBP1-AS2 attenuated HG-induced HGMC proliferation, oxidative stress, ECM accumulation, and inflammation through miR-155-5p/FOXO1 signaling."	32868076
242	Human	CTBP1-AS2	lncRNA	microwave ablation (MWA)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) tissues; HCC cell lines	microwave ablation (MWA) treatment	upregulated	32988587
243	Human	CTC-276P9.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29524086
244	Human	CTC-276P9.1	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines TE1, TE13, T.Tn, YES2, Eca109, and Kyse170"	histone deacetylase (HDAC) inhibitor TSA treatment	upregulated	29524086
245	Human	CTC-459I6.1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28316063
246	Human	CTD1-2003C8	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
247	Human	CTD-2201E18	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
248	Human	CTD-2215E18.3	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
249	Human	CTD-2639E6.9	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
250	Human	CUST_40243	lncRNA	benzene	benzene-induced hematotoxicity	peripheral lymphocytes	benzene treatment	upregulated	32730034
251	Human	CYTOR	lncRNA	tamoxifen (TAM)	breast cancer	tamoxifen resistant MCF7 cell lines (MCF7/TAM1 and MCF7/TAM2)	tamoxifen treatment	upregulated	31894257
252	Human	CYTOR	lncRNA	tamoxifen (TAM)	breast cancer	MCF7 / TAM2; MCF7 / TAM1	tamoxifen treatment	lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a-5p	31894257
253	Human	D63785	lncRNA	doxorubicin (DOX)	gastric cancer (GC)	BGC823 cells	doxorubicin (DOX) treatment	lncR-D63785 was downregulated in BGC823 cells treated by DOX.	30195778
254	Human	D63785	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neuron apoptosis	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	32999283
255	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK2 cells	Lipopolysaccharide (LPS) treatment	DANCR Suppressed Lipopolysaccharide-Induced Septic Acute Kidney Injury by Regulating miR-214 in HK-2 Cells	32222722
256	Human	DANCR	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	downregulated	32714991
257	Human	DANCR	lncRNA	compression force (CF)	cell differentiation	root resorption tissues	orthodontic tooth movement (OTM)	upregulated	31213122
258	Human	DANCR	lncRNA	cisplatin (DDP)	colorectal cancer (CRC)	SW480 cells	cisplatin treatment	upregulated	32766131
259	Human	DANCR	lncRNA	doxorubicin (DOX)	colorectal cancer (CRC)	HCT116 and RKO cells	doxorubicin (DOX) treatment	we found DANCR was suppressed by Doxorubicin and it acted as an important repressor of apoptosis in colorectal cancer.	33414433
260	Human	DANCR	lncRNA	cisplatin (DDP)	gastric cancer (GC)	"GC cell lines (SGC7901, BGC823) and cisplatin (DDP)-resistant cell lines (SGC7901/DDP, BGC823/DDP)"	cisplatin treatment	upregulated	31002130
261	Human	DANCR	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U87 cells; U251 cells	cisplatin treatment	DANCR highly expressed LN18 and U138MG cells were less sensitive to cisplatin than DANCR lowly expressed U87MG and U251MG cells.	29572052
262	Human	DANCR	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HEK-293T; Huh7; Hep3B cells	sorafenib treatment	LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells	32103983
263	Human	DANCR	lncRNA	resveratrol	nasopharyngeal carcinoma (NPC)	SUNE-1 cells; 5-8F cells	resveratrol (RS) treatment	Resveratrol downregulated the expression of DANCR	32683392
264	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human primary chondrocytes	lipopolysaccharide (LPS) treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
265	Human	DANCR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	primary chondrocytes	lipopolysaccharide (LPS)? treatment	"Expression of DANCR was upregulated, and miR-19a was downregulated in human OA cartilage and LPS-treated primary chondrocytes in vitro."	33283483
266	Human	DANCR	lncRNA	TGF-¦Â	ovarian cancer (OC)	A2780 cells; SKOV3 cells	TGF-¦Â treatment	Knockdown of DANCR Suppressed the Biological Behaviors of Ovarian Cancer Cells Treated with Transforming Growth Factor-¦Â (TGF-¦Â) by Sponging MiR-214	32417846
267	Human	DANCR	lncRNA	paclitaxel (PTX)	prostate cancer	"Human prostate cancer cells (PC3, C4-2 and DU145)"	Paclitaxel treatment	downregulated of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a	31486484
268	Human	DARS-AS1	lncRNA	hypoxia	myeloma	"RPMI 8226, LP-1, U266, H929 cells"	hypoxia induce	upregulated	31289203
269	Human	DDIT4-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
270	Human	DGCR5	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells	aurora kinase inhibitor (CCT137690) treatment	upregulated	31319040
271	Human	DGCR5	lncRNA	hypoxia	spinal cord injury (SCI)	AGE1.HN cells	hypoxia treatment	DGCR5 was downregulated in AGE1.HN cells treated with hypoxia.	30146926
272	Human	DICER1-AS1	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
273	Human	DICER1-AS1	lncRNA	arsenite	cell proliferation	A549 cells	arsenite exposure	we found that the expression of lncRNA DICER1-AS1 was significantly inhibited by sodium arsenite in a dose-dependent manner.	33609750
274	Human	DILC	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	downregulated	30365067
275	Human	DIO3OS	lncRNA	resveratrol	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	resveratrol (RS) treatment	downregulated	33718067
276	Human	DIO3OS	lncRNA	TGF-¦Â1	benign prostatic hyperplasia (BPH)	Benign prostatic hyperplasia epithelial-1 (BPH-1) cells; SV40 large-T antigen-immortalized stromal cell line WPMY-1	TGF-¦Â1 treatment	upregulated	33718067
277	Human	DKK3-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
278	Human	DLX6-AS1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	SH-SY5Ycells; N2a cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	33216728
279	Human	DLX6-AS1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS induced DLX6-AS1 expression in HK-2 cells	32666494
280	Human	DNM3OS	lncRNA	palmitic acid (PA)	diabetes mellitus (DM)	THP1 macrophages (TMC) and human primary macrophages	palmitic acid (PA) treatment	upregulated	29930005
281	Human	DNM3OS	lncRNA	TGF-¦Â1	prostatic hyperplasia (BPH)	prostate stromal cells (PrSCs) were primary cultured from BPH tissue	TGF¦Â1 treatment	"DNM3OS expression was the most upregulated lncRNA in PrSCs induced by TGF¦Â1, DNM3OS silencing decreases the protein level of COL3A1 upon TGF¦Â1 stimulation"	31694982
282	Human	DPP10-AS1	lncRNA	tetramethylpyrazine (TMP)	prostate cancer	PC3 cells; DU145 cells	Tetramethylpyrazine (TMP) treatment	upregulated	32319592
283	Human	DYNLRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	24493833
284	Human	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28815701
285	Human	DYN-LRB2-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	cholesterol efflux	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LincRNA DYN-LRB2-2 was upregulated in oxLDL-treated THP-1 cells.	28815701
286	Human	EBF3-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	Ab25¨C35 induced the upregulation of EBF3-AS.	29298096
287	Human	EBLN3P	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	upregulated	30314355
288	Human	EFNA3	lncRNA	hypoxia	breast cancer	MDA-MB231-EphrinA3-Luc cells;MDA-MB231-Luc cells	"cells were placed in a 1% O2, 5% CO2?and 94% N2?gas mixture treatment"	upregulated	25023702
289	Human	EGFR-AS1	lncRNA	gemcitabine and cisplatin	non small cell lung cancer (NSCLC)	plasma	gemcitabine and cisplatin treatment	"the plasma levels of EGFR-AS1 were increased in patients with NSCLC, particularly in GP-resistant patient plasma."	30431074
290	Human	EGFR-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	"The human NLCLC cell lines, A549, NCI-H460, NCI-H1299 and NCI-H358"	cisplatin (DPP) treatment	upregulated	30431074
291	Human	EGOT	lncRNA	hypoxia	autophagy	HK-2 cells	hypoxia treatment	The lncRNA EGOT expression was significantly downregulated in renal tubular cells during hypoxia-induced autophagy.	32030803
292	Human	ELIT-1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	"Huh7, A549, HepG2, HaCaT cells"	TGF¦Â treatment	upregulated	30952633
293	Human	LINC01480	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
294	Human	DSCAM-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
295	Human	LINC00843	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
296	Human	ANKRD20A8P	lncRNA	cadmium (Cd)	cadmium-induced toxicity	16HBE cells	cadmium (Cd) treatment	upregulated	33447366
297	Human	NALT1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
298	Human	lncRNA 74.1	lncRNA	TGF-¦Â	renal fibrosis	HK2 cells	TGF-¦Â treatment	LncRNA ENST000004537741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis	30317629
299	Human	lncRNA 74.1	lncRNA	TGF-¦Â	renal fibrosis	human HK-2 cell	TGF-¦Â treatment	The expression of LncRNA 741 was significantly downregulated in the TGF-¦Â-induced HK-2 cell fibrosis and clinical renal fibrosis specimens	30317629
300	Human	DSCAM-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
301	Human	ANKRD18DP	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
302	Human	LINC02577	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
303	Human	BG772796.1	lncRNA	paclitaxel (PTX)	lung cancer	A549 human lung cancer cells	paclitaxel (PTX) treatment	downregulated	31516584
304	Human	BE779106.1	lncRNA	coal tar pitch (CTP)	lung cancer	human bronchial epithelial cells (BAES-2B)	coal tar pitch (CTP) treatment	LncRNA-ENST00000501520 could promote the proliferation in malignant-transformed BEAS-2B cells induced with CTP extract which may be mediated by target genes.	31033183
305	Human	BE779106.1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
306	Human	uc063pbz.2	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
307	Human	C1RL-AS1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
308	Human	uc058qvk.1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT116 cells; LoVo cells	5-fluorouracil (5-FU) treatment	ENST00000547547 was downregulated in 5-FU-resistant CRC cells in comparison with the parental cells.	29115526
309	Human	CB852161.1	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	upregulated	32470693
310	Human	ENST00000567668.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
311	Human	BX116192.1	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
312	Human	ENST00000570843.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
313	Human	ENST00000574654.1	lncRNA	hypoxia	renal cell carcinoma (RCC)	SW839 cells; OSRC cells	hypoxia treatment	hypoxia promoted RCC cell invasion through HIF-1¦Á/lncRNA (ENST00000574654.1)/hnRNP/VEGF-A pathway.	32774742
314	Human	NARF-AS1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
315	Human	ZNF667-AS1	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
316	Human	ZNF528-AS1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
317	Human	ENST00000602478.1	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
318	Human	ZNF658B	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
319	Human	BC028413.1	lncRNA	¦Á-melanocyte-stimulating hormone (¦Á-MSH)	skin pigmentation disorders	human skin primary melanocytes (MCs)	¦Á-MSH treatment	upregulated	33318297
320	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
321	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	?HepG2 cell lines	dexamethasone (DEX) treatment	"ENST00000608794 plays an important role in dexamethasone induced steatosis, which was partly mediated by derepressing of PDK4 through competitively binding to miR-15b-5p."	31330194
322	Human	BF244201.1	lncRNA	dexamethasone (DEX)	steatosis	hepatocytes	dexamethasone (DEX) treatment	upregulated	31330194
323	Human	BC017676.1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
324	Human	AK123910.1	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
325	Human	EPB41L4A-AS1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
326	Human	EPB41L4A-AS2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	downregulated	29683761
327	Human	EPEL	lncRNA	carboplatin (CBP)	ovarian endometrioid adenocarcinoma	human ovarian endometrioid adenocarcinoma cell line SNU-251	carboplatin (CBP) treatment	"EPEL overexpression increased, whereas small interfering RNA (siRNA) silencing reduced the viability of SNU-251 cells under carboplatin treatment."	31621389
328	Human	EPIC1	lncRNA	dexamethasone (DEX)	osteoblast injury	OB-6 osteoblastic cells; primary human osteoblasts	dexamethasone (Dex) treatment	"In OB-6 osteoblastic cells and primary human osteoblasts, treatment with Dex increased expression of Lnc-EPIC1."	29959919
329	Human	EPIC1	lncRNA	H2O2	neuronal cell injury	SH-SY5Y neuronal cells and primary human neuron cultures	hydrogen peroxide (H2O2) treatment	downregulated	31812951
330	Human	EPR	lncRNA	TGF-¦Â	cell proliferation	human mammary gland adenocarcinoma cells MDAMB-231	TGF-¦Â treatment	TGF-¦Â induced a small increase in EPR levels followed by rapid downregulated	31036808
331	Human	ERLR	lncRNA	TGF-¦Â1	cell proliferation	ARPE-19 cells; phRPE cells	TGF-¦Â1 treatment	ERLR was upregulated in RPE cells stimulated with transforming growth factor (TGF)-¦Â1 as detected by lncRNA microarray and RT-PCR	33664479
332	Human	ES3	lncRNA	high glucose (HG)	calcification/senescence	human aortic vascular smooth muscle cells (HA-VSMCs)	high glucose (HG) treatment	upregulated	32483833
333	Human	ES3	lncRNA	high glucose (HG)	vascular calcification (VC)	human aorta vascular smooth muscle cells (HA-VSMCs)	high glucose treatment	lncRNA-ES3 inhibited miR-34c-5p expression by direct interaction and its knockdown suppressed the calcification/senescence of HA-VSMCs.	30654331
334	Human	F11-AS1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2.2.15 cells	HBx-induce	downregulated	31880390
335	Human	F11-AS1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2.2.15 cells	hepatitis B virus (HBV) infection	downregulated	31880390
336	Human	FA2H-2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	"human umbilical vein endothelial cells (ECs; ATCC CRL-1730), and human aorta vascular smooth muscle cells (SMCs; ATCC CRL-1999)"	oxidized low-density lipoprotein (OX-LDL) treatment	downregulated	30683918
337	Human	FAL1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	brain endothelial cell damage	human primary brain microvascular endothelial cells (HBMVECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	The lncRNA FAL1 protects against hypoxia-reoxygenation- induced brain endothelial damages through regulating PAK1	31927658
338	Human	FAL1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetic atherosclerosis	HUVECs	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30338819
339	Human	FAM133B-2	lncRNA	X-rays	nasopharyngeal carcinoma (NPC)	CNE-2 cells; 6-10B cells	X-ray radiation treatment	FAM133B-2 is highly expressed in the radio-resistant nasopharyngeal carcinoma cells.	32889799
340	Human	FAM225A	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells	sorafenib treatment	FAM225A expression is dramatically upregulated in sorafenib-resistant HepG2/SOR cells	33245102
341	Human	FAM83H-AS1	lncRNA	TGF-¦Â	oesophageal squamous cell carcinoma (ESCC)	Eca109 cells	TGF-¦Â treatment	upregulated	32583631
342	Human	FAM83H-AS1	lncRNA	staphylococcal protein A (SpA)	osteomyelitis	Human bone mesenchymal stem cells (hBMSCs)	staphylococcal protein A (SpA) treatment	FAM83H-AS1/miR-541-3p/WNT3A ameliorated SpA-mediated inhibition of the osteogenic differentiation of hBMSCs	31871129
343	Human	FANCI-2	lncRNA	human papilloma virus (HPV)	cervical cancer (CC)	human foreskin keratinocytes (HFK)K-derived organotypic raft cultures	HPV infectionn	upregulated	33436409
344	Human	FAS-AS1	lncRNA	hydroquinone (HQ)	benzene-induced carcinogenesis	TK6 cells	Hydroquinone (HQ) treatment	downregulated	32088430
345	Human	FBXL19-AS1	lncRNA	sophorae Fructus	hepatocellular carcinoma (HCC)	Huh7 cells	sophorae Fructus treatment	"Flavonoids of Sophorae Fructus could inhibite the proliferation, migration and invasion of hepatoma cells by regulating LncRNA FBXL19-AS1/miR-342-3p pathway"	33164374
346	Human	FENDRR	lncRNA	adriamycin (ADR)	chronic lymphocytic leukemia (CLL)	human chronic myeloid leukemia cell line K562 and KCL22	adriamycin (ADR) treatment	downregulated	31180580
347	Human	FENDRR	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	upregulated	30700211
348	Human	FENDRR	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
349	Human	FENDRR	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
350	Human	FER1L4	lncRNA	compression force (CF)	orthodontic tooth movement	human periodontal ligament stem cells (PDLSCs)	compressive force treatment	"After the application of compressive force, lncRNA FER1L4 was strongly upregulated."	33604341
351	Human	FER1L4	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells	paclitaxel (PTX) treatment	downregulated	30444026
352	Human	FEZF1-AS1	lncRNA	hypoxia	pancreatic cancer (PC)	human PC cell lines PANC©\1;SW1990	hypoxic condition induce	"In PC cell lines, FEZF1-AS1 acted as an oncogene via promoting PC cell proliferation and invasion through miR-142/HIF-1¦Á axis under hypoxic condition."	30693518
353	Human	FEZF1-AS1	lncRNA	normoxia	pancreatic cancer (PC)	"human PC cell lines PANC©\1, SW1990"	normoxia condition induce	upregulated	30693518
354	Human	FEZF1-AS1	lncRNA	TGF-¦Â2	posterior capsular opacification (PCO)	Human Lens Epithelial Cells SRA01/04	?TGF-¦Â2 treatment	upregulated	31281667
355	Human	FGD5-AS1	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; Hcc827 cells; lung adenocarcinoma (LAD) tissues	cisplatin treatment	FGD5-AS1 was highly expressed in DDP-resistant LAD tissues and cells.	33416094
356	Human	FGD5-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells; Non-small cell lung cancer (NSCLC) tissues	cisplatin treatment	FGD5-AS1 was upregulated in DDP-resistant tumors and cells compared with DDP-sensitive ones.	32534055
357	Human	FGD5-AS1	lncRNA	lipopolysaccharide (LPS)	periodontitis	primary human periodontal ligament cells (PDLC	lipopolysaccharide (LPS) treatment	upregulated of lncRNA FGD5-AS1 could protect against periodontitis via regulating the miR-142-3p/SOCS6/NF-¦ÊB signals.	31144533
358	Human	FLJ46906	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
359	Human	FLJ46906	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	upregulated	32457731
360	Human	FLJ46906	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
361	Human	FLJ46906	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
362	Human	FOXD2-AS1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	TE-1/DDP	cisplatin treatment	Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis	31558183
363	Human	FOXD2-AS1	lncRNA	cisplatin (DDP)	esophageal squamous cell carcinoma (ESCC)	The human ESCC cell line TE-1	cisplatin treatment	upregulated	31558183
364	Human	FoxD2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	The human glioma cell lines U251 and A172	temozolomide (TMZ) treatment	"Knockdown of FoxD2-AS1 decreased the proliferation, metastatic ability of glioma cells and promote the sensitivity to TMZ in glioma cells"	31680769
365	Human	FOXD2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"human glioma cell lines (U87, U251, LN229, A172)"	temozolomide (TMZ) treatment	"downregulated FOXD2-AS1 repressed invasion, proliferation, migration and drug resistance of drug-resistant glioma cells while stimulating their apoptosis via increasing miR-98-5p and inhibiting CPEB4 expression."	31770107
366	Human	FOXD2-AS1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 and HUH7 cells	sorafenib treatment	downregulated	31210410
367	Human	FOXD2-AS1	lncRNA	IL-1¦Â and/or TNF-¦Á	osteoarthritis (OA)	Human cartilage C28/I2 cells	IL-1¦Â and/or TNF-¦Á treatment	"IL-1¦Â and/or TNF-¦Á treatment could increase FOXD2-AS1 expression in chondrocytes. FOXD2-AS1 overexpression induced cell proliferation, inflammation and extracellular matrix (ECM) degradation in chondrocytes."	30945573
368	Human	FOXD2-AS1	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	osteosarcoma (OS)	"Normal osteoblastic cell line (hFOB); osteosarcoma cell lines (MG63, Saos-2, 143B, U2-OS)"	HIF-1¦Á overexpression	upregulated	31228799
369	Human	FOXD3-AS1	lncRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	Hypoxia exposure caused an upregulation of FOXD3-AS1 in AC16 cells.	32973515
370	Human	FOXD3-AS1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H1299 cells	cisplatin treatment	FOXD3-AS1 was upregulated in cisplatin-resistant NSCLC cells (A549/DDP and H1299/DDP cells) in comparison with their parental cell lines.	32742197
371	Human	FR075921	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
372	Human	FR324124	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
373	Human	FTH1P3	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells; MDA-MB-231 cells	paclitaxel (PTX) treatment	lncRNA FTH1P3 was upregulated in paclitaxel-resistant breast cancer tissue and cells (MCF-7/PTX and MDA-MB-231/PTX cells)	29971911
374	Human	GABPB1-AS1	lncRNA	human papilloma viruses 16 (HPV16) E6	cervical cancer (CC)	C33A cells; SiHa cells; CaSki cells	human papillomaviruses 16 (HPV16) E6 infection	upregulated	32844486
375	Human	GABPB1-AS1	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
376	Human	GABPB1-AS1	lncRNA	erastin	ferroptosis	HepG2 hepatocellular carcinoma cells	erastin treatment	upregulated	31700067
377	Human	GABPB1-AS1	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
378	Human	GABPB1-AS1	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
379	Human	GABPB1-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
380	Human	GACAT3	lncRNA	IL-6	gastric cancer (GC)	gastric cancer SGC-7901 cells	IL-6 treatment	upregulated	27644247
381	Human	GAEA	lncRNA	connective tissue growth factor (CTGF)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	CTGF treatment	upregulated	30631154
382	Human	GAEA	lncRNA	high glucose (HG)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	high glucose treatment	upregulated	30631154
383	Human	GAEA	lncRNA	IL-6	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	IL-6 treatment	upregulated	30631154
384	Human	GAEA	lncRNA	sonic hedgehog(SHH)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	SHH treatment	upregulated	30631154
385	Human	GAEA	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	TGF-¦Â treatment	upregulated	30631154
386	Human	GAPLINC	lncRNA	hypoxia	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia induce	upregulated	31589383
387	Human	GAPLINC	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	hypoxia-inducible factor 1¦Á (HIF-1¦Á) treatment	upregulated	31589383
388	Human	GAS5	lncRNA	C-terminal Hsp90 inhibitor KU758	adrenocortical carcinoma	NCI-H295R and SW13 cells	C-terminal Hsp90 inhibitor KU758 treatment	upregulated	31561992
389	Human	GAS5	lncRNA	ovalbumin (OVA)	allergic rhinitis (AR)	nasal epithelial cells secreted exosomes	ovalbumin (OVA) treatment	upregulated	31841965
390	Human	GAS5	lncRNA	amygdalin	anti-cancer therapy	"human cancer cells (A549, MCF7, AGS)"	amygdalin treatment	upregulated	30725348
391	Human	GAS5	lncRNA	2-o-methylmagnolol (MM1)	apoptosis	A375 (melanoma) and A431 (squamous cell carcinoma) cells	2-O-methylmagnolol (MM1) treatment	upregulated	28252643
392	Human	GAS5	lncRNA	TGF-¦Â1	asthma	human bronchial epithelial cells BEAS-2B	TGF-¦Â1 treatment	"TGF-¦Â1, GAS5, HDAC4 were upregulated, while miR-217 was downregulated in bronchial mucosal tissues of asthmatic children and TGF-¦Â1-treated BEAS-2B cells"	33864612
393	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 was enriched in atherosclerotic plaques and THP-1 macrophage exposed to oxidized low-density lipoprotein (ox-LDL).	29859752
394	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"We found that the abundance of GAS5 was markedly increased, and miR-135a was decreased in AS patient serums and ox-LDL-induced human THP-1 cells dose and time dependently. Interference of GAS5 suppressed inflammation and oxidative stress induced by ox-LDL in THP-1 cells."	33128668
395	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 knockdown suppresses inflammation and oxidative stress induced by oxidized low-density lipoprotein in macrophages by sponging miR-135a	33128668
396	Human	GAS5	lncRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	downregulated	32160712
397	Human	GAS5	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
398	Human	GAS5	lncRNA	chemotherapeutic agents£¨rapamycin; temsirolimus and everolimus; BEZ235 and AZD8055; and imatinib £©	breast cancer	breast cancer cell	chemotherapeutic agents treatment	downregulated	24789445
399	Human	GAS5	lncRNA	dendrosomal curcumin (DNC)	breast cancer	MCF7 cells; MDA-MB231 cells; SKBR3 cells	dendrosomal curcumin (DNC) treatment	"GAS5 was upregulated in DNC treatment of MCF7, MDA-MB231, and SKBR3 cells."	29655698
400	Human	GAS5	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7?cells	tamoxifen treatment	lncRNA GAS5 was downregulated in MCF-7R cells	29969658
401	Human	GAS5	lncRNA	high glucose (HG)	cell damage	human renal tubular epithelial HK-2	high glucose (HG) treatment	HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity.	31159592
402	Human	GAS5	lncRNA	cisplatin (DDP)	cervical cancer (CC)	Human cervical adenocarcinoma cell Hela and human cervical squamous cancer cell line Siha	cisplatin treatment	upregulated	30352127
403	Human	GAS5	lncRNA	radiation	cervical cancer (CC)	SiHa cells	radiation treatment	GAS5 was low expressed in the radio-resistant SiHa cells	30579899
404	Human	GAS5	lncRNA	X-rays	cervical cancer (CC)	CC tissues and cell lines (SiHa and ME180)	6 MV X-ray irradiation	downregulated	30579899
405	Human	GAS5	lncRNA	lipopolysaccharide (LPS)	chronic nonbacterial prostatitis (CNP)	Human prostate epithelial cell line RWPE-1	lipopolysaccharide (LPS) treatment	downregulated	30892130
406	Human	GAS5	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human lymphatic endothelial cells (LECs)	high glucose (HG) treatment	"GAS5 was significantly downregulated whereas miR-217 was obviously upregulated in diabetic skin, HG-induced lymphatic endothelial cells (LECs) and diabetic mouse model."	33865922
407	Human	GAS5	lncRNA	glucocorticoid (GC)	diabetes mellitus (DM)	EndoC-¦ÂH1 cells	glucocorticoid (GC) treatment	Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA	32029226
408	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cardiomyocytes	high glucose (HG) treatment	GAS5 expression was upregulated in HG-treated AC16 cardiomyocytes and the rat diabetic myocardial injury model	33682891
409	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	HG increased GAS5 expression in AC16 cells and knockdown of GAS5 protected AC16 cells from HG-induced injury.	31865425
410	Human	GAS5	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human cardiomyocyte-like AC16 cells	high glucose (HG) treatment	upregulated	31865425
411	Human	GAS5	lncRNA	mevastatin (MEV)	diabetic foot ulcer (DFU)	skin samples were used to generate acute wounds	"treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment"	upregulated	29158265
412	Human	GAS5	lncRNA	zaragozic acid (ZGA)	diabetic foot ulcer (DFU)	skin samples were used to generate acute wounds	"treat daily with 50 ¦Ìm ZGA, 10 ¦Ìm MEV, or both ZGA and MEV treatment"	upregulated	29158265
413	Human	GAS5	lncRNA	high fat diet (HFD)	diabetic nephropathy (DN)	kidney tissues	high fat diet (HFD) feed	LncRNA Gas5 (GAS5) expression was increased in kidneys of the DKD mouse model.	31810140
414	Human	GAS5	lncRNA	TGF-¦Â1	diabetic nephropathy (DN)	HK-2 cells	TGF-¦Â1 treatment	LncRNA Gas5(GAS5) expression was increased in TGF-¦Â1-induced HK-2 cells	31810140
415	Human	GAS5	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human renal tubular epithelial HK-2	high glucose (HG) treatment	HG enhances the expression of GAS5 in HK-2 cells; Silence of GAS5 alleviates the HG-caused HK-2 cell toxicity.	31159592
416	Human	GAS5	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose treatment	downregulated	31849505
417	Human	GAS5	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	downregulated	32467994
418	Human	GAS5	lncRNA	high glucose (HG)	endometrial cancer (EC)	"Human endometrial carcinoma cell lines (HEC1-B, HEC1-A and Ishikawa)"	high glucose (HG) treatment	downregulated	31105847
419	Human	GAS5	lncRNA	thapsigargin (Tg)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	thapsigargin (Tg) treatment	downregulated	30753838
420	Human	GAS5	lncRNA	tunicamycin (TM)	endoplasmic reticulum stress (ERS)	"human osteosarcoma cells U2OS, 143B, MG63, Saos-2"	tunicamycin (TM)? treatment	downregulated	30753838
421	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cells injury and autophagy dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	GAS5 expression was upregulated and miR-26a was downregulated in the plasma samples of patients with atherosclerosis and ox-LDL-treated HAECs.	30468731
422	Human	GAS5	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"GAS5 knockdown inhibited cell apoptosis and activated autophagy flux, whereas inhibition of miR-26a reversed the effect of GAS5 in HAECs."	30468731
423	Human	GAS5	lncRNA	radiation	esophageal squamous cell carcinoma (ESCC)	TE-1 cells; esophageal squamous cell carcinoma (ESCC) tissues	radiation treatment	GAS5 expression is far higher in radiation sensitive ESCC tissues/cells than radiation resistant tissues/cells	31866421
424	Human	GAS5	lncRNA	X-rays	esophageal squamous cell carcinoma (ESCC)	ESCC tissues and TE-1 celss	2 Gy X-ray treatment	upregulated	31866421
425	Human	GAS5	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	SGC-7901 and SGC-7901/ADM cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27466992
426	Human	GAS5	lncRNA	combination of rapamycin plus MP	gastric cancer (GC)	peripheral blood mononuclear cells (PBMCs)	combination of rapamycin plus MP treatment	downregulated	27001230
427	Human	GAS5	lncRNA	steroids	glucocorticoids effects	HeLa cells; LoVo cells	steroids treatment	GAS5 was upregulated in GC-resistant cells	28722800
428	Human	GAS5	lncRNA	dexamethasone (DEX)	glucocorticoid (GC)-mediated beta cell dysfunction	Human pancreatic islets and the human beta cell line EndoC-¦ÂH1	dexamethasone (DEX) treatment	Increasing GAS5 levels using GAS5 HREM alleviated the inhibitory effects of dexamethasone on insulin secretion.	32029226
429	Human	GAS5	lncRNA	corylin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Corylin treatment	upregulated	29382035
430	Human	GAS5	lncRNA	lipopolysaccharide (LPS)	hepatocellular carcinoma (HCC)	HepG2 cells	lipopolysaccharide (LPS) treatment	LPS stimulation promotes GNAS expression in HCC cells through increasing m6A methylation of GNAS mRNA.	32123532
431	Human	GAS5	lncRNA	platelet derived growth factor-BB (PDGF-BB)	hypertension	vascular smooth muscle cells (VSMCs)	PDGF©\bb treatment	"?GAS5 inhibits PDGF-bb-induced VSMC proliferation and migration, partly through acting as a competing endogenous RNA of miR-21"	31069831
432	Human	GAS5	lncRNA	hypoxic/ischemic	hypoxic/ischemic brain damage (HIBD)	neonatal brain tissues;hippocampal neurons tissues	hypoxic/ischemic treatment	GAS5 expression was significantly upregulated in hypoxic/ischemic-injured neonatal brain and hippocampal neurons.	29428721
433	Human	GAS5	lncRNA	X-rays	improved radiosensitivity	NSCLC cell lines (A549 and H1975)	X-ray irradiation treatment	upregulated	28117028
434	Human	GAS5	lncRNA	ionizing radiation (IR)	non-small cell lung cancer (NSCLC)	NCI-H460 cells; A549 cells	ionizing radiation (IR) treatment	IR enhanced the interaction between lncRNA GAS5 and the miR-21/PTEN/Akt axis.	32020207
435	Human	GAS5	lncRNA	propofol (PPF)	oral squamous cell carcinoma (OSCC)	UM-SCC6 and SCC090 cells	Propofol treatment	upregulated	31583913
436	Human	GAS5	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	downregulated	32901049
437	Human	GAS5	lncRNA	androgen	prostate cancer	"LNCaP, 22RV1, DU145, PC3"	androgen treatment	downregulated	28771526
438	Human	GAS5	lncRNA	¦Á-solanine	prostate cancer	Human normal prostate epithelial cell line RWPE-1 and PCa cell lines DU145 and PC-3	¦Á-Solanine treatment	upregulated	30970507
439	Human	GAS5	lncRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	"Human RCC cell lines, OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P"	sorafenib treatment	GAS5 was responsible for sorafenib resistance in RCC cells and GAS5 exerted its function through the miR-21/ SOX5 axis	29895198
440	Human	GAS5	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	lncRNA GAS5 was upregulated in TGF-¦Â1-treated HK-2 cells	31810140
441	Human	GAS5	lncRNA	hypoxia	renal ischemia/reperfusion (I/R) injury	HK2 cells	hypoxia induce	upregulated	30129267
442	Human	GAS5	lncRNA	tanshinone IIA (Tan IIA)	rheumatoid arthritis (RA)	fibroblast-like synoviocytes (FLS)	tanshinone IIA (Tan IIA) treatment	"Long non-coding RNA (lncRNA) GAS5 expression was significantly decreased in the synovial tissues and RAFLS, while Tan IIA treatment resulted in an upregulated of GAS5"	30232236
443	Human	GAS5	lncRNA	ribavirin	ribavirin-induced cardiac developmental toxicity	human induced pluripotent stem cells (hiPSCs)	ribavirin treatment	Exposuring to ribavirin (5 and 10 ¦ÌM) markedly upregulated the expression of lncRNAs Gas5 in both mid-phase and late phase of differentiation and HBL1 in the mid-phase	32112805
444	Human	GAS5	lncRNA	dexamethasone (DEX)	severe asthma (SA)	Human bronchial epithelial cells (HBECs)	dexamethasone (DEX) treatment	downregulated	32642099
445	Human	GAS5	lncRNA	IL-2 and IL-4	severe asthma (SA)	Human bronchial epithelial cells (HBECs)	IL-2 and IL-4 treatment	upregulated	32642099
446	Human	GAS5	lncRNA	cisplatin (DDP)	triple negative breast cancer (TNBC)	The TNBC cell lines MDA©\MB©\231 and BT549	cisplatin treatment	"the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS). More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS."	31692053
447	Human	GAS5	lncRNA	paclitaxel (PTX)	triple negative breast cancer (TNBC)	The TNBC cell lines MDA©\MB©\231 and BT549	paclitaxel (PTX) treatment	"the expression of lncRNA GAS5 was significantly downregulated in TNBC cells treated with paclitaxel (PTX) or cisplatin (CIS) More interestingly, the expression level of lncRNA GAS5 in TNBC patients was associated with tumor resistance to PTX and CIS"	31692053
448	Human	GAS5	lncRNA	phosphorus (Pi)	vascular calcification (VC)	human aortic vascular smooth muscle cells (HASMCs)	phosphorus treatment	downregulated	32347320
449	Human	GAS5-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) cells	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27489122
450	Human	GAS6-AS1	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
451	Human	GAS6-AS2	lncRNA	heat stress	hepatocellular carcinoma (HCC)	Huh7 cells; MHCC97 cells	heating treatment	GAS6-AS2 was upregulated in Huh7-H and MHCC97-H cells relative to Huh7 and MHCC97 cells.	32799553
452	Human	GATA6-AS	lncRNA	hypoxia	oxidative stress	human umbilical vein endothelial cells (HUVECs)	hypoxia induce	upregulated	29339785
453	Human	GBCDRlnc1	lncRNA	doxorubicin (DOX)	gallbladder cancer (GBC)	The NOZ and GBC-SD human gallbladder cancer cell lines	doxorubicin (Dox) treatment	upregulated	30953511
454	Human	GHET1	lncRNA	hypoxia	triple negative breast cancer (TNBC)	MDA-MB-468 cells; HCC1937 cells	hypoxia treatment	Highly expressed lncRNA GHET1 in TNBC tissues and cells and induction of lncRNA GHET1 by hypoxia were proved.	33869194
455	Human	GIHCG	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	LoVo cells	5-fluorouracil (5-FU) treatment	upregulated	30799935
456	Human	GIHCG	lncRNA	oxaliplatin	colorectal cancer (CRC)	LoVo cells	Oxaliplatin (Oxa) treatment	upregulated	30799935
457	Human	GIRGL	lncRNA	glutamine starvation	glutamine metabolism	(HEK) 293T cells	glutamine starvation treatment	"Here, we characterize a long noncoding RNA, GIRGL (glutamine insufficiency regulator of glutaminase lncRNA), that is induced upon glutamine starvation."	33762340
458	Human	GKN2-1:1	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
459	Human	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	human AC-16 cell lines	angiotensin II (Ang II) treatment	upregulated	33130312
460	Human	Gm15834	lncRNA	angiotensin II (Ang II)	cardiac hypertrophy	AC16 cells	angiotensin II (Ang II) treatment	upregulated	33130312
461	Human	Gm22	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
462	Human	Gm26945	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	upregulated	30314355
463	Human	GNAS-AS1	lncRNA	IL-4	macrophage polarization	peripheral blood mononuclear cells (PBMCs)	IL-4 treatment	upregulated	31267263
464	Human	GNAT1-1	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	SGC-7901 and MNK45 cells	Helicobacter (H.) pylori infection	downregulated	30132541
465	Human	GOLGA2P10	lncRNA	actinomycin D (actD)	endoplasmic reticulum stress (ERS)	MHCC-97H cells	actinomycin D (actD) treatment	Treatment with actinomycin D abrogated tunicamycin-induced GOLGA2P10 expression.	32332695
466	Human	GPX3-AS	lncRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	"GPX3-AS downregulated the apoptosis of LECs via promoting GPX3 expression, implying a novel therapeutic target for ARCs."	31814699
467	Human	GS1-600G8.5	lncRNA	ultraviolet (UV) irradiation	ultraviolet radiation (UV) effects	primary human skin fibroblasts; keratinocytes; fresh human explant whole skin	ultraviolet radiation (UVA) treatment	upregulated	29496359
468	Human	H19	lncRNA	curcumin (Cur)	breast cancer	tamoxifen-resistant breast cancer cells MCF-7/TAMR	curcumin treatment	"In addition, following treatment with curcumin for 48 h, H19 expression was decreased in a dose-dependent manner."	33179087
469	Human	H19	lncRNA	hesperetin	breast cancer	MDA-MB-231 and MCF-7 cells	hesperetin treatment	"?Hesperetin restored the expression of miR-486-5p, inhibited H19 lncRNA and ICAM-1 expression and selectively regressed mBC cell aggressiveness."	33882812
470	Human	H19	lncRNA	high glucose (HG)	inflammation	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
471	Human	H19	lncRNA	dexamethasone (DEX)	pulmonary inflammatory response	IL-1¦Â-treated A549 cells	dexamethasone (Dex) treatment	upregulated	33413425
472	Human	H19	lncRNA	IL-1¦Â	pulmonary inflammatory response	A549 cells	IL-1¦Â treatment	downregulated	33413425
473	Human	H19	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	upregulated	33716779
474	Human	H19	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4- LR1 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29703210
475	Human	H19	lncRNA	levonorgestrel (LNG)	adenomyosis	endometrial stromal cells (ESCs)	levonorgestrel (LNG) treatment	LNG ameliorates adenomyosis via lncRNA H19/miR-17/TLR4 pathway.	32921982
476	Human	H19	lncRNA	ultraviolet (UV) irradiation	age-related cataract (ARC)	Human lens epithelial cells (HLECs)	ultraviolet irradiation treatment	"the interaction among lncRNA H19, miR-29a and TDG is involved in early ARC lncRNA H19 could be a useful marker of early ARC and oxidative damage repair pathway of lncRNA H19/miR-29a/TDG may be a promising target for the treatment of ARC"	31282110
477	Human	H19	lncRNA	¦Â-glycerophosphate (¦Â-GP)	arterial calcification	vascular smooth muscle cells (VSMCs)	¦Â-glycerophosphate treatment	upregulated	32355545
478	Human	H19	lncRNA	astragaloside IV (AS-IV)	atherosclerosis (AS)	¦Â-Glycerophosphate-treated human vascular smooth muscle cells (VSMCs)	astragaloside (AS-IV) treatment	upregulated	30529164
479	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs).	oxidized low-density lipoprotein (ox-LDL) treatment	The level of H19 was increased and miR-148b expression was decreased in human AS patient serums and oxidized low-density lipoprotein (ox-LDL)-stimulated human aorta vascular smooth muscle cells (HA-VSMCs).	29415742
480	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"the expression of H19 in the serum of patients with AS and in the ox-LDL-treated human umbilical vein endothelial cells (HUVECs) was significantly upregulated. H19 knockdown by transfection with H19 siRNAs in ox-LDL-treated HUVECs remarkably promoted cell viability, suppressed the secretion of interleukin (IL)-1¦Â, IL-6, and tumour necrosis factor (TNF)-¦Á, decreased the expression of vascular cell adhesion molecule 1 (VCAM1), intercellular adhesion molecule 1 (ICAM1) and E-selectin, reduced levels of reactive oxygen species (ROS) and malondialdehyde (MDA), increased superoxide dismutase (SOD) levels, and reduced cell apoptosis."	31054453
481	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
482	Human	H19	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Our results showed that H19 expression was elevated in serum samples of patients with AS and ox-LDL-treated HA-VSMC.	33235026
483	Human	H19	lncRNA	¦Â-glycerophosphate (¦Â-GP)	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	¦Â-Glycerophosphate treatment	downregulated	30529164
484	Human	H19	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
485	Human	H19	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	downregulated	30251663
486	Human	H19	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin treatment	Quantitative real-time PCR (qRT-PCR) analyzed H19 expression in chemotherapy-resistant and sensitive breast cancer tissues.	32345117
487	Human	H19	lncRNA	huaier extract	breast cancer	"breast cancer cell lines MDA-MB-231, MDA-MB-468 and MCF7"		upregulated	29145193
488	Human	H19	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
489	Human	H19	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells; SK-BR-3 cells	tamoxifen treatment	lncRNA H19 in tamoxifen-resistance cells (MCF-7-R and SK-BR-3-R) was much higher than normal breast cancer cells (MCF-7 and SK-BR-3)	30519041
490	Human	H19	lncRNA	valproic acid (VPA)	apoptosis	A549 cells	VPA treatment	downregulated	28328238
491	Human	H19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia injury (CII)	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	H19 was upregulated whereas miR-19a-3p was downregulated in I/R tissues and OGD/R induced cells	32335212
492	Human	H19	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	28203482
493	Human	H19	lncRNA	platelet lysate (PL)	chondrogenesis	human umbilical cord-derived mesenchymal stem cells (hUCMSCs)	Platelet lysate (PL) treatment	PL induced chondrogenic differentiation of hUCMSCs by regulating the H19/miR-29b-3p/SOX9 axis	33058414
494	Human	H19	lncRNA	5-fluorouracil (5-Fu)	chondrosarcoma	human CC cell line JEG-3	5-fluorouracil (5-FU) treatment	upregulated	31020694
495	Human	H19	lncRNA	methotrexate (MTX)	chondrosarcoma	human CC cell line JEG-3	Methotrexate (MTX) treatment	upregulated	31020694
496	Human	H19	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	SW1116 cells; HCT8Fu cells	5-fluorouracil (5-FU) treatment	H19 expression was obviously upregulated both in primary 5-Fu resistant SW1116 cell line and acquired 5-Fu resistant HCT8Fu cell line.	30451820
497	Human	H19	lncRNA	hypoxia	colorectal cancer (CRC)	SW620 cells; HCT116 cells	hypoxia treatment	"During hypoxic stimulation, colorectal cancer cell lines upregulated the levels of both the lncH19 and its intragenic miR-675-5p."	32481626
498	Human	H19	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	downregulated	31362245
499	Human	H19	lncRNA	¦Á-Mangostin	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	¦Á-Mangostin treatment	¦Á-Mangostin restored the high glucose-induced inhibition of H19	31362245
500	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	upregulated	30815865
501	Human	H19	lncRNA	early growth response protein 1 (EGR1)	diabetic nephropathy (DN)	CIHP©\1 and HEK 293 cells	early growth response protein 1 (EGR1) treatment	upregulated	30815865
502	Human	H19	lncRNA	TGF-¦Â2	diabetic nephropathy (DN)	human dermal microvascular endothelial cells (HMVECs)	TGF-¦Â2 treatment	Knockdown of LncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT	32346618
503	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	H19 played an important role in regulating inflammatory processes in retinal endothelial cells under high-glucose condition through modulating miR-93/XBP1s axis.	31953562
504	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	LncRNA H19 inhibits high glucose-induced inflammatory responses of human retinal epithelial cells by targeting miR-19b to increase SIRT1 expression.	33022863
505	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	"Our results showed that lncRNA H19 and SIRT1 were reduced, while miR-19b was increased in ARPE-19 cells with HG condition."	33022863
506	Human	H19	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose conditions (25 mmol/l) treatment	downregulated	30612136
507	Human	H19	lncRNA	human MSC Growth Medium	cell differentiation	human adipose-derived stem cells (ASCs)	human MSC Growth Medium containing 10% MSCs-Qualified Fetal Bovine Serum (FBS)	upregulated	28662497
508	Human	H19	lncRNA	synthetic preimplantation factor (sPIF)	duchenne muscular dystrophy (DMD)	myoblast	Synthetic preimplantation factor (sPIF) treatment	upregulated	30692507
509	Human	H19	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	SKOV-3 cells; OVCAR3 cells	TGF-¦Â treatment	TGF-¦Â treatment upregulated H19 and downregulated miR-370-3p	29403287
510	Human	H19	lncRNA	epstein-barr virus (EBV)	Epstein-Barr virus (EBV) infection	human peripheral blood monocular cells	infecting with Epstein-Barr Virus	upregulated	27956246
511	Human	H19	lncRNA	cigarette smoke extract (CSE)	esophageal squamous cell carcinoma (ESCC)	SHEE cells	cigarette smoke?extract?(CSE) treatment	upregulated	32739445
512	Human	H19	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	GC tissues and cells	Helicobacter pylori (H. pylori) infection	upregulated	31787851
513	Human	H19	lncRNA	metformin (Met)	gastric cancer (GC)	AGS and SGC7901 cell lines	metformin treatment	downregulated	30192003
514	Human	H19	lncRNA	metformin (Met)	gastric cancer (GC)	SGC7901 cells	metformin treatment	downregulated	30192003
515	Human	H19	lncRNA	benzo(a)pyrene (BaP)	gene-methylation alterations by carcinogen BaP	16HBE cells; BEAS-2B cells; VA13 cells	benzo(a)pyrene (BaP) exposure	BaP-treated cells H19 expressions were increased in a dose- and time-dependent manner.	29772428
516	Human	H19	lncRNA	TGF-¦Â	glaucoma filtration surgery (GFS)	primary human Tenon's capsule fibroblasts (HTFs)	TGF-¦Â treatment	TGF-¦Â promoted the expression of H19 in HTFs and that suppression of H19 inhibited the effect of TGF-¦Â on HTFs	31877306
517	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	downregulated	31468534
518	Human	H19	lncRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH©\SY5Y and SNB©\19 cells	curcumin (CUR) treatment	downregulated	31468534
519	Human	H19	lncRNA	hypoxia	glioblastoma multiforme (GBM)	"human glioma cell lines U87, U251, Ln229, U373 and U118"	hypoxia treatment	upregulated	28327666
520	Human	H19	lncRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
521	Human	H19	lncRNA	"1,25-dihydroxyvitamin D 3 (calcitriol)"	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	"1,25-dihydroxyvitamin D 3 (calcitriol) treatment"	"1,25(OH) 2 D3 downregulated the expression of H19."	31468534
522	Human	H19	lncRNA	curcumin (Cur)	glioblastoma multiforme (GBM)	SH-SY5Y cells; SNB-19 cells	curcumin (CUR) treatment	CUR downregulated the expression of H19.	31468534
523	Human	H19	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-251 cells; M059 cells	Temozolomide (TMZ) treatment	H19 was significantly increased in U-251TMZ and M059JTMZ cells	29391808
524	Human	H19	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	downregulated	32998396
525	Human	H19	lncRNA	hepatitis B virus (HBV)	hepatoblastoma	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	30367502
526	Human	H19	lncRNA	apigenin	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	apigenin treatment	H19 was downregulated by API.	33345859
527	Human	H19	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	hepatoma carcinoma cells (Hep G2 and HCCLM3 cells)	hypoxia induce	upregulated	31196153
528	Human	H19	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU©\449; SNU©\387	sorafenib treatment	Long non-coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675	32627034
529	Human	H19	lncRNA	sorafenib or doxorubicin	hepatocellular carcinoma (HCC)	"human hepatoma cell lines (HepG2, Plc/Prf5, and Huh7)"	sorafenib or doxorubicin treatment	upregulated	31225433
530	Human	H19	lncRNA	hypoxia	hypoxia-induced injury	human hepatic sinusoidal endothelial cells (HHSEC)	hypoxia induce	upregulated	31082428
531	Human	H19	lncRNA	TGF-¦Â	idiopathic pulmonary fibrosis (IPF)	MRC-5 cells	TGF-¦Â treatment	the level of lncRNA H19 was significantly increased in activated fibroblasts compared with untreated cells	29411215
532	Human	H19	lncRNA	H2O2	intervertebral disc degeneration (IDD)	nucleus pulposus cells (NPCs)	H2O2 treatment	"In response to H2O2 treatment, H19 expression was dramatically increased."	29520849
533	Human	H19	lncRNA	cisplatin (DDP)	laryngeal squamous cell carcinoma (LSCC)	TU-177 cells; AMC-HN-8 cells	cisplatin treatment	H19/miR-107/HMGB1 axis sensitizes laryngeal squamous cell carcinoma to cisplatin by suppressing autophagy in vitro and in vivo.	33314408
534	Human	H19	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	hepatic stellate cells	carbon tetrachloride (CCl4) treatment	upregulated	32445757
535	Human	H19	lncRNA	hepatitis B virus X protein (HBx)	liver damage	L02 cells	hepatitis B X protein (HBx) treatment	"the expression of lncRNA H19 and miR-675 was upregulated in patients with chronic hepatitis B. Inhibition of lncRNA H19 or miR-675 in L02 cells increased cell viability, suppressed hepatitis B X protein (HBx)-induced cell apoptosis, inflammatory cytokine production, and oxidative stress, and remodelled energy metabolism."	31574452
536	Human	H19	lncRNA	first-generation EGFR tyrosine kinase inhibitors (TKIs)	lung cancer	HCC827 cells; PC9 cells	First-generation EGFR tyrosine kinase inhibitors (TKIs) treatment	downregulated	32439420
537	Human	H19	lncRNA	lipopolysaccharide (LPS)	lung injury	MRC-5 cells	lipopolysaccharide (LPS) treatment	upregulated	29315794
538	Human	H19	lncRNA	cisplatin (DDP)	melanoma	A375/DDP; M8/DDP cells	cisplatin treatment	lncRNA H19 could influence DDP-resistance by modulating the miR-18b/IGF axis in melanoma cells.	32265386
539	Human	H19	lncRNA	bortezomib	multiple myeloma (MM)	"Human MM cell lines H929, U266"	bortezomib? treatment	"H19 reduced cell sensitivity to the chemotherapeutic drug BTZ by working as a miRNA sponge to inhibit the expression of miR-29b-3p, enhance MCL-1 transcriptional translation and inhibit apoptosis."	30728351
540	Human	H19	lncRNA	hypoxia	multiple myeloma (MM)	MM cell lines (RPMI and MM1.S)	hypoxia induce	upregulated	30781795
541	Human	H19	lncRNA	hypoxia	myocardial infarction (MI)	peripheral blood	hypoxia treatment	Downregulated H19 and upregulated CYP1B1 were observed in MI patients.	33389498
542	Human	H19	lncRNA	angelica polysaccharide (AP)	neuroblastoma (NB)	SH-SY5Y cells	angelica polysaccharide (AP) treatment	downregulated	29465760
543	Human	H19	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; HCC4006 cells	gefitinib treatment	H19 was increased in gefitinib-resistant cells when compared to sensitive parent cells.	30542738
544	Human	H19	lncRNA	ghrelin	obesity-induced myocardial injury	human cardiac myocytes	ghrelin treatment	Ghrelin protects against PA-induced injury in cardiomyocytes via upregulating the expression of lncRNA H19.	32084395
545	Human	H19	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	31894109
546	Human	H19	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	A notably dose-dependent elevation of H19 levels was observed in LPS-treated C28/I2 cells.	30900425
547	Human	H19	lncRNA	mechanical stimulation	osteochondral activity	primary umbilical cord mesenchymal stem cells (U-MSCs)	mechanical stimulation	Exosomes derived from umbilical cord mesenchymal stem cells in mechanical environment show improved osteochondral activity via upregulation of LncRNA H19	33437630
548	Human	H19	lncRNA	"mechanical tension (10%, 0.5Hz)"	osteogenesis	human BMMSCs (hBMMSCs)	"mechanical tension (10%, 0.5Hz)"	upregulated	29253550
549	Human	H19	lncRNA	tension	osteogenic capability	Bone marrow mesenchymal stem cells (BMMSCs)	tension treatment	mechanical tension could enhance osteogenic differentiation and increase H19 expression	29253550
550	Human	H19	lncRNA	valproic acid (VPA)	ovarian cancer (OC)	A2780 cells	valproic acid (VPA) treatment	downregulated	29468525
551	Human	H19	lncRNA	high glucose (HG)	oxidative stress	HUVECs	high glucose (HG) treatment	positive modulation of miR29b and inhibition of H19 and VEGFA significantly attenuates high glucose-induced endothelial inflammation and oxidative stress.	31737629
552	Human	H19	lncRNA	sulforaphane (SFN)	pancreatic ductal adenocarcinoma (PDAC)	"human PDAC cell lines BxPc-3, AsPC-1, PANC-1, and MIA-PaCa2"	sulforaphane treatment	"Sulforaphane regulated the expression of all of five examined lncRNAs, but basal expression, biological function and inhibition of H19 were of highest significance"	33669381
553	Human	H19	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y Cells	1-methyl-4-phenylpyridinium (MPP+) treatment	H19 was downregulated in MPP+ treated SH-SY5Y cells.	32356199
554	Human	H19	lncRNA	perfluorooctane sulfonic acid (PFOS)	perfluorooctane sulfonic acid (PFOS)-induced placenta cell toxicity	HTR-8/SVneo cells	Perfluorooctane sulfonic acid (PFOS) treatment	upregulated	32738709
555	Human	H19	lncRNA	estrogen (ES)	postmenopausal osteoporosis (PMOP)	human bone marrow mesenchymal stem cells (BMSCs)	estrogen treatment	upregulated	33577975
556	Human	H19	lncRNA	metformin (Met)	preeclampsia (PE)	Trophoblast and HUVEC cells	Metformin (Met) treatment	downregulated	31203154
557	Human	H19	lncRNA	H2O2	premature senescence	C-kit(+) cardiac progenitor cells (CPCs)	H2 O2 treatment	downregulated	27062045
558	Human	H19	lncRNA	ginsenoside Rh2	cell proliferation	MC3T3-E1 cells	treat with Rh2	upregulated	28886306
559	Human	H19	lncRNA	dihydrotestosterone (DHT)	prostate cancer	LNCaP cells	dihydrotestosterone (DHT) treatment	downregulated	32356434
560	Human	H19	lncRNA	enzalutamide (Enz)	prostate cancer	LNCaP cells	enzalutamide treatment	upregulated	32356434
561	Human	H19	lncRNA	estradiol-17¦Â (E2)	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	estradiol-17¦Â (E2) treatment	upregulated	31426484
562	Human	H19	lncRNA	estradiol-17¦Â (E2)	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	estradiol-17¦Â (E2) treatment	downregulated	31426484
563	Human	H19	lncRNA	hypoxia	prostate cancer	prostate epithelial luminal cancer (PCa) cell lines (C27IM and C38IM)	hypoxia induce	upregulated	31426484
564	Human	H19	lncRNA	arsenite	lung fibrosis	THP-1 cells	arsenic (As) exposure	downregulated of H19 or upregulated of let-7a reversed the arsenite-induced M2 polarization of macrophages.	33162208
565	Human	H19	lncRNA	arsenite	lung fibrosis	THP-1 cells	arsenite exposure	upregulated	33162208
566	Human	H19	lncRNA	phorbol-12-myristate-13-acetate(PMA)	rheumatoid arthritis (RA)	peripheral blood mononuclear cells (PBMCs)	PMA treatment	The level of lncRNA H19 was higher in RA patients than in healthy volunteers	33540246
567	Human	H19	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	MH7A cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	32525617
568	Human	H19	lncRNA	lipopolysaccharide (LPS)	spinal cord injury (SCI)	human astrocyte (NHA)	lipopolysaccharide (LPS) treatment	lncRNA H19 expression was increased by LPS in NHAs.	32371379
569	Human	H19	lncRNA	melatonin	subarachnoid hemorrhage (SAH)	U87 cells; U251 cells	melatonin (MT) treatment	Melatonin increased H19 expression level by enhancing H19 transcriptional efficiency in a concentration-dependent manner.	29367587
570	Human	H19	lncRNA	estradiol	thyroid cancer (TC)	TPC-1cells; K-1 cells	estradiol (E2) treatment	upregulated	30389909
571	Human	H19	lncRNA	metformin (Met)	type 2 diabetes mellitus (T2DM)	ARK2 and MCF-7 cells	metformin treatment	downregulated	27775072
572	Human	H19	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
573	Human	H19	lncRNA	vincristine (VCR)	vincristine (VCR) resistance	RPMI 8226/VCR	vincristine (VCR) treatment	"The lnc-RNA H19/Akt pathway is closely related to the occurrence of VCR resistance in MM cells, and the downregulated of H19 can significantly improve the sensitivity of VCR in MM."	33040789
574	Human	H19	lncRNA	ginsenoside 20(S)-Rg3	warburg effect	SKOV3 cells; A2780 cells	ginsenoside 20(S)-Rg3 treatment	H19 was found to be decreased by 50% in 20(S)-Rg3-treated cells compared to control cells.	30481782
575	Human	H19	lncRNA	TGF-¦Â1	lung fibrosis	HBE and A549 cells	TGF-¦Â1 treatment	H19 knockdown attenuated pulmonary fibrosis via the regulatory network of lncRNA H19-miR-140-TGF-¦Â/Smad3 signaling	30988156
576	Human	H19	lncRNA	cigarette smoke extract (CSE)	smoke-induced lung injury (SILI)	A549 cells; H460 cells	cigarette smoke extract (CSE) treatment	upregulated	33523607
577	Human	H19	lncRNA	Rb3	smoke-induced lung injury (SILI)	A549 cells; H460 cells	Rb3 treatment	downregulated	33523607
578	Human	H19X	lncRNA	TGF-¦Â	fibrosis	primary dermal fibroblasts	TGF-¦Â treatment	upregulated	32603313
579	Human	HABON	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	human hepatocarcinoma cell SMMC-7721; Huh-7;MHCC-97 h;MHCC-97 L;Hep-G2; Hep-3B	hypoxia? treatment	"Among them, a hypoxia-activated lncRNA that we identified and termed Hypoxia-Activated BNIP3 Overlapping Non-coding RNA (HABON), was not only regulated by hypoxic-induced factor-1¦Á (HIF-1¦Á) but its expression increased significantly under hypoxia in tumour cells."	33478328
580	Human	HAGLR	lncRNA	lipopolysaccharide (LPS)	neuropathic pain (NP)	SH-SY5Y cells	lipopolysaccharide (LPS) treatment	HAGLR displayed high levels in spinal cords of CCI rats and in LPS treated SH-SY5Y cells.	33626373
581	Human	HAGLROS	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cell	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	31298038
582	Human	HAGLROS	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38?cells	lipopolysaccharide (LPS) treatment	LPS caused WI-38?cell injury and increased HAGLROS levels.	29673591
583	Human	HAND2-AS1	lncRNA	low glucose (LG)	osteosarcoma (OS)	MG-63 cells; SAOS- 2 cells; U-2OS cells; HOS cells; SW1353 cells	1mM glucose treatment	lncRNA HAND2-AS1 was significantly upregulated in glucose starved-cells	29637006
584	Human	HAS2-AS1	lncRNA	resveratrol	hyaluronan (HA) accumulation	human aortic smooth muscle cells (AoSMCs)	resveratrol (RS) treatment	downregulated	31932306
585	Human	HAS2-AS1	lncRNA	SIRT1 activators (SRT1720)	hyaluronan (HA) accumulation	human aortic smooth muscle cells (AoSMCs)	SIRT1 activators (SRT1720) treatment	downregulated	31932306
586	Human	HAS2-AS1	lncRNA	hypoxia	oral squamous cell carcinoma (OSCC)	"human OSCC cell lines, SCC-9 and CAL-27"	treat with hypoxia	upregulated	28485478
587	Human	HBBP1	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
588	Human	HCCL5	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human HCC cell lines HepG2, SMMC-7721 and HCCLM3"	TGF-¦Â1 treatment	upregulated	30482773
589	Human	HCG11	lncRNA	"oxidized low-density lipoprotein (ox-LDL), IL-6 and TNF-¦Á)"	atherosclerosis (AS)	human vascular smooth muscle cells (VSMCs)	"oxidation Low Lipoprotein (Ox-LDL), interleukin-6 (IL-6) and tumor necrosis factor ¦Á (TNF ¦Á) radiation"	LncRNA HCG11 regulates proliferation and apoptosis of vascular smooth muscle cell through targeting miR-144-3p/FOXF1 axis.	33008472
590	Human	HCG11	lncRNA	high glucose (HG)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	LncRNA HCG11/miR-26b-5p/QKI5 feedback loop reversed high glucose-induced proliferation and angiogenesis inhibition of HUVECs.	33128346
591	Human	HCG18	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
592	Human	HCP5	lncRNA	cisplatin (DDP)	breast cancer	MDA-MB-231 cells	cisplatin treatment	upregulated	31028999
593	Human	HCP5	lncRNA	geniposide (GEN)	diffuse large B-cell lymphoma (DLBCL)	OCI-LY7; OCI-LY3 cells	geniposide treatment	Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis	33162801
594	Human	HCP5	lncRNA	5-fluorouracil (5-FU)	gastric cancer (GC)	AGS cell; MKN45 cells	5-fluorouracil (5-FU) treatment	upregulated	32300102
595	Human	HCP5	lncRNA	oxaliplatin	gastric cancer (GC)	AGS cell; MKN45 cells	oxaliplatin (OXA) treatment	upregulated	32300102
596	Human	HCP5	lncRNA	TGF-¦Â	lung adenocarcinoma (LUAD)	A549 cell	TGF¦Â treatment	upregulated	31131047
597	Human	HCP5	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	PANC-1 and SW 1990 cells	gemcitabine (GEM) treatment	upregulated	31632071
598	Human	HEAL	lncRNA	human immunodeficiency virus (HIV)-1	acquired immune deficiency syndrome (AIDS)	"MT4, H9, E4 Jurkat, MDMs were prepared by culture of PBMCs cells"	?Human immunodeficiency virus (HIV)-1 infection treatment	upregulated	31551335
599	Human	HEIH	lncRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	serum; exosomes	hepatitis C virus (HCV) infection	"In patients with HCV-related HCC, lncRNA-HEIH expression in serum and exosomes was increased, but the ratio of lncRNA-HEIH expression in serum versus exosomes was decreased compared to patients with CHC."	29286922
600	Human	HEIH	lncRNA	paclitaxel (PTX)	endometrial cancer (EC)	"Human endometrial cancer cell lines (Ishikawa, HHUA) and hESC (Human endometrial stromal cells)"	paclitaxel (PTX) treatment	"LncRNA HEIH, the dysregulation of which involved in production of drug-resistance, was overexpressed in PTX-resistant endometrial cancer cells"	31650338
601	Human	HEIH	lncRNA	paclitaxel (PTX)	endometrial cancer (EC)	Ishikawa cells; HHUA cells	paclitaxel (PTX) treatment	Down-regulating lncRNA HEIH expression reversed the PTX-resistance of endometrial cancer cells through MAPK signaling pathway	31650338
602	Human	HEIH	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HCCLM3 cells; Huh7 cells	sorafenib treatment	HEIH was upregulated in sorafenib-resistant HCC tissues and cell lines	32821157
603	Human	HEIPP	lncRNA	hypoxia	preeclampsia (PE)	HTR-8 / Svneo cellsHTR-8/SVneo human trophoblast cells	hypoxia treatment	upregulated	33424915
604	Human	HIF1A-AS1	lncRNA	TGF-¦Â1	activation of hepatic stellate cells (HSCs)	HSCs LX-2	TGF-¦Â1 treatment	downregulated	25550811
605	Human	HIF1A-AS1	lncRNA	clopidogrel	cardiovascular disease (CVD)	HUVECs	clopidogrel treatment	clopidogrel rescues apoptosis and promotes proliferation of PA-induced damage model of HUVECs through inhibiting the mediator LncRNA HIF1A-AS1	25761653
606	Human	HIF1A-AS1	lncRNA	arecoline	oral submucous fibrosis (OSF)	fibrotic buccal mucosal fibroblasts (fBMFs)	arecoline treatment	Administration of arecoline induced the elevation of HIF1A-AS1 in BMFs.	31959495
607	Human	HIF1A-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human coronary artery endothelial cells (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Inhibition of long noncoding RNA HIF1A-AS2 confers protection against atherosclerosis via ATF2 downregulated.	33133688
608	Human	HIF1A-AS2	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
609	Human	HIF1A-AS2	lncRNA	cisplatin (DDP)	bladder cancer	T24 cells; 5937 cells; SW780 cells	cisplatin treatment	"hypoxia inducible factor 1¦Á-antisense RNA 2 (HIF1A-AS2), as a subtype-specific hypoxia inducible lncRNA, is upregulated in bladder cancer cells."	30216500
610	Human	HIF1A-AS2	lncRNA	cisplatin (DDP)	bladder cancer	"Bladder cancer cell lines, T24, 5637, and SW780"	cisplatin (DPP) treatment	upregulated	30216500
611	Human	HIF1A-AS2	lncRNA	hypoxia	ischemic stroke (IS)	HUVECs	hypoxia treatment	upregulated	28985553
612	Human	HIF1A-AS2	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocytes (HMCs)	hypoxia treatment	HIF1A-AS2 is upregulated in hypoxia-treated human cardiomyocytes (HMCs) compared with normal cardiomyocytes.	32222118
613	Human	HIFCAR	lncRNA	hypoxia	oral cancer	Hela cells; HEK293T cells	hypoxia conditions (1% oxygen)	upregulated	28639619
614	Human	HIPK1-AS	lncRNA	Sipi soup (SPS)	cervical cancer (CC)	HeLa	Sipi soup (SPS) treatment	"HIPK1-AS expression levels were upregulated in response to HeLa CM, but were decreased under SPS treatment"	29901171
615	Human	HITT	lncRNA	hypoxia	colorectal cancer (CRC)	HCT116 cells	hypoxia treatment	"The enrichment of HITT was significantly decreased, while that of the 5¡ä-UTR was increased in response to the hypoxic switch."	31700144
616	Human	HITT	lncRNA	Hypoxia	hypoxia-induced injury	HCT116 cells;HeLa cells	hypoxia induce	downregulated	31784651
617	Human	HITT	lncRNA	hypoxia	hypoxia-induced injury	HCT116 cells; Hela cells	hypoxia treatment	downregulated	31784651
618	Human	HMGCR	lncRNA	epigallocatechin-3-gallate (EGCG)	cholesterol metabolism	"human hepatoblastoma cell line, HepG2"	epigallocatechin-3-gallate (EGCG) treatment	downregulated	25563320
619	Human	HMGN1-1:12	lncRNA	nigericin	pancreatic cancer (PC)	PANC-2 cells	nigericin treatment	upregulated	32850392
620	Human	HOATIR	lncRNA	oestrogen (E2)	osteoporosis	HFOB and MG63 cells	oestrogen (E2) treatment	a dose-dependent upregulated of HOTAIR was observed in cells treated with oestrogen	33733597
621	Human	HORAS5	lncRNA	cabazitaxel	prostate cancer	LNCaP cells; DU145 cells	cabazitaxel treatment	HORAS5 stimulates the expression of BCL2A1 thereby decreasing apoptosis and enhancing cabazitaxel resistance in CRPC cells.	32618200
622	Human	HOST2	lncRNA	sinomenine hydrochloride (SH)	ovarian cancer (OC)	"Human ovarian epithelial cell line (HOEpiC), Caov3 and SKOV3 cells"	sinomenine hydrochloride (SH) treatment	downregulated	31701766
623	Human	HOST2	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	Hs766T cells; AsPC-1 cells	gemcitabine (GEM) treatment	upregulated	30406400
624	Human	HOST2	lncRNA	gemcitabine (GEM)	pancreatic neoplasms	Hs766T; AsPC-1 cells	gemcitabine treatment	down- expression of HOST2 observably enhanced sensibility of pancreatic cancer cell lines to gemcitabine.	30406400
625	Human	HOTAIR	lncRNA	metformin (Met)	breast cancer	MDA-MB-231 breast cancer cells	?metformin treatment	"Reduction in the expression of vimentin, ¦Â-catenin, and HOTAIR was detected as the result of metformin treatment"	33164274
626	Human	HOTAIR	lncRNA	tanshinone IIA (Tan IIA)	acetaminophen (APAP)-induced liver injury (AILI)	L02 cells	Tanshinone IIA (Tan IIA) treatment	Tan IIA induced the expression of Nrf2-MRP2/4 pathway by downregulating HOTAIR	32777703
627	Human	HOTAIR	lncRNA	all-trans retinoic acid (ATRA)	acute myeloid leukemia (AML)	HL-60 cells	all-trans retinoic acid (ATRA) treatment	upregulated	33241756
628	Human	HOTAIR	lncRNA	ethanol (EtOH)	alcohol-induced tumor angiogenesis	HUVECs endothelial extracellular vesicles (EVs)	ethanol treatment	upregulated in endothelial extracellular vesicles (EVs)	29062004
629	Human	HOTAIR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	HOTAIR was significantly increased in THP-1 cells treated with ox-LDL.	29698635
630	Human	HOTAIR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human macrophages THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	HOTAIR was significantly increased in THP-1 cells treated with ox-LDL.	30187491
631	Human	HOTAIR	lncRNA	sunitinib (SU)	autophagy	786-O-R cells; ACHN-R cells	sunitinib treatment	HOTAIR expression in sunitinib-resistant cells is higher than that in parental cells	32760216
632	Human	HOTAIR	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
633	Human	HOTAIR	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
634	Human	HOTAIR	lncRNA	bisphenol-A (BPA) and diethylstilbestrol (DES)	breast cancer	human breast cancer cells (MCF7)	BPA and DES treatment	upregulation	24533973
635	Human	HOTAIR	lncRNA	delphinidin	breast cancer	"Breast cancer cells MDA©\MB©\231, MCF©\7, and MDA©\MB©\453 w"	delphinidin treatment	downregulated	31325197
636	Human	HOTAIR	lncRNA	estradiol	breast cancer	breast cancer cells	estradiol treatment	HOTAIR is crucial for cell growth and viability and its knockdown induced apoptosis in breast cancer cells	23375982
637	Human	HOTAIR	lncRNA	hypoxia	breast cancer	MDA-MB-231 cells	hypoxia treatment	HOTAIR levels was upregulated after 48 h hypoxia relative to normoxia in breast cancer cell lines.	32466537
638	Human	HOTAIR	lncRNA	ionizing radiation (IR)	breast cancer	breast cancer cells and tissues	ionizing radiation treatment	upregulated	30429228
639	Human	HOTAIR	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
640	Human	HOTAIR	lncRNA	hypoxia	tumorigenesis	"colon adenocarcinoma,cervical cancer,breast cancer,neuroblastoma"	hypoxia treatment	downregulated	28756022
641	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	castration-resistant prostate cancer (CRPC)	castration-resistant prostate cancer (CRPC) cells	Polyphyllin I (PPI) treatment	downregulated	29221985
642	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	castration-resistant prostate cancer (CRPC)	DU145 cells; PC3 cells	polyphyllin I (PPI) treatment	PPI also decreased HOTAIR expression	29807357
643	Human	HOTAIR	lncRNA	LiCl	cervical cancer (CC)	radioresistant HeLa cells	LiCl treatment	"the short interfering ribonucleic acid (siRNA)-mediated knockdown of HOTAIR disturbed the Wnt signaling pathway, reduced autophagy, inhibited EMT, decreased cell proliferation, and induced apoptosis in radioresistant HeLa cells."	30367473
644	Human	HOTAIR	lncRNA	direct-acting antivirals (DAAs)	chronic hepatitis C virus (HCV) infection	polymorphonuclear leucocytes (PMNLs)	direct-acting antivirals (DAAs) treatment	upregulated	33074585
645	Human	HOTAIR	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	31128153
646	Human	HOTAIR	lncRNA	propofol (PPF)	colorectal cancer (CRC)	LOVO cells; SW480 cells	propofol treatment	Effects of propofol on colon cancer metastasis through STAT3/HOTAIR axis by activating WIF-1 and suppressing Wnt pathway	31953926
647	Human	HOTAIR	lncRNA	ionizing radiation (IR)	colorectal cancer (CRC)	SW480 cells; HCT116 cells	ionizing radiation (IR) treatment	HOTAIR expression was markedly upregulated in plasma from CRC patients after radiotherapy and CRC cells after irradiation.	32144238
648	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	cytokines expression	"C3A, HepG2, and SMMC-7721"	lipopolysaccharide (LPS) treatment	HOTAIR exerted a crucial role in cytokines expression by activating JAK/STAT and NF-¦ÊB.	31621909
649	Human	HOTAIR	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	downregulated	30542437
650	Human	HOTAIR	lncRNA	cisplatin (DDP)	endometrial cancer (EC)	arental Ishikawa cells	cisplatin treatment	downregulated	28721581
651	Human	HOTAIR	lncRNA	TGF-¦Â1	endometrial fibrosis	endometrial stromal cells (ESCs)	TGF-¦Â1 treatment	HOTAIR was significantly elevated in ESCs that had been treated with TGF-¦Â1	33313721
652	Human	HOTAIR	lncRNA	metformin (Met)	epithelial-mesenchymal transition (EMT)	MDA-MB-231 cells	metformin (Met) treatment	downregulated	33164274
653	Human	HOTAIR	lncRNA	5-fluorouracil (5-Fu)	esophageal cancer (EC)	TE-1 cells	5-fluorouracil (5-FU) treatment	LncRNA HOTAIR-mediated MTHFR methylation inhibits 5-fluorouracil sensitivity in esophageal cancer cells.	32653028
654	Human	HOTAIR	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U-87 cells; A172 cells	temozolomide (TMZ) treatment	upregulated	32279420
655	Human	HOTAIR	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	A172 ; LN229	temozolomide (TMZ) treatment	Exosomal lncRNA HOTAIR mediated TMZ resistance through miR-519a-3p/RRM1 axis in GB	32721218
656	Human	HOTAIR	lncRNA	polyphyllin I (PPI)	growth of CRPC cells	castration-resistant prostate cancer cells	Polyphyllin I (PPI) treatment	downregulated	29221985
657	Human	HOTAIR	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	hepatic insulin resistance	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30536334
658	Human	HOTAIR	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2; Huh7	hypoxia treatment	knockdown of HOTAIR suppressed glycolysis by regulating miR-130a-3p and HIF1A in HCC cells treated by hypoxia	32062551
659	Human	HOTAIR	lncRNA	orafenib	hepatocellular carcinoma (HCC)	Huh7; Hep3B; SNU-387; SNU-449	orafenib treatment	Lnc HOTAIR could increase sorafenib resistance in HCC by inhibiting miR-217.	32462038
660	Human	HOTAIR	lncRNA	taxol	hepatocellular carcinoma (HCC)	HepG2/Taxol; SMMC7721/Taxol	Taxol treatment	LncRNA HOTAIR contributes Taxol-resistance of hepatocellular carcinoma cells via activating AKT phosphorylation by down-regulating miR-34a	32700738
661	Human	HOTAIR	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
662	Human	HOTAIR	lncRNA	cigarette smoke extract (CSE)	inflammation	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	25447409
663	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	inflammation	"L02, C3A, HepG2, and SMMC-7721 cells."	lipopolysaccharide (LPS) treatment	"LPS induced the overexpression of HOTAIR in L02, C3A, HepG2, and SMMC-7721 cells."	31621909
664	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	kidney damage	HK-2 cells	lipopolysaccharide (LPS) treatment	HOTAIR was also upregulated in LPS-induced human renal tubular epithelial cells (HK-2).	30130540
665	Human	HOTAIR	lncRNA	X-rays	laryngeal cancer	"Laryngeal cancer cell lines TU212, LLN and TU686"	X-ray radiation treatment	HOTAIR overexpression reduced laryngeal cancer cell radiosensitivity	31849488
666	Human	HOTAIR	lncRNA	TGF-¦Â1	multidrug resistance (MDR)	The HepG2 cells	transforming growth factor-¦Â1 (TGF-¦Â1) treatment	upregulated	30698830
667	Human	HOTAIR	lncRNA	doxorubicin (DOX)	multidrug resistance (MDR)	K562/A02 cells	doxorubicin treatment	Overexpression of LncRNA-HOTAIR promotes chemoresistance in acute leukemia cells.	33425105
668	Human	HOTAIR	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NCI-H1299 cells	criplatin treatment	upregulated	29805510
669	Human	HOTAIR	lncRNA	crizotinib	non-small cell lung cancer (NSCLC)	A549?cells	crizotinib treatment	upregulated	29470986
670	Human	HOTAIR	lncRNA	type I collagen (Col-1)	non-small cell lung cancer (NSCLC)	NSCLC cells	type I collagen (Col-1) treatment	upregulated	23668363
671	Human	HOTAIR	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1650 cells	Xiaoji decoction (XJD) treatment	downregulated	30910577
672	Human	HOTAIR	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	apoptosis	nucleus pulposus cell (NPC)	tumor necrosis factor alpha (TNF-¦Á) treatment	31 HOTAIR is downregulated in NPCs induced by TNF-¦Á	30138895
673	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human articular chondrocyte C28/I2 cells	lipopolysaccharide (LPS) treatment	upregulated	31966787
674	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	CHON-001 chondrocytes	lipopolysaccharide (LPS) treatment	"HOTAIR and SGTB were upregulated, while miR-1277-5p was downregulated in OA cartilages and LPS-stimulated CHON-001 chondrocytes."	33721916
675	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteosarcoma (OS)	The cell lines MG63 and Saos-2	lipopolysaccharides (LPS) treatment	upregulated	30240881
676	Human	HOTAIR	lncRNA	lipopolysaccharide (LPS)	osteosarcoma (OS)	MG63 and Saos-2 cells	lipopolysaccharides (LPS) treatment	upregulated	30240881
677	Human	HOTAIR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	SKOV3 cells; A2780 cells	cisplatin treatment	HOTAIR was upregulated in DDP-resistant cells.	32349783
678	Human	HOTAIR	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	pancreatic cancer stem-like cells (CSCs)	gemcitabine treatment	upregulated	29201179
679	Human	HOTAIR	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	28445933
680	Human	HOTAIR	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	HOTAIR promoted MPP+-induced neuronal injury via modulating the miR-874-5p/ATG10 axis in SK-N-SH cells.	33013268
681	Human	HOTAIR	lncRNA	TGF-¦Â2	posterior capsular opacification (PCO)	SRA01/04 cells	transforming growth factor ¦Â2 (TGF-¦Â2) treatment	TGF-¦Â2 induces EMT in SRA01/04 cells via the upregulated of the long non-coding RNA (lncRNA) HOTAIR	30239553
682	Human	HOTAIR	lncRNA	androgen	prostate cancer	prostate cancer cell	low androgen treatment	upregulated	26411689
683	Human	HOTAIR	lncRNA	bufalin	prostate cancer	prostate cancer DU145 and PC3 cells	bufalin treatment	downregulated	31028291
684	Human	HOTAIR	lncRNA	radiation	radiation resistance of breast cancer (BRCA)	MCF©\7; T47D; LM©\MCF©\7; BT©\474;SKBR©\3; MDA©\MB©\231	radiation treatment	LncRNA HOTAIR facilitates the expression of HSPA1A by sequestering miR-449b-5p post-transcriptionally and thereby endows BRCA with radiation resistance	32374522
685	Human	HOTAIR	lncRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	upregulated	29717517
686	Human	HOTAIR	lncRNA	arsenite	toxicity of arsenic	A549 cells	arsenic (As) exposure	upregulated	32816178
687	Human	HOTAIR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
688	Human	HOTAIR	lncRNA	ultraviolet (UV) irradiation	UVB-induced apoptosis and inflammatory	HaCaT cells	UVB treatment	UVB also promoted the expression of HOTAIR	29898032
689	Human	HOTTIP	lncRNA	platelet derived growth factor-BB (PDGF-BB)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	platelet derived growth factor-BB (PDGF-BB) treatment	The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB	29058802
690	Human	HOTTIP	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	tumor necrosis factor alpha (TNF-¦Á) treatment	The expression level of HOTTIP was upregulated in the proliferating endothelial cells induced by TNF-¦Á or PDGF-BB	29058802
691	Human	HOTTIP	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
692	Human	HOTTIP	lncRNA	"TNF-¦Á,PDGF-BB"	coronary artery disease (CAD)	HU-VECs	TNF-¦Á or PDGF-BB treatment	upregulated	29058802
693	Human	HOTTIP	lncRNA	hypoxia	epithelial-mesenchymal transition (EMT)	U87 and U251 cell lines	hypoxia treatment	upregulated	28886531
694	Human	HOTTIP	lncRNA	salinomycin	gastric cancer (GC)	SGC7901/cisplatin (CDDP) gastric cancer cell	salinomycin treatment	downregulated	30882398
695	Human	HOTTIP	lncRNA	hypoxia	non-small cell lung cancer (NSCLC)	two NSCLC cell lines (A549 and H1299)	hypoxia induce	upregulated	31422060
696	Human	HOTTIP	lncRNA	IL-1¦Â	osteoarthritis (OA)	cultured chondrocytes	interleukin-1¦Â (IL-1¦Â) treatment	upregulated	31508417
697	Human	HOTTIP	lncRNA	IL-1¦Â	osteoarthritis (OA)	OA cartilage tissues	IL-1¦Â treatment	"The expression of HOTTIP and FRK were upregulated, while miR-663a was downregulated in OA cartilage tissues."	33435956
698	Human	HOTTIP	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
699	Human	HOTTIP	lncRNA	cisplatin (DDP)	pancreatic cancer (PC)	PANC-1 cells; HS766T cells; AsPC-1 cells	cisplatin treatment	upregulated	32280243
700	Human	HOX	lncRNA	TGF-¦Â1	liver fibrosis	hepatic stellate cells (HSCs)	TGF-¦Â1 treatment	upregulated	27979710
701	Human	HOXA11-AS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
702	Human	HOXA11-AS	lncRNA	calcium oxalate (CaOx)	calcium oxalate (CaOx) nephrolithiasis	HK-2 cell	calcium oxalate (CaOx) treatment	HOXA11-AS mediated CaOx crystal-induced renal inflammation via the miR-124-3p/MCP-1 axis.	31878844
703	Human	HOXA11-AS	lncRNA	calcium oxalate monohydrate (COM)	calcium oxalate (CaOx) nephrolithiasis	calcium oxalate monohydrate (COM)-treated HK-2 cells	calcium oxalate monohydrate (COM)-treatment	HOXA11-AS was significantly upregulated in calcium oxalate monohydrate (COM)-treated HK-2 cells.	31680444
704	Human	HOXA11-AS	lncRNA	propofol (PPF)	colorectal cancer (CRC)	Colo205; SW620 cells	"Propofol (2,6-diisopropylphenol) treatment"	Propofol suppresses colorectal cancer tumorigenesis by modulating the HOXA11-AS-let-7i-ABCC10 regulatory network	31013434
705	Human	HOXA11-AS	lncRNA	propofol (PPF)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B cells	propofol treatment	Propofol suppressed the expression of HOXA11-AS in HCC cells	32705160
706	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells; H157 cells	cisplatin treatment	The expression of HOXA11-AS was much stronger in cisplatin-resistant LUAD cells.	30099826
707	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	lung cancer	A549 cell line	cisplatin treatment	upregulated	31144606
708	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	C666-1 cells; HNE1 cells	cisplatin treatment	elevated HOXA11-AS and reduced miR-454-3p were found in NPC tissue and cisplatin-resistant NPC cells.	33115978
709	Human	HOXA11-AS	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	"The normal human oral keratinocyte (NHOK) and OSCC cell lines, including TSCCA, CAL-27, SCC-9, and Tca8113"	cisplatin treatment	upregulated	31275988
710	Human	HOXA6-AS	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	downregulated	30441874
711	Human	HOXA-AS2	lncRNA	prednisone	acute lymphoblastic leukemia (ALL)	Jurkat cells; CEM/C1 cells	prednisone treatment	lncRNA HOXA-AS2 was highly expressed both in prednisone insensitive ALL cell lines.	30551418
712	Human	HOXA-AS2	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	upregulated	30466095
713	Human	HOXA-AS2	lncRNA	adriamycin (ADR)	breast cancer	T47D cells	adriamycin (ADR) treatment	upregulated	32163894
714	Human	HOXA-AS2	lncRNA	oxidized low density lipoprotein (ox-LDL)	human aortic vascular smooth muscle cells (HA-VSMCs) injury	human aortic vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31957850
715	Human	HOXA-AS3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32982172
716	Human	HOXD10-35	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
717	Human	HOXD-AS2	lncRNA	TGF-¦Â1	glioblastoma multiforme (GBM)	glioblastoma cells	TGF-¦Â1 treatment	?We identified and characterized 2 lncRNAs (H19 and HOXD-AS2) that were upregulated by TGF-¦Â1 through Smad signaling	32813021
718	Human	HSRL	lncRNA	tanshinone IIA (Tan IIA)	hypertrophic scars (HS)	human skin fibroblast (HSF)	tanshinone IIA (TSIIA) treatment	TSIIA treatment for 24h inhibited HSRL and SNX9 gene transcription in comparison with TGF-¦Â1 group	33049375
719	Human	HTR2A-AS1	lncRNA	patrinia herba aqueous extract	hepatocellular carcinoma (HCC)	MHCC97-H cells	P. herba aqueous extract treatment	"P herba aqueous extract may inhibit the proliferation, invasion and migration of hepatocellular carcinoma cells by up-regulating the expression of HTR2A-AS1 in hepatocellular carcinoma cells and induce apoptosis"	32538757
720	Human	HULC	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
721	Human	HULC	lncRNA	prostaglandin E1 (PGE1)	contrast-induced nephropathy (CIN)	THP-1 cells; peripheral blood samples	PGE1 treatment	HULC was positively correlated with the expression of PTGS1 and PGE1	32678165
722	Human	HULC	lncRNA	¦Â-Elemene	diffuse large B-cell lymphoma (DLBCL)	SU-DHL-8; SU-DHL-10	¦Â-Elemene treatment	¦Â-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway	32010942
723	Human	HULC	lncRNA	"oxaliplatin, 5-fluorouracil and pirarubicin (THP)"	hepatocellular carcinoma (HCC)	"human HCC cell lines including HepG2, Hep3B, PLC, Huh7, smmc7721 and hepatic cell line L02 w"	THP treatment	upregulated	28166203
724	Human	HULC	lncRNA	ultraviolet (UV) irradiation	hepatocellular carcinoma (HCC)	HaCaT cells	Ultraviolet radiation b (UVB) treatment	upregulated	29803927
725	Human	HULC	lncRNA	ionizing radiation (IR)	prostate cancer	PC3 cells; LNCaP cells	ionizing radiation (IR) treatment	upregulated	29694502
726	Human	HULC	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
727	Human	HULC	lncRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"LPS impaired cell viability, and promoted cell apoptosis, inflammatory response and oxidative stress in HUVECs by regulating HULC/miR-204-5p/TRPM7 axis."	32484206
728	Human	HUR1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	29790592
729	Human	HZ02	lncRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	miscarriage	trophoblast Swan 71 and HTR-8/SVneo cells	"BPDE (benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide) treatment"	"If trophoblast cells are exposed to BPDE, both miR-hz02 and lnc-HZ02 are upregulated"	33851497
730	Human	HZ08	lncRNA	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE)"	recurrent miscarriage (RM)	Swan 71 and HTR-8/SVneo cell lines	"benzo(a)pyren-7,8-dihydrodiol-9,10-epoxide (BPDE) treatment"	upregulated	33864160
731	Human	IGF2AS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells	aurora kinase inhibitor (CCT137690) treatment	upregulated	31319040
732	Human	IGF2AS	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
733	Human	IGF2-AS	lncRNA	high glucose (HG)	apoptosis	"human retinal pigment epithelial cell line, ARPE-19"	high glucose (HG) treatment	"High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells."	31317640
734	Human	IGF2-AS	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	"human retinal pigment epithelial cell line, ARPE-19"	high glucose (HG) treatment	"High-glucose induced apoptosis in ARPE-19 cells, and upregulated IGF-2AS in a dose-dependent manner. SiRNA-mediated IGF2-AS downregulated ameliorated apoptosis, upregulated IGF2/AKT and decreased Casp-9, in high-glucose-treated ARPE-19 cells."	31317640
735	Human	IHAT	lncRNA	hypoxia	breast cancer	MDA-MB-231 cells	hypoxia treatment	LncIHAT Is Induced by Hypoxia-Inducible Factor 1 and Promotes Breast Cancer Progression	33380467
736	Human	IL7AS	lncRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	upregulated	30619270
737	Human	lnc-IL7R	lncRNA	lipopolysaccharide (LPS)	inflammation	human monocytic cell line	lipopolysaccharide (LPS) treatment	upregulated	24723426
738	Human	INXS	lncRNA	three apoptosis	apoptosis	786-O kidney tumor cell line	three apoptosis treatment	upregulation	24992962
739	Human	IPAN	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31189112
740	Human	IRAK3-3	lncRNA	enterovirus 71 (EV71)	apoptosis	Human rhabdomyosarcoma cells (RD)	EV71 infection	downregulated	31099182
741	Human	IRF1-AS	lncRNA	IFNs	oesophageal squamous cell carcinoma (ESCC)	The ESCC cell lines	Interferons (IFNs) treatment	upregulated	31173852
742	Human	ISG20	lncRNA	influenza A virus (IAV)	antiviral immune response	A549 and HEK293T cells	influenza A virus (IAV) infection	upregulated	29899085
743	Human	ISR	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	A549 cells	influenza A virus (IAV) infection	upregulated	31623059
744	Human	IUR	lncRNA	imatinib	leukemia	Abl-transformed primary bone marrow cells	imatinib treatment	Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment.	30961617
745	Human	JHDMD1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
746	Human	KAT14	lncRNA	"DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester)"	tongue squamous cell carcinoma (TSCC)	CAL-27 cell; SCC-9 cells	"DAPT (N-[(3,5-Difluorophenyl)-acetyl]-L-al- anyl-2-phenyl]-glycine-1,1-dimethylethylester) treatment"	"Proliferation was inhibited after treatment with DAPT, and the expression of lncRNA-KAT14 was upregulated."	31957832
747	Human	KB-1980E6.3	lncRNA	hypoxia	breast cancer	BT549 cells	hypoxia induce	"We identified a hypoxia-induced long noncoding RNA (lncRNA) KB-1980E6.3, which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor prognosis of breast cancer patients."	33469161
748	Human	KCNK15-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31572012
749	Human	KCNK15-AS1	lncRNA	chidamide	gastric cancer (GC)	"BGC-823 cells, SCG7901 cells"	chidamide treatment	upregulated	31572012
750	Human	KCNQ1OT1	lncRNA	acetaminophen (APAP)	acetaminophen (APAP)-induced liver injury (AILI)	HepaRG cells	acetaminophen (APAP) treatment	downregulated	32779042
751	Human	KCNQ1OT1	lncRNA	TGF-¦Â2	age-related cataract (ARC)	SRA01/04 cells	TGF-¦Â2 traetment treatment	"miR-29c-3p regulated FOS to repress EMT, cell proliferation and facilitate apoptosis in TGF-¦Â2-treated SRA01/04 cells mediated by KCNQ1OT1"	32534225
752	Human	KCNQ1OT1	lncRNA	phenytoin	antiepileptic drug (AED) resistance	human brain microvascular endothelial cells (HBMECs)	phenytoin treatment	upregulated	31920517
753	Human	KCNQ1OT1	lncRNA	H2O2	cataract	SRA01/04 cell lines	H2O2 treatment	upregulated	28535504
754	Human	KCNQ1OT1	lncRNA	H2O2	cataract	lens epithelial cells (SRA01/04)	H2O2 treatment	We found that KCNQ1OT1 was upregulated in cataract anterior lens capsule samples and H2O2-induced SRA01/04 cells.	33744257
755	Human	KCNQ1OT1	lncRNA	TGF-¦Â2	cataract	SRA01/04 cells	TGF-¦Â2 treatment	KCNQ1OT1 was upregulated in transforming growth factor (TGF)-¦Â2-treated SRA01/04 cells	29749509
756	Human	KCNQ1OT1	lncRNA	cisplatin (DDP)	colorectal cancer (CRC)	HCT8 cells	cisplatin treatment	"Compared with CRC cell line HCT8, the cisplatin-resistant CRC cell line HCT8/DDP exhibited a higher expression level of KCNQ1OT1."	32757174
757	Human	KCNQ1OT1	lncRNA	methotrexate (MTX)	colorectal cancer (CRC)	The human CRC cell line HT29 and Caco2 cells	methotrexate (MTX) treatment	KCNQ1OT1 enhanced the MTX resistance of CRC cells by regulating miR-760-mediated PPP1R1B expression via the cAMP signalling pathway	30997746
758	Human	KCNQ1OT1	lncRNA	oxaliplatin	colorectal cancer (CRC)	HCT116 ; SW480 cells	oxaliplatin (L-OHP) treatment	upregulated	31040703
759	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	cardiac tissues	high glucose (HG) treatment	Kcnq1ot1 expression was dramatically elevated in cardiac tissue of the diabetic mice.	30250027
760	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	upregulated	30355944
761	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	SRA01/04 cells	high glucose treatment	upregulated	32950535
762	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic corneal endothelial keratopathy	HCEC-B4G12 cells	high glucose (HG) treatment	upregulated	31693400
763	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human glomerular mesangial cells (HGMCs) cells; human renal glomerular endothelial cells (HRGECs)	high glucose (HG) treatment	KCNQ1OT1 was upregulated in DN patients and high glucose-induced HGMCs and HRGECs.	32905431
764	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	KCNQ1OT1 expression was increased and miR-18b expression was decreased in DN patients and HG-challenged HMCs.	32989627
765	Human	KCNQ1OT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells	high glucose treatment	upregulated	30784065
766	Human	KCNQ1OT1	lncRNA	sevoflurane (SEV)	glioblastoma multiforme (GBM)	A172 cells; U251 cells	sevoflurane (Sev) treatment	"KCNQ1OT1 knockdown mediated the role of Sev in glioma cell proliferation, apoptosis, migration, and invasion both in vitro and in vivo through miR-146b-5p/STC1 pathway"	32996777
767	Human	KCNQ1OT1	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells	cisplatin treatment	LncRNA KCNQ1OT1 targets miR-338-3p to regulate the survival rate and autophagy of SK-HEP-1/DDP cells and improve the cisplatin sensitivity of SK-HEP-1/DDP cells.	32538770
768	Human	KCNQ1OT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	SK-HEP-1 cells; Huh-7 cells; HCC tissues	sorafenib treatment	KCNQ1OT1 was found to be upregulated in sorafenib-resistant HCC tissues and cells	33000204
769	Human	KCNQ1OT1	lncRNA	¦Â-glycerophosphate + ascorbic acid + dexamethasone	osteogenesis	human Bone marrow mesenchymal stem cells (BMSCs)	"10 mM ¦Â-glycerophosphate (Sigma-Aldrich, USA), 200 ¦ÌM ascorbic acid (Sigma-Aldrich, USA) and 100 nM dexamethasone (Sigma-Aldrich, USA) treatment"	KCNQ1OT1 was significantly upregulated during the process of osteogenic induction while miR-214 was contrarily downregulated	30703347
770	Human	KCNQ1OT1	lncRNA	high glucose (HG)	oxidative stress	HK-2 cells	high glucose (HG) treatment	"downregulated of KCNQ1OT1 inhibited the inflammation, oxidative stress and pyroptosis of HG-induced HK-2 cells by up-regulating the expression of miR-506-3p."	32104033
771	Human	KRAL	lncRNA	5-fluorouracil (5-Fu)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	5-fluorouracil (5-FU) treatment	KRAL was significantly decreased in HepG2/5-FU and SMMC-7721/5-FU cells.	30119680
772	Human	LASI	lncRNA	lipopolysaccharide (LPS)	allergic asthma (AA)	human airway epithelial cells (HAECs)	lipopolysaccharides (LPS) treatment	upregulated	33122732
773	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE)	DNA damage	Beas-2B cells	cigarette smoke extract (CSE) treatment	upregulated	30509493
774	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	Beas-2B cells	cigarette smoke extract (CSE) treatment	"With increased concentration of exposure to CSE, there was higher expression of LCPAT1."	30509493
775	Human	LCPAT1	lncRNA	cigarette smoke extract (CSE) and particulate matter (PM2.5)	lung cancer	H1299 cells; H520 cells	cigarette smoke extract (CSE) and PM2.5 exposure	LCPAT1 was upregulated after the treatment of CSE and PM2.5.	29913439
776	Human	LET	lncRNA	gemcitabine (GEM)	urinary bladder cancers (UBCs)	"human UBC cell lines, T24, 5637, J82, SW780, BIU87, ScaBER and UMUC3"	treat with gemcitabine	downregulated	28839463
777	Human	LGALS9	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
778	Human	LIFR-AS1	lncRNA	photodynamic therapy (PDT)	colorectal cancer (CRC)	HCT116 cells	PDT treatment	upregulated	29807108
779	Human	LILRP2	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
780	Human	LIN28B-AS1	lncRNA	lipopolysaccharide (LPS)	inflammatory response	?THP-1 macrophages	lipopolysaccharide (LPS) treatment	upregulated	31537384
781	Human	LINC00114	lncRNA	X-rays	nasopharyngeal carcinoma (NPC)	5-8F; SUNE-1 cells	X-ray treatment	LINC00114 contributed to NPC development and radioresistance through the regulation of ERK/JNK signaling pathway and the mediation of miR-203	32196600
782	Human	LINC00115	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
783	Human	LINC00115	lncRNA	TGF-¦Â	tumorigenicity	glioma stem-like cell (GSC)	TGF-¦Â treatment	upregulated	31599491
784	Human	LINC00115-201	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
785	Human	LINC00152	lncRNA	oxidized low density lipoprotein (ox-LDL)	cardiovascular disease (CVD)	human umbilical vein VECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	29156700
786	Human	LINC00152	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial cells 16HBE	cigarette smoke extract (CSE) exposure	upregulated	30289508
787	Human	LINC00160	lncRNA	paclitaxel (PTX)	breast cancer	breast cancer (BC) tissues	paclitaxel (PTX) treatment	downregulated	32652877
788	Human	LINC00162	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	?gastric cancer cell lines	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	"LINC00162, as highly and frequently expressed in gastric cancer cell lines sensitive to 5-aza-2'-deoxycytidine (5-aza-dC)."	30914798
789	Human	LINC00173	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
790	Human	LINC00173	lncRNA	cisplatin (DDP)	small-cell lung cancer (SCLC)	NCI-H69 cells	cisplatin treatment	Linc00173 promotes chemoresistance and progression of small cell lung cancer by sponging miR-218 to regulate Etk expression	31477834
791	Human	LINC00174	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells; U87 cells	temozolomide (TMZ) treatment	LINC00174 downregulated decreases chemoresistance to temozolomide in human glioma cells by regulating miR-138-5p/SOX9 axis	31713817
792	Human	LINC00261	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	downregulated	33481135
793	Human	LINC00273	lncRNA	TGF-¦Â	lung cancer	A549	Transforming growth factor ¦Â (TGF¦Â) treatment	LINC00273 promoted TGF¦Â-induced lung cancer EMT through miR-200a-3p/ZEB1 feedback loop	32017082
794	Human	LINC00294	lncRNA	bakkenolide-IIIa (Bak-IIIa)	inflammation	human umbilical vein endothelial cells (HUVECs)	bakkenolide-IIIa (Bak-IIIa) treatment	Bak-IIIa ameliorated LPS-induced inflammatory damage in HUVECs by upregulating LINC00294.	33760129
795	Human	LINC00294	lncRNA	lipopolysaccharide (LPS)	inflammation	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	downregulated	33760129
796	Human	LINC00299	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human aortic vascular smooth muscle cells (T/G HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00299 regulated ox-LDL-induced T/G HA-VSMCs injury through the miR-135a-5p/XBP1 axis.	32700888
797	Human	LINC00305	lncRNA	hypoxia	VECs apoptosis	human umbilical vein endothelial cells (HUVECs)	hypoxia (1% O2) treatment	upregulated	28763747
798	Human	LINC00324	lncRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	upregulated	33376537
799	Human	LINC00338-008	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
800	Human	LINC00339	lncRNA	calcium oxalate monohydrate (COM)	kidney stone disease	human renal proximal tubular epithelial (HK-2) cells	?calcium oxalate monohydrate (COM)?treatment treatment	lncRNA LINC00339 promotes cell pyroptosis by sponging miR-22-3p to regulate NLRP3 expression in COM-treated HK-2 cells	30614043
801	Human	LINC00339	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
802	Human	LINC00341	lncRNA	particulate matter (PM2.5)	cell cycle arrest	16HBE cell	treated with PM2.5 treatment	upregulated	28366736
803	Human	LINC00346	lncRNA	cisplatin (DDP)	nasopharyngeal carcinoma (NPC)	HNE1cells; CNE2 cells	cisplatin treatment	LINC00346 regulates the cisplatin resistance of NPC cells by inhibiting miR-342-5p.	32397872
804	Human	LINC00460	lncRNA	oxaliplatin	advanced colorectal cancer (CRC)	SW480 cells	oxaliplatin (OXA) treatment	LINC00460-miR-149-5p/miR-150-5p-Mutant p53 Feedback Loop Promotes Oxaliplatin Resistance in Colorectal Cancer	33251049
805	Human	LINC00460	lncRNA	nicotine	lung cancer	The NSCLC cell lines A549 and H1299	nicotine treatment	upregulated	31123168
806	Human	LINC00461	lncRNA	IL-6 and TNF-¦Á	osteoarthritis (OA)	chondrocytes	IL-6 and TNF-¦Á treatment	LINC00461 may modulate the development of OA by suppressing miR-30a-5p expression in chondrocytes.	32155130
807	Human	LINC00461	lncRNA	cisplatin (DDP)	rectal cancer	SW837 cells; HR8348 cells	cisplatin treatment	"LINC00461 mediates cisplatin resistance of rectal cancer by targeting miR-593-5p/CCND1 axis, shedding new light on the treatment of rectal cancer."	31972361
808	Human	LINC00467	lncRNA	signal transducers and activators of transcription 1 (STAT1)	lung adenocarcinoma (LUAD)	"Four acknowledged human LUAD cell lines (H1299, Calu, SPCA1, and A549)"	STAT1 overexpression	LINC00467 was activated by STAT1 in LUAD.	31027730
809	Human	LINC00472	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	THLE-3 cells	Lipopolysaccharide (LPS) treatment	downregulated of long noncoding RNA LINC00472 alleviates sepsis-induced acute hepatic injury by regulating miR-373-3p/TRIM8 axis.	33129786
810	Human	LINC00473	lncRNA	H2O2	abdominal aortic aneurysm (AAA)	human vascular smooth muscle cells (VSMCs)	H2O2 treatment	LINC00473 inhibits vascular smooth muscle cell viability to promote aneurysm formation via miR-212-5p/BASP1 axis.	31954705
811	Human	LINC00473	lncRNA	taxol	colorectal cancer (CRC)	HCT116 cells	taxol treatment	upregulated	30126852
812	Human	LINC00473	lncRNA	X-rays	radiosensitivity	"KYSE-30, KYSE-180, KYSE-150 and TE-5"	X-ray radiation treatment	LINC00473 reduces the radiosensitivity of ESCC cells by modulating the miR-497-5p/CDC25A axis	32468021
813	Human	LINC00475	lncRNA	hypoxia	glioblastoma multiforme (GBM)	LN229 cells	hypoxia treatment	LINC00475 was upregulated in hypoxic glioma samples.	32849915
814	Human	LINC00511	lncRNA	epigallocatechin-3-gallate (EGCG)	anti-cancer therapy	AGS and SGC7901 GC cells	Epigallocatechin gallate (EGCG) treatment	Epigallocatechin gallate reverses gastric cancer by regulating the long noncoding RNA LINC00511/miR-29b/KDM2A axis	32512188
815	Human	LINC00511	lncRNA	paclitaxel (PTX)	breast cancer	"The breast cancer cell lines (MDA-MB-231, MCF-7, Hs-578T, and T47D) and the immortalized breast epithelial cell line MCF-10A"	paclitaxel treatment	LINC00511 knockdown enhanced paclitaxel cytotoxicity in breast cancer cells by upregulating miR-29c	31047896
816	Human	LINC00511	lncRNA	paclitaxel (PTX)	cervical cancer (CC)	PTX-resistant Hela/PTX cells	paclitaxel (PTX) treatment	"silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells"	31180057
817	Human	LINC00511	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	SPCA1 cells; H1975 cells	TGF-¦Â1 treatment	upregulated	32092827
818	Human	LINC00518	lncRNA	adriamycin (ADR)	breast cancer	MCF-7 cells	adriamycin (ADR) treatment	linc00518 level was almost 2.5 fold higher and MRP1 level was about 2 fold increased in ADR-resistant MCF-7 cells.	30001527
819	Human	LINC00574	lncRNA	toxic acetaminophen (APAP)	drug metabolizing enzymes (DMEs) expression	HepaRG cells	toxic acetaminophen (APAP) treatment	The expression of lncRNA LINC00574 was decreased in APAP-treated HepaRG cells	32273307
820	Human	LINC00595	lncRNA	Vitamins A and D	bacterial infection	human monocytes during A.fumigatus infections	Vitamins A and D treatment	dysregulated	28094339
821	Human	LINC00618	lncRNA	vincristine (VCR)	acute myeloid leukemia (AML)	K562 cells; MV4-11 cells	vincristine (VCR) treatment	upregulated	33002417
822	Human	LINC00618	lncRNA	vincristine (VCR)	leukemia	human leukemia	vincristine (VCR) treatment	"Here, we show that the expression of a nuclear long non-coding RNA (lncRNA), LINC00618, is reduced in human leukemia and strongly increased by vincristine (VCR) treatment"	33002417
823	Human	LINC00623	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary OA chondrocytes	IL-1¦Â treatment	"LINC00623/miR-101/HRAS axis modulates OA chondrocyte apoptosis, senescence and ECM degradation through MAPK signaling"	32062610
824	Human	LINC00632	lncRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	downregulated	31315126
825	Human	LINC00632	lncRNA	IL-13	allergic rhinitis (AR)	nasal epithelial cells (NECs)	IL-13 treatment	"Linc00632 inhibited IL-13-induced GM-CSF, eotaxin, and MUAC5AC production in IL-13-treated NECs by targeting miR-498"	31315126
826	Human	LINC00641	lncRNA	nutritional stress	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	low nutritional (LN) condition induce	Upregulation of LINC00641 and downregulated of miR-153-3p are detected in NP cells under nutritional stress.	30378116
827	Human	LINC00645	lncRNA	TGF-¦Â	glioblastoma multiforme (GBM)	glioma cell lines	TGF-¦Â treatment	upregulated	31558707
828	Human	LINC00657	lncRNA	oxidized low density lipoprotein (ox-LDL)	angiogenesis	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	oxLDL also upregulated LINC00657 expression.	29436491
829	Human	LINC00657	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	"Silence of LINC00657 repressed ox-LDL-induced injury via inhibiting EndMT, inflammatory response, and apoptosis in HUVEC cells by regulating miR-30c-5p/Wnt7b/¦Â-catenin."	32577947
830	Human	LINC00659	lncRNA	peiminine	colorectal cancer (CRC)	SW620 and HT29 cells	peiminine treatment	"Peiminine notably downregulated the expression of LINC00659, while the expression of miR-760 was upregulated by peiminine treatment"	32740014
831	Human	LINC00665	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	lung cancer tissues and cells (Human LAD cell line PC9)	gefitinib treatment	upregulated	30889481
832	Human	LINC00665	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
833	Human	LINC00667	lncRNA	yin yang 1 (YY1)	cholangiocarcinoma (CCA)	CCLP-1 and QBC939 cells	yin yang 1 (YY1) treatment	"Our data indicated that LINC00667 was highly expressed in CCA tissues and cells, and transcription factor Yin Yang 1 (YY1) induced LINC00667 expression in CCA cells"	33040228
834	Human	LINC00667:6	lncRNA	nigericin	pancreatic cancer (PC)	PANC-1 cells	nigericin treatment	upregulated	32850392
835	Human	LINC00668	lncRNA	sodium new houttuyfonate (SNH)	non-small cell lung cancer (NSCLC)	A549 and NCI-H1299 cells	sodium new houttuyfonate (SNH) treatment	downregulated	30971296
836	Human	LINC00673	lncRNA	benzo(a)pyrene (BaP)	non-small cell lung cancer (NSCLC)	A549 cells	benzo(a)pyrene (BaP) exposure	upregulated	31778776
837	Human	LINC00673	lncRNA	benzo(a)pyrene (BaP)	non-small cell lung cancer (NSCLC)	A549 cells	benzo(a)pyrene (BaP) exposure	BaP significantly elevated the expression level of linc00673.	31778776
838	Human	LINC00707	lncRNA	acetyl-11-keto-¦Â-boswellic acid (AKBA)	breast cancer	MCF-10AT cells	Acetyl-11-keto-¦Â-boswellic acid (AKBA) treatment	AKBA could induce cell apoptosis and G1-phase arrest and inhibit ER-¦Á expression via LINC00707/miR-206 in MCF-10AT cells.	32013235
839	Human	LINC00707	lncRNA	osteogenic differentiation medium	osteogenesis	human bone marrow-derived mesenchymal stem cells (HBMSCs)	"osteogenic differentiation medium with 100 mmol/L dexamethasone, 0.05 mmol/L ascorbic acid, and 10 mmol/L ¦Â-glycerophosphate treatment"	upregulated	30795799
840	Human	LINC00707	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	"?LINC00707 was increased, and miR-223-5p was decreased in LPS-treated MRC-5 cells."	33604647
841	Human	LINC00844	lncRNA	acetaminophen (APAP)	drug-induced liver injury (DILI)	HepaRG cells	acetaminophen (APAP) treatment	"In HepaRG cells, LINC00844 was significantly downregulated by 5 and 10 mM APAP in a concentration-dependent manner."	31904498
842	Human	LINC00847	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
843	Human	LINC00847	lncRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	HL7702 cells	microcystin-LR(MC-LR) treatment	upregulated	30430930
844	Human	LINC00882	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
845	Human	LINC00882	lncRNA	platelet-derived growth factor (PDGF)	asthma	Human fetal airway smooth muscle (ASM) cells	platelet-derived growth factor (PDGF) treatment	upregulated	31014672
846	Human	LINC00883	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
847	Human	LINC00894-002	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells	Tamoxifen treatment	downregulated	29738694
848	Human	LINC00941	lncRNA	TGF-¦Â1	papillary thyroid cancer (PTC)	"B-CPAP, TPC1, Cal62 and 8505c cells"	TGF-¦Â1 treatment	?Linc00941 was identified as transcribed starting from one of the TGF¦Â-induced ENHs Linc00941 expression was significantly higher in aggressive cancer both in the TCGA dataset and in a separate validation cohort from our institution	32495722
849	Human	LINC00943	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
850	Human	LINC00943	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	LINC00943 abundance was upregulated in MPP+-challenged SK-N-SH cells.	33208053
851	Human	LINC00958	lncRNA	X-rays	cervical cancer (CC)	Hela cells	irradiated with 6?Gy of X-ray treatment	upregulated	31169309
852	Human	LINC00958	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
853	Human	LINC00961	lncRNA	c-reactive protein (CRP)	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	CRP treatment	downregulated	31646586
854	Human	LINC00961	lncRNA	hypoxia	atherosclerosis (AS)	Human vascular smooth muscle cell line HA-VSMC	hypoxia induce	downregulated	31646586
855	Human	LINC00968	lncRNA	oxidized low density lipoprotein (ox-LDL)	coronary artery disease (CAD)	endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	LINC00968 was upregulated by oxidized low-density lipoprotein (oxLDL) treatment in endothelial cell.	30485507
856	Human	LINC00968	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
857	Human	LINC00987	lncRNA	lipopolysaccharide (LPS)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"LINC00987 Ameliorates COPD by Regulating LPS-Induced Cell Apoptosis, Oxidative Stress, Inflammation and Autophagy Through Let-7b-5p/SIRT1 Axis."	33311978
858	Human	LINC01116	lncRNA	cisplatin (DDP)	lung adenocarcinoma (LUAD)	A549 cells	cisplatin treatment	upregulated	33061421
859	Human	LINC01116	lncRNA	sulforaphane (SFN)	prostate cancer	normal human prostate epithelial cells and prostate cancer cells	treated with 15 ¦ÌM SFN treatment	downregulated	28131897
860	Human	LINC01121	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
861	Human	LINC01125	lncRNA	LXR-623 (WAY-252623)	breast cancer	MDA-MB-231 cells	LXR-623 (WAY-252623) treatment	upregulated	30867411
862	Human	LINC01125	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	OC lines (SKOV-3 and A2780)	cisplatin treatment	downregulated	31865363
863	Human	LINC01126	lncRNA	hypoxia	periodontitis	human periodontal ligament cells (hPDLCs)	hypoxia treatment	"We selected LINC01126, which was the most highly expressed lncRNA, to further verify its functions in periodontitis-induced hypoxia."	33231338
864	Human	LINC01133	lncRNA	periostin	pancreatic ductal adenocarcinoma (PDAC)	human PSCs cells	periostin treatment	upregulated	33824474
865	Human	LINC01137	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
866	Human	LINC01137	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
867	Human	LINC01137	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
868	Human	LINC01140	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	"LINC01140 was downregulated, while p53 and miR-23b were upregulated in oxLDL-induced inflammatory response of macrophages."	31748847
869	Human	LINC01186	lncRNA	TGF-¦Â1	lung cancer	A549 cells	treat with TGF-¦Â1 treatment	downregulated	28119085
870	Human	LINC01234	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells and Huh7 cells	cisplatin treatment	"When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion."	31838274
871	Human	LINC01297	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
872	Human	LINC01311	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid ¦Â1-42?(A¦Â) treatment	LINC01311 was downregulated whereas hsa-miR-146a-5p upregulated in AB1-42 treated SH-SY5Y cells.	33830627
873	Human	LINC01391	lncRNA	piplartine	hepatocellular carcinoma (HCC)	HepG2 and SMMC-7721?cells	piplartine treatment	upregulated	31207322
874	Human	LINC01541	lncRNA	estradiol-17¦Â (E2)	endometriosis	Human endometrial stromal cells (ESCs)	estradiol-17¦Â (E2) treatment	downregulated	30608887
875	Human	LINC01541	lncRNA	estradiol-17¦Â (E2)	endometriosis	ectopic endometrial tissue	estradiol-17¦Â (E2) treatment	LINC01541 functions as a ceRNA that modulates the Wnt/¦Â-catenin pathway by decoying miR-506-5p.	32833189
876	Human	LINC01572	lncRNA	cisplatin (DDP)	gastric cancer (GC)	BGC823 cells; SGC7901	cisplatin treatment	upregulated	33149605
877	Human	LINC01667	lncRNA	bruceine D (BD)	gastric cancer (GC)	HGC27 cells; MKN45 cells	bruceine D (BD) treatment	LINC01667 was significantly downregulated after BD treatment.	33390953
878	Human	linc-p21	lncRNA	ginkgo biloba extract EGb 761	colorectal cancer (CRC)	"The human colorectal cancer cell lines SW480, SW620"	Ginkgo biloba extract EGb 761 treatment	upregulated	29207671
879	Human	linc-p21	lncRNA	hypoxia	warburg effect	HeLa cells;MCF7 ccells; H1299 cells;IMR90 cells	culture under hypoxic conditions for 24 hr treatment	upregulated	24316222
880	Human	linc-p21	lncRNA	hypoxia	warburg effect	HeLa cells	hypoxia treatment	LincRNA-p21 is Induced by Hypoxia and Is Essential for Hypoxia-Enhanced Glycolysis	24316222
881	Human	LINP1	lncRNA	doxorubicin- and 5-fluorouracil	breast cancer	MDA-MB-468 cells	doxorubicin- and 5-fluorouracil treatment	LINP1 was upregulated in doxorubicin- and 5-fluorouracil-resistant cells and induced chemoresistance.	29293402
882	Human	LINP1	lncRNA	tamoxifen (TAM)	breast cancer	MCF-7 cells; T47D cells	Tamoxifen (TAM) treatment	upregulated	31927036
883	Human	LINP1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells; H1299 cells; H358 cells	TGF-¦Â treatment	"In three lung cancer cell lines A549, H1299, and H358, TGF-¦Â1 significantly inhibited LINP1 expression"	30416386
884	Human	LMCD1-AS1	lncRNA	aspirin	hepatocellular carcinoma (HCC)	HepG2 and Huh-7 cell lines	aspirin treatment	downregulated	31278071
885	Human	lnc949	lncRNA	TGF-¦Â1	lung fibrosis	L929 cells	TGF-¦Â1 treatment	Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-¦Â1-Smad2/3 and JNK signalling pathways	33181025
886	Human	LncDC	lncRNA	hepatitis B virus (HBV)	immune response	DC cells induced by isolated peripheral blood mononuclear cells	hepatitis B virus (HBV) infection	upregulated	30202418
887	Human	lncIHAT	lncRNA	hypoxia	triple negative breast cancer (TNBC)	MDA-MB-231 cells	hypoxia treatment	Hypoxia-inducible factor 1 (HIF1) but not HIF2 bound to the hypoxia response element at the promoter of lncIHAT to activate its transcription in hypoxic TNBC cells. LncIHAT promoted TNBC cell survival?in vitro?and tumor growth and lung metastasis in mice.	33380467
888	Human	linc-p21	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HCAECs	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	28983628
889	Human	linc-p21	lncRNA	oligo-fucoidan	hepatocellular carcinoma (HCC)	HepG2 cells	oligo-fucoidan treatment	apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan.	30632031
890	Human	linc-p21	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	?human neuroblastoma SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	lnc-p21 was highly expressed in human neuroblastoma SH-SY5Y cells treated with MPP+.	31004593
891	Human	lncRNA00364	lncRNA	IFN-¦Ã	hepatocellular carcinoma (HCC)	HCC cells	IFN¦Ã treatment	upregulated	29254221
892	Human	lncRNA01126	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide of Porphyromonas Gingivalis (LPS-PG) treatment	upregulated	32240552
893	Human	lncRNA1403	lncRNA	7.5% hypertonic saline (HS)	traumatic brain injury (TBI)	peripheral blood mononuclear cells	7.5% hypertonic saline (HS) treatment	downregulated	30569101
894	Human	lncRNA155	lncRNA	influenza A virus (IAV)	innate immune response	"Human lung epithelial cells (A549), human embryonic kidney cells (HEK293T/293T), human acute monocytic leukemia cells (THP-1), mouse embryonic fibroblasts (NIH/3T3), mouse Lewis lung carcinoma cells (LLC), mouse Abelson murine leukemia virus transformed macrophages (RAW 264.7)and madin-darby canine kidney cells (MDCK)"	influenza A virus (IAV) infection	expression of lncRNA-155 was markedly upregulated during influenza A virus (IAV) infection both in vitro (several cell lines) and in vivo (mouse model)	31045320
895	Human	lncRNA2448-11	lncRNA	7.5% hypertonic saline (HS)	traumatic brain injury (TBI)	peripheral blood mononuclear cells	7.5% hypertonic saline (HS) treatment	downregulated	30569101
896	Human	lncRNA51663	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	AGS cells	Helicobacter pylori (H. pylori) infection	upregulated	32457731
897	Human	lncRNA8	lncRNA	hepatitis C virus (HCV)	chronic hepatitis C virus (HCV) infection	Huh-7.5 hepatoma cells	hepatitis C virus (HCV) infection	upregulated	31200545
898	Human	lncRNA91H	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	cell line TE-1 and Eca-109	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	24706416
899	Human	lncRNA-p19461	lncRNA	diet	weight loss	fasting venous blood	diet treatment	upregulated	27767123
900	Human	LOC101927497	lncRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	human gastric epithelial cells	treat with MNNG	upregulated	29223541
901	Human	LOC101927497	lncRNA	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)	gastric cancer (GC)	MKN28 cells; MGC-803 cells	N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) treatment	downregulated	29223541
902	Human	LOC101927514	lncRNA	particulate matter (PM2.5)	respiratory inflammation	16HBE cells	fine particulate matter (PM2.5) exposure treatment	upregulated	31682869
903	Human	LOC101927514	lncRNA	particulate matter (PM2.5)	respiratory inflammation	human normal bronchial 16HBE cells	particulate matter (PM2.5) treatment	"Inhibiting LncRNA LOC101927514 expression by RNAi, reflected in a reduction in inflammation, is driven by PM25"	31682869
904	Human	LOC102724017	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
905	Human	LOC105374902	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	cervical cancer (CC)	HeLa cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"TNF-¦Á-induced lncRNA LOC105374902 may function as a ceRNA for miR-1285-3p to promote the expression of RPL14, promoting the migration, invasion and EMT of CC cells."	30935691
906	Human	loc105377478	lncRNA	neodymium oxide nanoparticles (NPs-Nd2O3)	airway inflammation	human bronchial epithelial cells (16HBE)	neodymium oxide nanoparticles (NPs-Nd2O3) exposure	upregulated	33396129
907	Human	loc105377478	lncRNA	neodymium oxide nanoparticles (NPs-Nd2O3)	cytotoxicity	human bronchial epithelial cells (16HBE)	neodymium oxide nanoparticles (NPs-Nd2O3) treatment	upregulated	33396129
908	Human	loc107985872	lncRNA	traffic-originated PM2.5 organic component (tPo)	toxicity of PM2.5	A549 cells; H1299 cells	Traffic-originated PM2.5 organic component (tPo) treatment	tPo treatment upregulated the expression of loc107985872	32829169
909	Human	loc146880	lncRNA	particulate matter (PM2.5)	cytotoxicity	A549 cells	treated with PM2.5 treatment	upregulated	27836757
910	Human	LOC285194	lncRNA	propofol (PPF)	pancreatic cancer (PC)	PANC-1 cells	propofol treatment	"Propofol upregulated miR-34a expression, which, in turn, upregulated LOC285194 expression"	32303144
911	Human	LOC286367	lncRNA	propofol (PPF)	inflammation	THP-1 macrophages	propofol treatment	downregulated	30647536
912	Human	LOC338799	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
913	Human	LOC344887	lncRNA	hydroquinone (HQ)	leukemia	TK6 cells	HQ	dysregulated	29221148
914	Human	LOC645166	lncRNA	adriamycin (ADR)	adriamycin (ADR) treatment in breast cancer	MCF-7 cells	adriamycin (ADR) treatment	lncRNA LOC645166 mediated adriamycin chemoresistance in breast cancer by regulating GATA3 via NF-¦ÊB.	32461377
915	Human	LOC728228	lncRNA	"anti-benzo[a]pyrene-trans-7,8-diol-9,10-epoxide (anti-BPDE)"	bronchial epithelial cell cancer	human bronchial epithelial cell line (16HBE-T cells)	"anti-benzo(a) pyrene-7,8-diol-9,10-epoxide (anti-BPDE) treatment"	upregulated	25820656
916	Human	LOC729178	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	Our data indicated that LOC729178 was underexpressed in COPD tissues and CSE-treated 16HBE cells.	33847879
917	Human	LOXL1-AS1	lncRNA	doxorubicin (DOX)	prostate cancer	prostate cancer DU-145 cells	doxorubicin (DOX) treatment	downregulated	31188543
918	Human	LRRC24-2:1	lncRNA	nigericin	pancreatic cancer (PC)	PANC-3 cells	nigericin treatment	downregulated	32850392
919	Human	LSINCT5	lncRNA	B-type-natriuretic peptide (BNP)	chronic heart failure (CHF)	HCM human myocardial cells	B-type-natriuretic peptide (BNP) treatment	"lncRNA LSINCT5, upregulated by BNP, is able to regulate myocardial cell apoptosis via the activation of the caspase-1/interleukin (IL)-1¦Â signaling pathway."	26323562
920	Human	LUADT1	lncRNA	lipopolysaccharide (LPS)	sepsis	primary cardiac endothelial cells	lipopolysaccharide (LPS) treatment	LPS treatment downregulated the expression of LUADT1 in primary cardiac endothelial cells.	33225891
921	Human	LUCAT1	lncRNA	hypoxia	colorectal cancer (CRC)	HCT-116;RKO cells	hypoxia treatment	Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response.	31964396
922	Human	LUCAT1	lncRNA	methotrexate (MTX)	osteosarcoma (OS)	MG63 cells; HOS cells	methotrexate (MTX) treatment	"LUCAT1 was upregulated in MTX-resistant cells (MG63/MTX, HOS/MTX) compared to that in parental cells."	29170124
923	Human	LUCAT1	lncRNA	methotrexate (MTX)	osteosarcoma (OS)	"osteosarcoma cell lines (MG-63, U2OS, HOS and SAOS-2)"	methotrexate treatment	upregulated	29170124
924	Human	LUCAT1	lncRNA	particulate matter (PM2.5)	PM2.5 exposure	BEAS-2B cells	PM2.5 treatment	lncLUCAT1 was increased in PM25 treated BEAS-2B cells	30231965
925	Human	LUCAT1	lncRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	LUCAT1 likely promotes HG-induced EMT through ZEB1 by sponging miR-199a-5p.	33426083
926	Human	MACC1-AS1	lncRNA	TGF-¦Â1	gastric cancer (GC)	AGS and MKN45 cancer cells	transforming growth factor ¦Â1 (TGF-¦Â1) secretion by MSCs treatment	upregulated	30742067
927	Human	MACC1-AS1	lncRNA	hypoxia	ischemic stroke (IS)	human brain microvascular endothelial cells (HBMECs)	hypoxia treatment	downregulated	32793720
928	Human	MAF-4	lncRNA	brucella.suis	brucellosis	blood samples	brucellosis infection	Linc-MAF-4 was significantly increased in the acute group in comparison to control and relapse groups.	32417631
929	Human	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"The expression of MAGI2-AS3 was increased, and miR-374b-5p was decreased in both SH-SY5Y and BV2 cells exposed to A¦Â25-35."	33279663
930	Human	MAGI2-AS3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	MAGI2-AS3/miR-374b-5p axis regulates A¦Â-induced neurotoxicity in SH-SY5Y cells and neuroinflammation in BV2 cells.	33279663
931	Human	MALAT1	lncRNA	IL-6	abdominal aortic aneurysm (AAA)	human aortic endothelial cells (HAOECs)	IL-6 treatment	upregulated	29441928
932	Human	MALAT1	lncRNA	arsenite	accelerated glycolysis	"L-02 cells, a normal human liver cell line"	arsenite exposure	arsenite-increased MALAT1 enhances the disassociation of Von Hippel-Lindau (VHL) tumor suppressor from HIF-1¦Á	27287256
933	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	LPS treatment upregulated MALAT1 expression and suppressed the proliferation of A549 cells.	31257497
934	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary alveolar epithelial cells (HPAEpiC)	lipopolysaccharide (LPS) treatment	MALAT1 knockdown alleviated HPAEpiC apoptosis by competitively binding to miR-194-5p and then elevating the inhibitory effect on its target FOXP2.	33117815
935	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	downregulated	33197806
936	Human	MALAT1	lncRNA	cytarabine (Ara-C)	acute myeloid leukemia (AML)	human AML cell lines HL60 and THP-1	cytarabine (Ara-C) treatment	"Knockdown of MALAT1 inhibited the proliferation, induced apoptosis, and enhanced Ara-C sensitivity of AML cells."	30970520
937	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	MALAT1 silencing can potentially suppress HPMEC apoptosis and alleviate lung injury in ARDS via miR-150-5p-targeted ICAM-1.	32315984
938	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	33197806
939	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	upregulated	33407436
940	Human	MALAT1	lncRNA	ethanol (EtOH)	alcohol-induced tumor angiogenesis	HUVECs endothelial extracellular vesicles (EVs)	ethanol treatment	upregulated in endothelial extracellular vesicles (EVs)	29062004
941	Human	MALAT1	lncRNA	tubercidin	alternative splicing	HeLa cells	tubercidin treatment	downregulated	24569078
942	Human	MALAT1	lncRNA	dual MEK/Aurora kinase inhibitor BI-847325	anaplastic thyroid carcinoma (ATC)	ATC cell lines (C643 and SW1736)	dual MEK/Aurora kinase inhibitor BI-847325 treatment	downregulated	31077090
943	Human	MALAT1	lncRNA	hyperbaric oxygen (HBO)	angiogenesis	human coronary artery endothelial cells (HCAECs)	Hyperbaric oxygen (HBO) treatment	upregulated	30301563
944	Human	MALAT1	lncRNA	amygdalin	anti-cancer therapy	"human cancer cells (A549, MCF7, AGS)"	amygdalin treatment	downregulated	30725348
945	Human	MALAT1	lncRNA	bone morphogenetic protein 7 (BMP7)	apoptosis	HA-VSMCs	bone morphogenetic protein 7 (BMP7) treatment	upregulated	29435112
946	Human	MALAT1	lncRNA	high glucose (HG)	apoptosis	human vascular endothelial cells (HUVECs)	high glucose (HG) treatment	"MALAT1 is upregulated in HG-induced HUVECs, and inhibition of MALAT1 inhibits HG-induced apoptosis and inflammation in HUVECs by suppression of the NF-¦ÊB signaling pathway."	32502356
947	Human	MALAT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor BB (PDGF-BB) treatment	upregulated	31695627
948	Human	MALAT1	lncRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926?cells	high glucose (HG) treatment	lncRNA MALAT1 expression and found that it was upregulated in high glucose-treated EA.hy926?cells.	30591217
949	Human	MALAT1	lncRNA	high glucose (HG)	atherosclerosis (AS)	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
950	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	"VSMCs were treated with different doses of ox-LDL (0, 25, 50, and 100 mg/L) and for different time points (0, 12, 24, and 48 h) to mimic an in vitro environment of hyperlipidemia."	MALAT1 were dose-dependently downregulated in ox-LDL-treated VSMCs.	31696492
951	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29258822
952	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29258822
953	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human Coronary Artery Endothelial Cells (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 expression was upregulated under oxidative low-density lipoprotein (ox-LDL) treatment.	30314869
954	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31029709
955	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	exosomes from Human umbilical VECs (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31305205
956	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVEC)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 suppression protects the endothelium from oxLDL-induced inflammation and oxidative stress in endothelial cells by upregulation of miR-181b and downregulated of TOX.	31949884
957	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA MALAT1 Enhances ox-LDL-Induced Autophagy through the SIRT1/MAPK/NF-¦ÊB Pathway in Macrophages	32183682
958	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein ECs (HUVECs); human coronary artery ECs (HCAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 was upregulated in ECs treated with ox-LDL.	33022677
959	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 was increased in oxLDL-treated human umbilical vein endothelial cells.	29750307
960	Human	MALAT1	lncRNA	IL-1¦Â	autoimmune thyroiditis (AIT)	Nthy-ori 3-1 cells	IL-1¦Â treatment	upregulated	33452572
961	Human	MALAT1	lncRNA	ursolic acid (UA)	autoimmune thyroiditis (AIT)	IL-1¦Â-treated Nthy-ori 3-1 cells	ursolic acid (UA) treatment	downregulated	33452572
962	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	MALAT1 expression was markedly increased in HUVECs treated with ox-LDL.	30485490
963	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	autophagy	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	autophagy was upregulated and MALAT1 expression was markedly increased in HUVECs treated with ox-LDL.	30485490
964	Human	MALAT1	lncRNA	dexamethasone (DEX)	avascular necrosis of the femoral head (ANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	upregulated	31678133
965	Human	MALAT1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	downregulated	32714991
966	Human	MALAT1	lncRNA	cisplatin (DDP)	bladder cancer	The 5637 and EJ-M3 cells	cisplatin treatment	suppression of MALAT1 enhanced the chemotherapeutic drug sensitivity and inhibited the cisplatin resistance of the BC cells.	31650173
967	Human	MALAT1	lncRNA	TGF-¦Â	bladder cancer	bladder cancer cells	TGF-¦Â treatment	upregulation	24449823
968	Human	MALAT1	lncRNA	receptor activator of nuclear factor-¦ÊB ligand (RANKL)	bone metabolism	RANKL inhibited hFOB 1.19 cells	Receptor activator of NF&mdash;&#954;B ligand (RANKL) treatment	upregulated	25817340
969	Human	MALAT1	lncRNA	paclitaxel (PTX)	breast cancer	SK-BR-3 cells	paclitaxel (PTX) treatment	upregulated	32897218
970	Human	MALAT1	lncRNA	cadmium (Cd)	cadmium-induced toxicity	16HBE cells	cadmium (Cd) treatment	upregulated	30090505
971	Human	MALAT1	lncRNA	TGF-¦Â1	cardiovascular disease (CVD)	HUVECs	TGF-¦Â1 treatment	upregulated	27144026
972	Human	MALAT1	lncRNA	androgen deprivation therapies (ADT)	castration-resistant prostate cancer (CRPC)	patients with CRPC	androgen deprivation therapies (ADT) treatment	upregulated	25189356
973	Human	MALAT1	lncRNA	high glucose (HG)	cell function	Human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	31646587
974	Human	MALAT1	lncRNA	high glucose (HG)	cell pyroptosis	EA.hy926 human endothelial cells (EA.hy926?cells)	high glucose treatment	Long?noncoding?RNA?MALAT1 promotes high glucose-induced?human endothelial cells pyroptosis by affecting NLRP3 expression through competitively binding miR-22.	30591217
975	Human	MALAT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	HA-VSMCs	platelet-derived growth factor-BB (PDGF-BB) treatment	upregulated	29435112
976	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	cerebrovascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"Under the normal culture condition, MALAT1 reached 15 times after reoxygenation treatment for 9 h, and the expression level decreased to 027 times significantly after reoxygenation treatment for 36h"	29575939
977	Human	MALAT1	lncRNA	casiopeina II-gly (Cas-II-gly)	cervical cancer (CC)	HeLa and CaSki cells	Casiopeina II-gly (Cas-II-gly) treatment	downregulated	31524268
978	Human	MALAT1	lncRNA	radiation	cervical cancer (CC)	CaSki cells	radiation treatment	"Comparing to radiotherapy sensitive tissues, the MALAT1 level was significantly elevated in radiotherapy resistant tissues"	30178834
979	Human	MALAT1	lncRNA	oxaliplatin	colorectal cancer (CRC)	CRC tissues; HCT116 cells; HCT8 cells	oxaliplatin (OXA) treatment	MALAT1 was upregulated in Ox-resistant CRC tissues and cells	33005106
980	Human	MALAT1	lncRNA	oxymatrine	colorectal cancer (CRC)	HT29 cells	oxymatrine treatment	lncRNA MALAT1 was significantly upregulated in the oxymatrine resistant cells	29328404
981	Human	MALAT1	lncRNA	radiation	colorectal cancer (CRC)	CCL244 cells	radiation treatment	upregulated	32380053
982	Human	MALAT1	lncRNA	radiation	colorectal cancer (CRC)	LOVO cells	radiation treatment	downregulated	32380053
983	Human	MALAT1	lncRNA	dihydromyricetin (DHM)	cutaneous squamous cell carcinoma (CSCC)	A431 cells	Dihydromyricetin (DHM) treatment	downregulated	31413743
984	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	delayed union of femoral neck fracture	MG-63 cells	lipopolysaccharide (LPS) treatment	MALAT1 expression was upregulated in serum of patients with delayed union of femoral neck fracture.	33725277
985	Human	MALAT1	lncRNA	dexamethasone (DEX)	dexamethasone (DEX)-induced injuries	B-6 cells; hFOB1.19 cells; necrotic femoral head tissues	dexamethasone (Dex) treatment	Lnc-MALAT1 expression was downregulated by Dex treatment.	30439702
986	Human	MALAT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	human lens epithelial cells (HLECs)	high glucose (HG) treatment	MALAT1 not only was aberrantly expressed in DC anterior lens capsule tissues and high glucose (HG)-treated HLECs.	29936249
987	Human	MALAT1	lncRNA	high glucose (HG)	diabetic gastroparesis (DGP)	human gastric SMCs	high glucose (HG) treatment	upregulated	29317209
988	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high-glucose	upregulated	27964927
989	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	streptozotocin treatment	upregulated	27964927
990	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	hyperglycemia significantly increased the level of MALAT1 but decreased miR-145 expression in a time-dependent manner in HK-2 cells.	31081103
991	Human	MALAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human proximal tubular cells (HK-2 cells)	high glucose (HG) treatment	upregulated	31388927
992	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal endothelial cells	high glucose (HG) treatment	Glucose increased LncRNA?MALAT1?levels by increasing Sp1 transcription factor binding at its promoter.	33051272
993	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retina microvascular endothelial cells (hRMECs)	high glucose (HG) treatment	upregulated	30988072
994	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	MALAT1 affect angiogenesis by sponging miR-203a-3p in DR.	31689123
995	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRMECs)	high glucose (HG) treatment	upregulated	31689123
996	Human	MALAT1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal vascular endothelial cells (RVECs)	high glucose (HG) treatment	upregulated	31986419
997	Human	MALAT1	lncRNA	hypoxia	doxorubicin (DOX)-induced cardiotoxicity	human adipose-derived mesenchymal stem cells	hypoxia treatment	Treatment of the human adipose-derived mesenchymal stem cells with hypoxia induced lncRNA-MALAT1 accumulation in the secreted exosomes.	32384281
998	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	endometriosis	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	upregulated	30500775
999	Human	MALAT1	lncRNA	hypoxia	endometriosis	ectopic endometrium and cultured human endometrial stromal cells	hypoxia induce	upregulated	30324652
1000	Human	MALAT1	lncRNA	hypoxia	endometriosis	primary human endometrial stromal cells	hypoxia treatment	lncRNA-MALAT1 and autophagy were induced by hypoxia in a time-dependent manner and lncRNA-MALAT1 upregulated was dependent on HIF-1¦Á signalling.	30324652
1001	Human	MALAT1	lncRNA	hypoxia	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	upregulated	31933110
1002	Human	MALAT1	lncRNA	high glucose (HG)	endothelial dysfunction	human renal glomerular endothelial cells (HRGECs)	high glucose (HG) treatment	upregulated	30762931
1003	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	epithelial-mesenchymal transition (EMT)	Human primary endometrial glandular epithelial cells (EECs) and Ishikawa cells	estradiol-17¦Â (E2) treatment	upregulated	30500775
1004	Human	MALAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30871555
1005	Human	MALAT1	lncRNA	particulate matter (PM2.5)	epithelial-mesenchymal transition (EMT)	human bronchial epithelial cell lines (HBE and BEAS-2B)	Organic extracts of PM2.5 treatment	"NF-¦ÊB transcriptionally regulates MALAT1, which, by binding with miR-204 and releasing ZEB1, promotes the EMT"	31042084
1006	Human	MALAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human lens epithelial cells (LECs)	TGF-¦Â2 treatment	upregulated	31143769
1007	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	endothelial progenitor cells (EPCs)	treat with TGF-¦Â1 treatment	upregulated	28535533
1008	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	ARPE-19 cells	TGF-¦Â1 treatment	upregulated	27019196
1009	Human	MALAT1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
1010	Human	MALAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	human lens epithelial cells (LECs)	TGF-¦Â2 treatment	upregulated	33327804
1011	Human	MALAT1	lncRNA	TGF-¦Â1	esophageal squamous cell carcinoma (ESCC)	KYSE30 cells; KYSE150 cells; KYSE450 cells	TGF-¦Â1 treatment	upregulated	33123280
1012	Human	MALAT1	lncRNA	¦Ã-rays	esophageal squamous cell carcinoma (ESCC)	mice xenografted with KYSE150 cells	10 Gy dose of ¦Ã-ray irradiation by the 137Cesium irradiator at 2 Gy/1f/day for 5 days treatment	downregulated	27935117
1013	Human	MALAT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	The human GC cell line AGS;HGC-27 cells	cisplatin treatment	upregulated	30365113
1014	Human	MALAT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	AGS cells; HGC-27 cells	cisplatin treatment	MALAT1 was found to be highly expressed in CDDP-resistant AGS(AGS/CDDP) cells and CDDP-resistant HGC-27 (HGC-27/CDDP) cells.	30365113
1015	Human	MALAT1	lncRNA	hydrogen gas (H2)	gastric cancer (GC)	MGC-803 cells;and BGC-823 cells	?hydrogen treatment	"H2?gas significantly inhibited gastric tumor growth in vivo and the proliferation, migration, and lncRNA MALAT1 and EZH2 expression of gastric cancer cells while upregulated miR-124-3p expression"	33482814
1016	Human	MALAT1	lncRNA	oxaliplatin	gastric cancer (GC)	"GC tissues;Normal cells (GES-1); GC cells (SGC-7901, BGC-823); GC/OXA cells (SGC-7901/OXA; BCG-823/OXA"	oxaliplatin (OXA) treatment	MALAT1 modulates ZFP91 to promote GC cells OXA resistance via sponging miR-22-3p	32104001
1017	Human	MALAT1	lncRNA	propofol (PPF)	gastric cancer (GC)	SGC7901/CDDP	propofol treatment	lncRNA MALAT1/miR-30e/ATG5 mediated autophagy-related chemoresistance in GC	32302291
1018	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM patients tissues and serum	TMZ treatment	downregulated	28187000
1019	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 cells	temozolomide (TMZ) treatment	MALAT1 was significantly upregulated in TMZ-resistant GBM cells	29479863
1020	Human	MALAT1	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
1021	Human	MALAT1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells	temozolomide (TMZ) treatment	upregulated	30940658
1022	Human	MALAT1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2 cells	Hepatitis B virus X protein (HBx) infection	HBx upregulated lncRNA-MALAT1 expression while downregulating miR-124 expression in HepG2-X cells.	30500989
1023	Human	MALAT1	lncRNA	hepatitis B virus X protein (HBx)	HBV-associated hepatocellular carcinoma (HCC)	HepG2-X cell line was induced by transfect HBx into HepG2 cells.	HBx-induce	HBx upregulated lncRNA-MALAT1 expression in HepG2-X cells.	30500989
1024	Human	MALAT1	lncRNA	hypoxia	hepatic ischemia/reperfusion injury (HIRI)	human hepatocytes	hypoxia induce	upregulated	31075559
1025	Human	MALAT1	lncRNA	betulinic acid (BA)	hepatocellular carcinoma (HCC)	PLC/PRF/5; MHCC97L	betulinic acid (BA) treatment	lncRNA MALAT1 functioned as a ceRNA (competing endogenous RNA) to contribute to BA-mediated degradation of IAPs by sponging miR-22-3p.	33135336
1026	Human	MALAT1	lncRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	Huh-7 cell; Hep3B cells	doxorubicin treatment	upregulated	32965597
1027	Human	MALAT1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	Hep3B cells	hypoxia induce	"LncRNA MALAT1 was involved in proliferation, migration, invasion, and apoptosis by interacting with miR-200a in hypoxic Hep3B cells, revealing a new mechanism of MALAT1 involved in hypoxic HCC progression."	31347327
1028	Human	MALAT1	lncRNA	hypoxia-inducible factor 2¦Á (HIF-2¦Á)	hepatocellular carcinoma (HCC)	hepatocellular carcinoma (HCC) cells	HIF-2¦Á treatment	upregulated	27524242
1029	Human	MALAT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC cells	sorafenib treatment	upregulated	32220970
1030	Human	MALAT1	lncRNA	human immunodeficiency virus (HIV)-1	human immunodeficiency virus (HIV)-1 infection	CD4+ T cells	human immunodeficiency virus (HIV)-1 infection	upregulated	30788509
1031	Human	MALAT1	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cell (HUVEC)	high glucose (HG) treatment	Knockdown of MALAT1 inhibits HG-induced vascular endothelial injury through regulating miR-361-3p/SOCS3 axis.	32509100
1032	Human	MALAT1	lncRNA	hypoxia/reoxygenation (H/R)	hypoxia/reoxygenation (H/R) injury	human umbilical vein endothelial cell (HUVEC)	hypoxia/reoxygenation (H/R) treatment	MALAT1 represses H/R-stimulated HUVEC injury by targeting the miR-320a/RAC1 axis.	31408432
1033	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	human microvascular endothelial cells (HMECs)	lipopolysaccharides (LPS) treatment	downregulated	31291804
1034	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	human lung fibroblasts WI-38	lipopolysaccharides (LPS) treatment	upregulated	31633220
1035	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	innate immune response	macrophages	lipopolysaccharide (LPS) treatment	upregulated	27434861
1036	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemia/reperfusion (I/R) injury	human brain microvascular endothelial cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	downregulated	28413461
1037	Human	MALAT1	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	brain microvascular endothelial cells (BMECs)	oxygen glucose deprivation (OGD) treatment	OGD induced upregulation of MALAT1 in HBMECs.	32591985
1038	Human	MALAT1	lncRNA	arsenite	liver fibrosis	lihuman hepatic (L-02) cells	arsenite exposure	Co-cultures with arsenite-treated L-02 cells induced the activation of LX-2 cells and overexpression of MALAT1.	31513886
1039	Human	MALAT1	lncRNA	E2F transcription factor 3 (E2F3)	lung adenocarcinoma (LUAD)	"SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells"	E2F transcription factor 3 (E2F3) overexpression	upregulated	30771618
1040	Human	MALAT1	lncRNA	ZEB1	lung adenocarcinoma (LUAD)	"SPC-A1/docetaxel (DTX), H1299/docetaxel (DTX), and A549/docetaxel (DTX) cells"	ZEB1 overexpression treatment	upregulated	30771618
1041	Human	MALAT1	lncRNA	cigarette smoke extract (CSE)	lung cancer	human bronchial epithelial (HBE) cells	cigarette smoke extract (CSE) treatment	upregulated	26415832
1042	Human	MALAT1	lncRNA	gefitinib	lung cancer	A549 cells	gefitinib treatment	"MALAT1 promoted the proliferation and gefitinib resistance of lung cancer cells by sponging miR-200a, which regulates expression of ZEB1 in the A549 cells."	31133357
1043	Human	MALAT1	lncRNA	hypoxia	lung cancer	A549 lung adenocarcinoma cells	hypoxia induce	upregulated	29928414
1044	Human	MALAT1	lncRNA	IL-4	macrophage polarization	human PBMC-derived macrophages and THP-1-derived macrophages.	IL-4 treatment	downregulated	30676324
1045	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	macrophage polarization	human PBMC-derived macrophages and THP-1-derived macrophages.	lipopolysaccharide (LPS) treatment	upregulated	30676324
1046	Human	MALAT1	lncRNA	hypoxia	multiple myeloma (MM)	"multiple myeloma (MM) cell lines MM1S, 8226, KMS12BM, KMS11, U266"	hypoxia induce	upregulated	29444873
1047	Human	MALAT1	lncRNA	palmitic acid (PA)	myocardial lipotoxic injury	human cardiomyocytes (AC16 cells)	palmitic acid (PA) treatment	upregulated	31123414
1048	Human	MALAT1	lncRNA	hyperbaric oxygen (HBO)	neovascularization	human coronary artery endothelial cells (HCAECs)	hyperbaric oxygen (HBO) treatment	HBO at 2.5?ATA significantly increased MALAT1 expression in HCAECs and HCAECs-derived exosomes.	30301563
1049	Human	MALAT1	lncRNA	hypoxia	neuroblastoma (NB)	human neuroblastoma cell lines	hypoxia treatment	upregulated	26848616
1050	Human	MALAT1	lncRNA	bupivacaine	neurotoxicity	The human neuroblastoma cell line SH-SY5Y	bupivacaine treatment	"The expression of lncRNA MALAT1 was upregulated upon exposure to bupivacaine. Knockdown of lncRNA MALAT1 significantly increased the cell death rates, and Caspase3 activity assays revealed that the apoptosis rates were manifestly increased in the MALAT1 downregulated group."	31254586
1051	Human	MALAT1	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	CAL-27 cells; SCC-9 cells	cisplatin treatment	DDP-resistant cells showed higher expression level of MALAT1 compared to cisplatin-na?ve cells.	32494159
1052	Human	MALAT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary cultured chondrocytes	IL-1¦Â treatment	upregulated	31637891
1053	Human	MALAT1	lncRNA	osteogenic differentiation medium	osteogenesis	Adipose-derived mesenchymal stem cells (ADSCs)	osteogenic differentiation media induce	upregulated	30511267
1054	Human	MALAT1	lncRNA	estradiol-17¦Â (E2)	osteosarcoma (OS)	U2OS cells	estradiol-17¦Â (E2) treatment	upregulated	28098894
1055	Human	MALAT1	lncRNA	IL-17A	otitis media (OM)	human middle ear epithelial cells (HMEECs)	IL-17A treatment	RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs	33506040
1056	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	otitis media (OM)	human middle ear epithelial cells (HMEECs)	lipopolysaccharide (LPS) treatment	RT-qPCR analysis revealed that long noncoding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was verified to be upregulated in LPS- or IL-17A-stimulated HMEECs	33506040
1057	Human	MALAT1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
1058	Human	MALAT1	lncRNA	cisplatin (DDP)	ovarian cancer cell stemness	SKOV3 cells	cisplatin treatment	upregulated	32433460
1059	Human	MALAT1	lncRNA	high glucose (HG)	oxidative stress	retinal microvessels	high glucose (HG) treatment	upregulated	33051272
1060	Human	MALAT1	lncRNA	"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)"	parkinson's disease (PD)	SH-SY5Y cells	"1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment"	upregulated	30260025
1061	Human	MALAT1	lncRNA	resveratrol	parkinson's disease (PD)	MPTP-treated human neuroblastoma cell line SH©\SY5Y	resveratrol (RS) treatment	downregulated	30260025
1062	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	periodontal inflammation	Primary human gingival fibroblasts (HGFs)	lipopolysaccharide (LPS) treatment	upregulated	31552681
1063	Human	MALAT1	lncRNA	androgen	prostate cancer	Human prostate cancer cell lines DU145	androgen stimulation	lung adenocarcinoma transcript 1 (MALAT1) was increased in prostate cancer cells after androgen stimulation	30642743
1064	Human	MALAT1	lncRNA	docetaxel (DTX)	prostate cancer	DU-145 cells; PC-3 cells	docetaxel (DTX) treatment	LncRNA MALAT1 was overexpressed in human DTX-resistant PCa.	29633510
1065	Human	MALAT1	lncRNA	enzalutamide (Enz)	prostate cancer	Pca patients	enzalutamide (Enz) treatment	upregulated	28528814
1066	Human	MALAT1	lncRNA	Paris forrestii (PCT3)	prostate cancer	PC-3 cells	Paris forrestii (PCT3) treatment	upregulated	31810132
1067	Human	MALAT1	lncRNA	quercetin	prostate cancer	PC-3 cells	Quercetin (Quer) treatment	MALAT1 expression was significantly downregulated in quercetin-treated PC cells in a dose- and time-dependent manner	32210615
1068	Human	MALAT1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (hPASMCs)	hypoxia treatment	lncRNA MALAT1 promotes the proliferation and migration of hPASMCs and inhibits their apoptosis by inhibiting the miR-503/TLR4 signal axis.	32712618
1069	Human	MALAT1	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
1070	Human	MALAT1	lncRNA	ionizing radiation (IR)	radiation-induced acute and chronic complications	EA.hy926 cells	ionizing radiation (IR) treatment	radiation-induced DNA damage triggers cGAS signaling and subsequently increases the expression of MALAT1.	32532422
1071	Human	MALAT1	lncRNA	sunitinib (SU)	renal cell carcinoma (RCC)	769P cells; 786O cells	sunitinib (SU) treatment	MALAT1 expression was dramatically upregulated in SU-resistance RCC tissues and cell lines.	32663095
1072	Human	MALAT1	lncRNA	TGF-¦Â1	renal fibrosis	human renal proximal tubular epithelial (HK2) cells	TGF-¦Â1 treatment	TGF-¦Â1 induced fibrosis via upregulating MALAT1 expression in HK2 cells	32203053
1073	Human	MALAT1	lncRNA	CoCl2	renal ischemia/reperfusion (I/R) injury	HK-2 cells	cobalt chloride (CoCl 2) treatment	upregulated	30277425
1074	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cell line	lipopolysaccharide (LPS) treatment	upregulated	30896848
1075	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	g human skeletal muscle cells (HSMKMC 3500)	lipopolysaccharide (LPS) treatment	upregulated	31830649
1076	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	HSMKMC 3500 cells	lipopolysaccharide (LPS) treatment	upregulated	32882524
1077	Human	MALAT1	lncRNA	hypoxia	spinal cord ischemia/reperfusion injury (SCII)	AGE1.HN cells; P12 cells	hypoxia treatment	"The expression of MALAT1 and Bcl-2 was decreased, while miRNA-204 (miR-204) was upregulated in rats SCIRI model and neurocyte lines under hypoxic conditions."	29998804
1078	Human	MALAT1	lncRNA	dexamethasone (DEX)	steroid-induced avascular necrosis of femoral head (SANFH)	human bone marrow stromal cells (BMSC)	dexamethasone (DEX) treatment	downregulated	31678133
1079	Human	MALAT1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	stroke	human brain microvascular endothelial cells (HBMECs)	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	32217110
1080	Human	MALAT1	lncRNA	liposomal spherical nucleic acid (LSNA)	therapeutic potential of a LSNA	A549 (lung carcinoma) cells	liposomal spherical nucleic acid (LSNA)	downregulated	28026123
1081	Human	MALAT1	lncRNA	particulate matter (PM2.5)	toxicity of PM2.5	human bronchial epithelial cell lines (BEAS-2B and A549).	PM2.5 treatment	upregulated	28839203
1082	Human	MALAT1	lncRNA	high glucose (HG)	tubular injury	HK-2?cells	high glucose (HG) treatment	LncRNA MALAT1 was upregulated in HK-2?cells treated with high glucose.	29928873
1083	Human	MALAT1	lncRNA	rapamycin	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin (RPM) treatment	RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs	29845247
1084	Human	MALAT1	lncRNA	hypoxia	vascular growth	HUVECs	exposed to hypoxia (0.2% O2) treatment	upregulated	24602777
1085	Human	MALAT1	lncRNA	hypoxia	vascular remodeling	human pulmonary artery smooth muscle cells	hypoxia treatment	upregulated	28056547
1086	Human	MALAT-1	lncRNA	estradiol-17¦Â (E2)	breast cancer	"MCF10a, MCF7 and MB231 cells"	estradiol-17¦Â (E2) treatment	downregulated	24525122
1087	Human	MALAT-1	lncRNA	rosmarinic acid (RA)	ovarian cancer (OC)	OVCAR-3 human ovarian cancer cells	rosmarinic acid treatment	Rosmarinic acid induced upregulation of lncRNA MALAT-1 expression	30003749
1088	Human	MALAT-1	lncRNA	androgen	prostate cancer	human prostate cancer tissues and male nude mice	androgen treatment	MALAT-1 was upregulated in human prostate cancer tissues and cell lines.	23845456
1089	Human	MALAT-1	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
1090	Human	MALAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	MiR-150 was downregulated in LPS-induced HUVECs.	33181172
1091	Human	MANTIS	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1092	Human	MANTIS	lncRNA	HSA-bound P-cresol	chronic kidney disease (CKD) and end-stage renal disease (ESRD)	human umbilical vein endothelial cells (HUVECs)	HSA-bound P-cresol treatment	HSA-bound P-cresol induced HUVECs injury and decreased MANTIS expression.	31949698
1093	Human	MATR3	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
1094	Human	MCM3AP-AS1	lncRNA	doxorubicin (DOX)	chemoresistance of lymphoma	Daudi and Namalwa cells	doxorubicin treatment	MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma	32765087
1095	Human	MCM3AP-AS1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human chondrocytes	lipopolysaccharide (LPS) treatment	upregulated	31836002
1096	Human	MEG3	lncRNA	CoCl2	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	CoCl2 treatment	upregulated	33175458
1097	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	HK-2 cells	hypoxia/reoxygenation (H/R) treatment	upregulated	33175458
1098	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	upregulated	33602903
1099	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	TKPTS cells	lipopolysaccharide (LPS) treatment	MEG3 was significantly increased in TKPTS cells induced by lipopolysaccharide (LPS).	29923218
1100	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	human lung fibroblast WI-38 cells and human PMVECs	lipopolysaccharide (LPS) treatment	MEG3 was downregulated by LPS and its knockdown aggravated LPS-induced injury of human lung cells through miR-4262-mediated downregulated of KLF4.	31184231
1101	Human	MEG3	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	U937 cells; THP-1 cells	adriamycin (ADR) treatment	downregulated	32359033
1102	Human	MEG3	lncRNA	caerulein (Cae)	acute pancreatitis (AP)	Human pancreatic duct epithelial cells (HPDE)	caerulein (Cae) treatment	"As a result, the expression of MEG3 and FGFR2 was decreased in caerulein-induced HPDE cells, while the expression of miR-195-5p was increased."	32856219
1103	Human	MEG3	lncRNA	H2O2	age-related cataract (ARC)	SRA01/04 cells	H2O2 treatment	MEG3 promoted ARC progression by up-regulating TP53INP1 expression through suppressing miR-223 and promoting P53 expression.	32841649
1104	Human	MEG3	lncRNA	arsenite	apoptosis	A549 cells	arsenic (As) exposure	"Our results demonstrated that MEG3 expression was positively correlated with the concentration of three arsenic species (inorganic arsenic (iAs), monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA)"	33033900
1105	Human	MEG3	lncRNA	CoCl2	apoptosis	HK-2 cells	CoCl2 treatment	upregulated	33175458
1106	Human	MEG3	lncRNA	arsenite	arsenic-induced apoptosis	A549	arsenic (As) exposure	upregulated	33033900
1107	Human	MEG3	lncRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-induced human aorta vascular smooth muscle cells (HA-VSMCs)	baicalin (BAI) treatment	upregulated	30535498
1108	Human	MEG3	lncRNA	baicalin (BAI)	atherosclerosis (AS)	ox-LDL-treated human aorta vascular smooth muscle cells (HA-VSMCs)	baicalin (BAI) treatment	upregulated	30535498
1109	Human	MEG3	lncRNA	melatonin	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	melatonin treatment	downregulated	29024030
1110	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29024030
1111	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30535498
1112	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	30535498
1113	Human	MEG3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31312370
1114	Human	MEG3	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
1115	Human	MEG3	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
1116	Human	MEG3	lncRNA	angiotensin II (Ang II)	cardiovascular disease (CVD)	human umbilical vein endothelial cell (HUVECs)	angiotensin II (Ang II) treatment	downregulated	30838022
1117	Human	MEG3	lncRNA	etoposide (VP-16)	cell senescence	A549 and MCF-7 cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
1118	Human	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SK-N-SH; SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	MEG3/miR-485/AIM2 axis contributes to pyroptosis via activating caspase1 signaling during cerebral I/R	31794744
1119	Human	MEG3	lncRNA	lidocaine	cervical cancer (CC)	HeLa cells	lidocaine treatment	"Long noncoding RNA maternally expressed gene 3 (lncRNA-MEG3) was significantly downregulated in cervical cancer cells, and lidocaine increased the expression of lncRNA-MEG3 in HeLa cells."	31632519
1120	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 was upregulated in (CSE)-treated 16HBE cells.	31668807
1121	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMEC)	cigarette smoke extract (CSE) treatment	upregulated	32201430
1122	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	MEG3 expression was enhanced while miR-181a-2-3p abundance was reduced in the serum of patients with COPD and CSE-treated 16HBE cells.	33262837
1123	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	HBE135-E6E7 cells	cigarette smoke extract (CSE) treatment	MEG3 promoted proliferation and inhibited apoptosis by regulating the NF-¦ÊB signal pathway via miR-149-3p in CSE-treated HBE cells.	33365060
1124	Human	MEG3	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	CSE-treated 16HBE cells	cigarette smoke extract (CSE) treatment	"MEG3 was upregulated in COPD tissues and CSE-treated 16HBE cells, and knockdown of MEG3 mitigated CSE-repressed proliferation and CSE-triggered apoptosis or inflammation"	31668807
1125	Human	MEG3	lncRNA	particulate matter (PM2.5)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	PM2.5 treatment	LncRNA maternally expressed gene 3 ( MEG3) was significantly upregulated in HBECs after PM25 treatment	29899163
1126	Human	MEG3	lncRNA	smoking	chronic obstructive pulmonary disease (COPD)	lung tissues	smoking treatment	MEG3 was upregulated in COPD tissues	31668807
1127	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	upregulated	32269710
1128	Human	MEG3	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	coronary artery disease (CAD)	human endothelial cell from umbilical vein (HU-VECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28804550
1129	Human	MEG3	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	human AC16 cardiomyocytes	high glucose (HG) treatment	"MEG3 was overexpressed in HG-treated AC16 cells, and MEG3 knockdown suppressed the HG-induced apoptosis in AC16 cells"	31085717
1130	Human	MEG3	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells (HMCs)	high glucose treatment	upregulated	31737219
1131	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
1132	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose (HG) treatment	High glucose (HG) inhibited MEG3 and SIRT1 expression and enhanced miR-34a expression.	30529346
1133	Human	MEG3	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	Primary human retinal pigment epithelium (RPE) cells and ARPE-19 cells	high glucose (HG) treatment	"lncRNA MEG3 depresses HG-induced apoptosis and inflammation of RPE via miR-93/Nrf2 axis, providing a novel perspective on the genesis and development of DR."	32473920
1134	Human	MEG3	lncRNA	melatonin	diabetic retinopathy (DR)	MIO-M1 cells	melatonin (MEL) treatment	"MEG3 level was lower in HG-treated MIO-M1 cells, and melatonin (MEL) reversed the HG-induced decrease of MEG3."	32324260
1135	Human	MEG3	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic vasculopathy	human umbilical vein endothelial cells (HUVECs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	upregulated	30544204
1136	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	epithelial ovarian cancer (EOC)	"OVCAR3, SKOV3, HP8910 and ES-2 cells"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	24859196
1137	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	KYSE-410	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	27778235
1138	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"human esophageal cancer cell lines TE1, TE13, Eca109, YES2, and T.Tn"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28539329
1139	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	gastric cancer (GC)	"human gastric cancer cell lines MKN45, SGC7901, BGC823, and AGS"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	28345805
1140	Human	MEG3	lncRNA	TGF-¦Â1	glaucoma	Glaucoma Tenon's capsule fibroblasts (GTFs) from patients with glaucoma filtration surgery	TGF-¦Â2 (5ng/mL) treatment	downregulated	28081465
1141	Human	MEG3	lncRNA	cisplatin (DDP)	glioblastoma multiforme (GBM)	U87 cells	cisplatin treatment	upregulated	28677749
1142	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	glioblastoma multiforme (GBM)	"U251, U87 and A172 human glioma cell lines"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	5-Aza-2'-deoxycytidine (5-AzadC) decreased aberrant hypermethylation of the MEG3 promoter and prevented the loss of MEG3 expression.	26676363
1143	Human	MEG3	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	downregulated	32998396
1144	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	downregulated	28708282
1145	Human	MEG3	lncRNA	hypoxia/reoxygenation (H/R)	hepatic ischemia/reperfusion injury (HIRI)	HL7702 cells	hypoxia re-oxygenation (H/R) treatment	upregulated	28708282
1146	Human	MEG3	lncRNA	adenosine	hepatocellular carcinoma (HCC)	HepG2 cells	adenosine treatment	upregulated	31144362
1147	Human	MEG3	lncRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	"Four human hepatocellular carcinoma cell lines, SMMC-7721, Huh7, MHCC97H, and HCCLM3, and one human liver cell line L02"	arsenic trioxide (ATO) treatment	upregulated	31003765
1148	Human	MEG3	lncRNA	high glucose (HG)	high glucose-induced endothelial dysfunction	human umbilical vein endothelial cells (HUVEC)	high glucose (HG) treatment	MEG3 is significantly downregulated in an endothelial cell model of hyperglycemia.	31938204
1149	Human	MEG3	lncRNA	hypoxia	hypoxia-induced injury	HK-2 cells	hypoxia induce	upregulated	30860638
1150	Human	MEG3	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells	hypoxia treatment	lncRNA MEG3 was downregulated in human pulmonary artery smooth muscle cell in hypoxia.	29198701
1151	Human	MEG3	lncRNA	dexamethasone (DEX)	immune thrombocytopenic purpura (ITP)	peripheral blood	dexamethasone (DEX) treatment	downregulated	27522004
1152	Human	MEG3	lncRNA	palmitate	insulin resistance (IR)	Human HepG2 cells and primary hepatocytes	"To establish an insulin-resistant hepatocyte cell model, hepatocytes were stimulated by palmitate (0.25 mM, Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and treated with insulin (100 nM) for 20 min before harvest. treatment"	MEG3 were upregulated in palmitate-treated insulin resistance hepatocytes and HFD mice	31298399
1153	Human	MEG3	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic stroke (IS)	human neuroblastoma cell lines SK-N-SH and SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31794744
1154	Human	MEG3	lncRNA	etoposide (VP-16)	lung adenocarcinoma (LUAD)	human senescent cells	etoposide treatment	?the expression of lncRNA MEG3 and VGLL4 was significantly upregulated in senescent cells.	33141998
1155	Human	MEG3	lncRNA	curcumin (Cur)	lung cancer	lung cancer cell lines A549 and H520	curcumin treatment	Curcumin upregulated the expression of lncRNA-MEG3 and PTEN	33566305
1156	Human	MEG3	lncRNA	TGF-¦Â	lung cancer	human lung cancer cell lines	TGF-¦Â treatment	upregulated	27852821
1157	Human	MEG3	lncRNA	vincristine (VCR)	lung cancer	A549 cells; H292 cells	vincristine treatment	downregulated	29509250
1158	Human	MEG3	lncRNA	nickel	lung tumorigenesis	human bronchial epithelial cells	nickel treatment	downregulated	28263966
1159	Human	MEG3	lncRNA	respiratory syncytial virus (RSV)	nasopharyngeal carcinoma (NPC)	BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	downregulated	29257348
1160	Human	MEG3	lncRNA	all-trans retinoic acid (ATRA)	neurogenesis	amniotic epithelial cells (AECs)	all-trans retinoic acid (ATRA) treatment	"lncRNA MEG3 is upregulated by the ATRA/cAMP/CREB pathway, and it, in turn, is directly downregulated by miR-128-3p to increase the amount of neuron differentiation."	31921854
1161	Human	MEG3	lncRNA	paclitaxel (PTX)	non-small cell lung cancer (NSCLC)	A549 cells	paclitaxel (PTX) treatment	upregulated	30173893
1162	Human	MEG3	lncRNA	mineralizing solution	osteogenesis	human periodontal ligament cells (hPDLCs)	mineralizing solution treatment	downregulated	30256394
1163	Human	MEG3	lncRNA	mineralizing solution	osteogenesis	human periodontal ligament cells (hPDLCs)	mineralizing solution treatment	MEG3 was downregulated in osteogenic differentiation hPDLCs induced by mineralizing solution.	30256394
1164	Human	MEG3	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	ovarian cancer (OC)	cisplatin-resistant A2780cp cells treated with curcumin	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	28175963
1165	Human	MEG3	lncRNA	curcumin (Cur)	ovarian cancer (OC)	cisplatin-resistant A2780cp cells	curcumin treatment	upregulated	28175963
1166	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	periodontitis	periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	MEG3 level was decreased in LPS-treated PDLCs.	32520926
1167	Human	MEG3	lncRNA	high glucose (HG)	podocyte injury	human podocytes	high glucose (HG) treatment	upregulated	33061608
1168	Human	MEG3	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	psoriasis	HaCaT and NHEKs cell lines	tumor necrosis factor alpha (TNF-¦Á) treatment	"MEG3/miR-21 axis may regulate the expression of caspase-8, and further influence the proliferation and apoptosis of psoriasis keratinocyte, Act-HaCaT and Act- HHEK"	31660855
1169	Human	MEG3	lncRNA	nickel oxide nanoparticles (NiO NPs)	lung fibrosis	A549 cells	Nickel oxide nanoparticles (NiO NPs) treatment	NiO NPs also evoked EMT and decreased MEG3 expression in a dose-dependent manner in A549 cells.	33547861
1170	Human	MEG3	lncRNA	hypoxia	pulmonary hypertension (PH)	human pulmonary artery smooth muscle cell	hypoxia treatment	downregulated	29198701
1171	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (hDPCs)	lipopolysaccharide (LPS) treatment	"Here, we performed high-throughput sequencing to identify dysregulated lncRNAs between human normal and inflamed pulp and concluded that lncMEG3 (lncRNA maternally expressed gene 3, MEG3) was signi?cantly upregulated in both inflamed pulp and LPS-treated hDPCs."	33524362
1172	Human	MEG3	lncRNA	TGF-¦Â1	renal fibrosis	HK2 cells	TGF-¦Â1 treatment	downregulated	30095214
1173	Human	MEG3	lncRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	BEAS-2B cells	respiratory syncytial virus (RSV) infection treatment	lncRNA MEG3 was reduced in the NPA samples of RSV-infected patients and in BEAS-2B cells infected with RSV	29257348
1174	Human	MEG3	lncRNA	etoposide (VP-16)	cell senescence	A549; MCF-7 cells	etoposide treatment	upregulated	33141998
1175	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	sepsis	Human primary renal mixed epithelial cells	lipopolysaccharide (LPS) treatment	"lncRNA MEG3 overexpression and silencing using siRNA promoted and inhibited renal epithelial cell and cardiomyocyte apoptosis induced by lipopolysaccharide, respectively."	31641380
1176	Human	MEG3	lncRNA	lipopolysaccharide (LPS)	sepsis	U937 cells	lipopolysaccharide (LPS) treatment	downregulated	33040826
1177	Human	MEG3	lncRNA	iodine-131 (131I)	thyroid cancer (TC)	FTC-133 cells; TPC-1 cells	iodine-131 (131I) treatment	MEG3 expression appeared a decline and miR-182 expression displayed an increase in 131I-resistant FTC-133 (res-FTC-133) and TPC-1 (res-TPC-1) cells.	30021359
1178	Human	MEG3	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
1179	Human	MEG3	lncRNA	H2O2	ulcerative colitis (UC)	Caco-2 cells	H2O2 treatment	downregulated	33394187
1180	Human	MEG3	lncRNA	dNK/IFN-¦Á	uterovascular transformation	vascular smooth muscle cell (VSMC)	dNK/IFN-¦Á treatment	upregulated	28161059
1181	Human	MEG3	lncRNA	dNK/IFN-¦Ã	spiral artery remodeling	human aorta VSMC (HA-VSMC) line	dNK/IFN-¦Ã treatment	upregulated	28161059
1182	Human	MEG4	lncRNA	carbon tetrachloride (CCl4)	liver fibrosis	human hepatic stellate cell lines LX-2 cells	CCl4 treatment	downregulated	25201081
1183	Human	MEG5	lncRNA	TGF-¦Â1	liver fibrosis	human hepatic stellate cell lines LX-3 cells	in response to transforming growth factor-¦Â1 (TGF-¦Â1) treatment	downregulated	25201082
1184	Human	MEG8	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	A549 cells; LC2/ad cells; Panc1 cells	TGF-¦Â treatment	MEG8 lncRNA expression was immediately induced during TGF-¦Â-mediated EMT of A549 and LC2/ad lung cancer and Panc1 pancreatic cancer cell lines	30262664
1185	Human	MER11C	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1186	Human	METTL8	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1187	Human	MFI2-AS1	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	C28/I2 cells	lipopolysaccharide (LPS) treatment	MFI2-AS1 expression was increased in osteoarthritis tissues and LPS-treated C28/I2 cells.	31678554
1188	Human	MHRT	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
1189	Human	MHRT	lncRNA	H2O2	chronic heart failure (CHF)	human cardiomyocyte cell line AC16	H2O2 treatment	downregulated	31853247
1190	Human	MIAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	29136944
1191	Human	MIAT	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aorta vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Proliferation and migration were modified by MIAT/miR-148b/PAPPA axis in ox-LDL induced AS cell model.	32470448
1192	Human	MIAT	lncRNA	diethylstilbestrol (DES)	breast cancer	MCF-7?cells	diethylstilbestrol (DES) treatment	Activating estrogen signaling by diethylstilbestrol (DES) led to a dose- and time-dependent upregulated of MIAT in MCF-7?cells.	29792859
1193	Human	MIAT	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (HMCs)	high glucose (HG) treatment	upregulated	33009725
1194	Human	MIAT	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	"MIAT and CASP1 expression were substantially increased, while that of miR-342-3p was decreased in AGE-BSA-treated HRPCs."	33065089
1195	Human	MIAT	lncRNA	advanced glycation end product modified bovine serum albumin (AGE-BSA)	diabetic retinopathy (DR)	primary human retinal pericytes (HRPCs)	advanced glycation end product modified bovine serum albumin (AGE-BSA) treatment	Long noncoding RNA MIAT regulates primary human retinal pericyte pyroptosis by mdulating miR-342-3p targeting of CASP1 in diabetic retinopathy.	33065089
1196	Human	MIAT	lncRNA	high glucose (HG)	angiogenesis 	diabetic retinas and endothelial cells	high glucose treatment	upregulated	25587098
1197	Human	MIAT	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human renal proximal tubular epithelial (HK-2) cells	TGF-¦Â1 treatment	"MIAT knockdown reduced cell viability, proliferation, migration, and the EMT in HK-2 cells"	31863776
1198	Human	MIAT	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HepG2 cells	hypoxia treatment	upregulated	32468055
1199	Human	MIAT	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary alveolar epithelial cells (HPAECS)	hypoxia treatment	"MIAT was upregulated in both in vivo and in vitro HPH models, while miR-29a-5p was downregulated."	32964992
1200	Human	MIAT	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	human adipose-derived stem cells (hASCs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	27797128
1201	Human	MIAT	lncRNA	bortezomib	multiple myeloma (MM)	Bone marrow	bortezomib? treatment	upregulated	30967527
1202	Human	MIAT	lncRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	TGF-¦Â1 treatment	upregulated	31863776
1203	Human	MIAT	lncRNA	high glucose (HG)	renal tubules injury	human renal tubular epithelial cell line (HK-2)	high glucose treatment	downregulated	26551455
1204	Human	MIAT2	lncRNA	lipopolysaccharide (LPS)	inflammation	Human WI©\38 cells	lipopolysaccharide (LPS) treatment	?MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage.	31566734
1205	Human	MIAT2	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	MIAT2 was negatively regulated by LPS and it alleviated LPS-induced damage.	31566734
1206	Human	MINCR	lncRNA	radiation	nasopharyngeal carcinoma (NPC)	NP460; CNE2; CNE2R cells	radiation treatment	"MINCR diminished NPC cell radiosensitivity by sponging miR-223, increasing ZEB1 and activating the AKT/PI3K axis"	33290841
1207	Human	MIR100HG	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
1208	Human	MIR100HG	lncRNA	CoCl2	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	CoCl2 treatment	upregulated	32391042
1209	Human	MIR155HG	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
1210	Human	MIR155HG	lncRNA	resveratrol	cellular defense against genotoxic agents	human glioma cell lines	resveratrol (Res) treatment	upregulated	25645334
1211	Human	MIR155HG	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	human pulmonary microvascular endothelial cell (HPMECs)	cigarette smoke extract (CSE) treatment	upregulated	32129458
1212	Human	MIR155HG	lncRNA	TGF-¦Â1	lung fibrosis	normal human primary lung fibroblasts (NHLFs)	TGF-¦Â1 treatment	The lncRNA MIR155 host gene (MIR155HG) was found to be abnormally upregulated in pulmonary fibrosis tissues and TGF¦Â1-stimulated normal human primary lung fibroblasts (NHLFs)	33482190
1213	Human	MIR181A2HG	lncRNA	high glucose (HG)	diabetic vasculopathy	Human umbilical vein endothelial cells (HUVECs)	high-glucose (HG) treatment	"he persistent exposure of HUVECs to HG resulted in MIR181A2HG downregulated and thus reduced its ability to sponge miR-6832-5p, miR-6842-5p and miR-8056, subsequently leading to an increase in miR-6832-5p, miR-6842-5p and miR-8056 levels."	33537821
1214	Human	MIR210HG	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
1215	Human	MIR210HG	lncRNA	Hypoxia	warburg effect	MCF7; T47D; ZR-75-1 cells	hypoxia treatment	upregulated	33392077
1216	Human	MIR22	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1217	Human	MIR22HG	lncRNA	6-thioguanine (6-TG)	breast cancer	MCF-7 cells	6-thioguanine (6-TG) treatment	upregulated	33376537
1218	Human	MIR22HG	lncRNA	microcystin-leucine arginine (MC-LR)	MC-LR-induced hepatotoxicity	HL7702 cells	microcystin-LR(MC-LR) treatment	upregulated	30430930
1219	Human	MIR22HG	lncRNA	hypoxia	myocardial infarction (MI)	AC16 cardiomyocytes	hypoxia treatment	Results showed that hypoxia treatment decreased viability and increased MIR22HG expression in AC16 cardiomyocytes.	33631962
1220	Human	MIR3142HG	lncRNA	IL-1¦Â	inflammation	human lung fibroblasts	IL-1¦Â treatment	upregulated	30619270
1221	Human	MIR31HG	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	gefitinib-resistant PC9 (PC9-R) cell lines	gefitinib	upregulated	28529576
1222	Human	MIR4435-2HG	lncRNA	Fusobacterium nucleatum (F. nucleatum)	oral squamous cell carcinoma (OSCC)	human immortalized oral epithelial cells (HIOECs); SCC-9 cells; HSC-4 cells	F. nucleatum infection	upregulated	31997506
1223	Human	MIR497HG	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (HRECs)	high glucose (HG) treatment	High-level glucose (HG) treatment significantly downregulated MIR497HG in HRECs.	32572899
1224	Human	MIR503HG	lncRNA	high glucose (HG)	proximal tubular cell apoptosis	Human proximal tubular (HK-2) cells	high glucose (HG) treatment	MIR503HG indirectly regulates Bcl-2 by promoting the co-transcription of miRNA-503 to participate high-glucose-induced proximal tubular cell apoptosis.	33262626
1225	Human	MIR503HG	lncRNA	XAV939	non-small cell lung cancer (NSCLC)	"The NSCLC cell line, NCI-H1299"	10 ?M XAV939 for 12 h treatment	The downregulated of lncRNA?MIR503HG?induced by XAV939 may serve an important role in NSCLC suppression via sponging?miR-1273c?and regulating?SOX4?expression	31186710
1226	Human	MIR6516	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1227	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	cell damage	HK-2 cells	lipopolysaccharide (LPS) treatment	LncRNA?Mirt2 prohibits lipopolysaccharide-evoked HK-2 cell injury via modulation of?microRNA-126.	31889348
1228	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	IgA nephropathy (IgAN)	HK-2 cells	lipopolysaccharide (LPS) treatment	LPS inhibited Mirt2 expression in HK-2 cells.	31889348
1229	Human	Mirt2	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	inflammation	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
1230	Human	Mirt2	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	parkinson's disease (PD)	SH-Sy5y cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"Mirt2 overexpression moderated TNF-¦Á-caused apoptosis associated with inflammation and oxidative stress Mirt2 suppressed TNF-¦Á-induced accumulation of miR-101, and based on this Mirt2 exhibited anti-inflammatory roles"	31513985
1231	Human	Mirt2	lncRNA	lipopolysaccharide (LPS)	ulcerative colitis (UC)	colonic epithelial cells	lipopolysaccharide (LPS) treatment	downregulated	31687015
1232	Human	MKI67IP-3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	28195197
1233	Human	MM2P	lncRNA	lipopolysaccharide- and MSU	acute gouty arthritis (AGA)	THP-1 cells	lipopolysaccharide-and MSU treatment	downregulated	32705194
1234	Human	Morrbid	lncRNA	lymphocytic choriomeningitis virus (LCMV)	lymphocytic choriomeningitis virus (LCMV) infection	CD8 T cell	lymphocytic choriomeningitis virus (LCMV) infection	upregulated	31138702
1235	Human	MPRL	lncRNA	cisplatin (DDP)	tongue squamous cell carcinoma (TSCC)	"human TSCC cell lines, CAL-27, SCC-9 and SCC-25"	cisplatin treatment	MPRL expression was significantly upregulated in TSCC cell lines treated with cisplatin and transactivated by E2F1.	30885939
1236	Human	MSC-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	LN229 cells; SHG-44 cells	temozolomide (TMZ) treatment	MSC-AS1 was upregulated in TMZ-resistant glioma tissues and cells	33106913
1237	Human	MSC-AS1	lncRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	Human pancreatic cancer cell lines PANC-1 and BxPC-3	gemcitabine treatment	MSC-AS1/miR-29b-3p axis modulates the cell proliferation and GEM-induced cell apoptosis in PDAC cell lines through CDK14.	30915884
1238	Human	MST1P2	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	SW 780 cells	cisplatin treatment	MST1P2 serves as a competing endogenous RNA for miR-133b to counteract miR-133b-induced suppression on Sirt1.	32052927
1239	Human	MSTRG.292666.16	lncRNA	osimertinib	non-small cell lung cancer (NSCLC)	plasma; H1975R cells; H1975R cells-derived exosomes	osimertinib treatment	"lncRNA MSTRG.292666.16 was significantly upregulated in osimertinib-resistant plasma, osimertinib-resistant H1975R cells and their derived exosomes, compared with those in osimertinib-sensitive plasma, H1975 cells and exosomes."	32375124
1240	Human	MSX2P1	lncRNA	IL-22	psoriasis	HaCaT cells	IL-22 treatment	upregulated	29339075
1241	Human	MT1DP	lncRNA	cadmium (Cd)	cadmium (Cd)-induced hepatoxicity	HepG2 cells	cadmium (Cd) treatment	upregulated	30027041
1242	Human	MT1DP	lncRNA	cadmium (Cd)	cadmium-induced toxicity	blood; blood exosomes; liver cells	cadmium (Cd) treatment	upregulated	31864927
1243	Human	MTA2TR	lncRNA	hypoxia	pancreatic cancer (PC)	PANC-1;BxPC-3;SW1990 cell;	hypoxia induce	upregulated	31410216
1244	Human	MTMR9LP	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1245	Human	MUDENG	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
1246	Human	MUDENG	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
1247	Human	MX1-215	lncRNA	IFN-¦Á	head and neck squamous cell carcinoma (HNSCC)	Cal27 cells; HN30 cells	IFN-¦Á treatment	upregulated	31907020
1248	Human	n335586	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HCC tissues; HepG2.2.15cells	hepatitis B virus (HBV) infection	n335586 was significantly increased in HBV positive HCC tissues and cells.	29753758
1249	Human	n336098	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
1250	Human	n337041	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
1251	Human	n344988	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
1252	Human	n345751	lncRNA	radiation and microgravity	astronaut health	human lymphoblastoid TK6 cells	radiation and microgravity treatment	upregulated	31987473
1253	Human	NBR2	lncRNA	curcumin (Cur)	colorectal cancer (CRC)	"4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620"	curcumin treatment	"when colorectal cancer cells were treated with curcumin, the expression of NBR2 was significantly increased."	31888414
1254	Human	NBR2	lncRNA	glucose	colorectal cancer (CRC)	"4 human CRC cell lines, including HCT116, HCT8, SW480, and SW620"	glucose starvation	"glucose deficiency increased the expression of NBR2 in colorectal cancer cells, and NBR2 knockdown affected the progression of colorectal cancer cells under glucose starvation conditions."	31888414
1255	Human	nc886	lncRNA	doxorubicin (DOX)	cytotoxicity	"HCT116 cells, Nthy-ori 3-1 cells"	doxorubicin treatment	downregulated	30948645
1256	Human	nc886	lncRNA	ultraviolet (UV) irradiation	inflammation	?human keratinocytes HaCaT cells	ultraviolet B (UVB) radiation treatment	downregulated	30685091
1257	Human	nc886	lncRNA	TGF-¦Â	ovarian cancer (OC)	SKOV3 cells	transforming growth factor-¦Â (TGF-¦Â) treatment	upregulated	29563500
1258	Human	nc886	lncRNA	ultraviolet (UV) irradiation	photoaging	human keratinocyte (HaCaT) cells	UVB irradiation treatment	"UVB irradiation accelerates the methylation of the nc886 gene, therefore, reducing its expression"	32630038
1259	Human	NCK1-AS1	lncRNA	cisplatin (DDP)	cervical cancer (CC)	Cervical cancer HeLa cells	cisplatin treatment	si-NCK1-AS1 and miR-134-5p mimic both reduced MSH2 activity and increased cisplatin-induced apoptosis in cervical cancer cells.	30221354
1260	Human	NCK1-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251 and A172 cells	temozolomide (TMZ) treatment	upregulated	31750728
1261	Human	NCK1-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U251; A172 cells	temozolomide (TMZ) treatment	NCK1-AS1 could increase drug resistance of glioma cells to TMZ by modulating miR-137/TRIM24 pathway	31750728
1262	Human	NCRMS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1263	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	inflammation	"The human osteosarcoma cell line, MG63"	lipopolysaccharide (LPS) treatment	"?There were 427 dysregulated genes in the LPS-stimulated MG63 cells, in which NEAT1 was significantly downregulated"	33416115
1264	Human	NEAT1	lncRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	IL-1¦Â treatment	TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells	33478594
1265	Human	NEAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TNF-¦Á/IL-1¦Â induced a time- and dose-dependent increase in the mRNA expression of lncRNA NEAT1 in the nucleus pulposus cells	33478594
1266	Human	NEAT1	lncRNA	Iodine-131 (131I)	papillary thyroid cancer (PTC)	thyroid papillary cell line TPC-1 (BNCC337912) and B-CPAP (BNCC338685)	131I treatment	NEAT1 suppression could inhibit 131I resistance of PTC by upregulating miR-101-3p/FN1 expression and inactivated PI3K/AKT signaling pathway both in vitro and in vivo.	30596336
1267	Human	NEAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	HCT8; SW480 cells	5-fluorouracil (5-FU) treatment	LncRNA NEAT1 could target miR-34a and promote autophagy to facilitate 5-FU chemoresistance in CRC.	31802650
1268	Human	NEAT1	lncRNA	CoCl2	acute kidney injury (AKI)	human kidney tubular cells (HK-2)	CoCl2?-stimulated HK-2 cells	NEAT1 was upregulated in AKI patients compared with healthy control.	31090110
1269	Human	NEAT1	lncRNA	ischemia	acute kidney injury (AKI)	serum from AKI patients	ischemia©\induced AKI	The level of NEAT1 in HK©\2 cells treated with CoCl2 was higher in a dose©\dependent manner.	31090110
1270	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	NEAT1 was upregulated in LPS-stimulated HK-2 cells.	33335994
1271	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	NEAT1 was upregulated in serum of sepsis patients and LPS-induced HK2 cells.	33885954
1272	Human	NEAT1	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	NB4 cells	all-trans retinoic acid (ATRA) treatment	upregulated	29111326
1273	Human	NEAT1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y and SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	"NEAT1 expression was enhanced in A¦Â-treated SH-SY5Y and SK-N-SH cells, miR-107 abundance was reduced in A¦Â-treated cells, and its overexpression reversed A¦Â-induced injury. Moreover, interference of miR-107 abated silencing of NEAT1-mediated inhibition of neuronal damage in A¦Â-treated SH-SY5Y and SK-N-SH cells."	31250578
1274	Human	NEAT1	lncRNA	acrolein	apoptosis	vascular smooth muscle cells (VSMCs)	acrolein treatment	downregulated	31864078
1275	Human	NEAT1	lncRNA	acrolein	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	Acrolein treatment	downregulated	31864078
1276	Human	NEAT1	lncRNA	asparagus extract (AE)	atherosclerosis (AS)	Acrolein-treated vascular smooth muscle cells (VSMCs)	asparagus extract (AE) treatment	upregulated	31864078
1277	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 was significantly increased in THP-1 cells incubated with ox-LDL and meanwhile miR-342-3p was greatly decreased.	30259979
1278	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	30259979
1279	Human	NEAT1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human aortic endothelial cells (HAECs)	oxidized low-density lipoprotein (ox-LDL) treatment	NEAT1 adjusted the AKT/mTOR signaling pathway via miR-638 in ox-LDL-induced HAECs to accelerate their proliferation and impede their apoptosis.	32377692
1280	Human	NEAT1	lncRNA	Trimethylamine N-oxide (TMAO)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	Trimethylamine N-oxide (TMAO) exposure treatment	upregulated	31173767
1281	Human	NEAT1	lncRNA	t-butylhydroperoxide (t-BHP)	atherosclerotic coronary heart disease (CHD)	Primary HUVECs	t-butylhydroperoxide (t-BHP) treatment	upregulated	31352814
1282	Human	NEAT1	lncRNA	bharangin	breast cancer	MCF 7 cells	bharangin treatment	upregulated	30251663
1283	Human	NEAT1	lncRNA	hypoxia	breast cancer	MCF-7 cells	1% O2 treatment	upregulated	26289678
1284	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	bronchopneumonia	BEAS-2B cells	lipopolysaccharide (LPS) treatment	"NEAT1 and MyD88 were upregulated in BEAS-2B cells by LPS, while miR-155-5p was downregulated."	33719773
1285	Human	NEAT1	lncRNA	macrophage migration inhibitory factor (MIF)	cardioprotective therapy	human adipose-derived MSCs (ADMSCs); Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes	macrophage migration inhibitory factor (MIF) treatment	LncRNA-NEAT1/miR-142-3p/FOXO1 at least partially mediates the cardioprotective roles of exosomeMIF in protecting cardiomyocytes from apoptosis.	31964409
1286	Human	NEAT1	lncRNA	H2O2	cataract	human lens epithelial cells (HLECs)	H2O2 treatment	upregulated	33490165
1287	Human	NEAT1	lncRNA	resveratrol	cellular defense against genotoxic agents	human glioma cell lines	resveratrol (Res) treatment	upregulated	25645334
1288	Human	NEAT1	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Human normal colonic epithelial cell line, FHC, and colorectal carcinoma cell lines, HT29, HCT8, HCT116, SW480, SW620"	5-fluorouracil (5-FU) treatment	NEAT1 knockdown noticeably inhibited the proliferation of CRC cells and enhanced 5-FU sensitivity.	31802650
1289	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	corneal neovascularization (CNV)	human corneal fibroblasts (HCFs)	lipopolysaccharide (LPS) treatment	The expression of NEAT1 in HCFs was upregulated by LPS.	30328354
1290	Human	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	Human mesangial cells	high glucose (HG) treatment	Real-time PCR was performed to detect the relative NEAT1 and miR-222-3p expressions and further confirmed the relationship between NEAT1 and miR-222-3p.	33585566
1291	Human	NEAT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK-2 cells	high glucose (HG) treatment	"Our results showed that NEAT1 and Drp1 levels were upregulated, while miR-150-5p level was downregulated in HK-2 cells in response to HG."	33914383
1292	Human	NEAT1	lncRNA	fenofibrate	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	fenofibrate treatment	upregulated	31311324
1293	Human	NEAT1	lncRNA	paraquat (PQ)	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	paraquat (PQ) treatment	upregulated	31311324
1294	Human	NEAT1	lncRNA	simvastatin	drug-inducible neuroprotection from oxidative stress	SH-SY5Y cells	simvastatin treatment	upregulated	31311324
1295	Human	NEAT1	lncRNA	rapamycin	dyslipidemia	serum	rapamycin treatment	hsa-miR-372-3p was filtered using RNA sequencing and identified as a key regulator in rapamycin-induced TGs accumulation	33705959
1296	Human	NEAT1	lncRNA	progesterone (P4)	endometrial cancer (EC)	human Ishikawa cells	Progesterone treatment	NEAT1 or LEF1 was overexpressed in endometrial cancer cells while downregulated following post-treatment with progesterone	30452118
1297	Human	NEAT1	lncRNA	progesterone (P4)	endometrial cancer (EC)	Ishikawa cells	progesterone treatment	LncRNA nuclear enriched abundant transcript 1 (NEAT1) was the most significantly downregulated lncRNA in endometrial cancer cells treated with progesterone	30452118
1298	Human	NEAT1	lncRNA	TGF-¦Â2	epithelial-mesenchymal transition (EMT)	Primary human LECs (HLECs)	TGF-¦Â2 treatment	"TGF-¦Â2 induces NEAT1 overexpression, which in turn suggests that NEAT1 acts as a ceRNA targeting Snail1 or Zeb1 by binding miR-34a or miR-204"	32596382
1299	Human	NEAT1	lncRNA	adriamycin (ADR)	gastric cancer (GC)	SGC7901 cells	adriamycin (ADR) treatment	"NEAT1 was upregulated in GC tissues and cells, especially in in GC adriamycin-resistant cells."	28401449
1300	Human	NEAT1	lncRNA	oxaliplatin	gastric cancer (GC)	GC cell lines HGC-27;BGC-823	oxaliplatin treatment	upregulated	31617275
1301	Human	NEAT1	lncRNA	oxaliplatin	gastric cancer (GC)	HGC-27 cells; BGC-823 cells	oxaliplatin (OXA) treatment	upregulated	31617275
1302	Human	NEAT1	lncRNA	radiation	gastric cancer (GC)	MKN-45 and AGS cells	radiation treatment	NEAT1 depletion enhanced radio-sensitivity of GC by negatively regulating miR-27b-3p in vitro and in vivo	33292252
1303	Human	NEAT1	lncRNA	adenovirus (ADV)	glioblastoma multiforme (GBM)	FMXJ-1 cells	adenovirus (ADV) treatment	ADV infection upregulated lncRNA NEAT1.	32843056
1304	Human	NEAT1	lncRNA	estradiol-17¦Â (E2)	hepatic steatosis	HepG2 cells	estradiol-17¦Â (E2) treatment	upregulated	31062612
1305	Human	NEAT1	lncRNA	oleacein (OA)	hepatic steatosis	HepG2 cells	oleic acids treatment	upregulated	31062612
1306	Human	NEAT1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	SNU-182 cells; HUH7 cells	hypoxia treatment	LncRNA-NEAT1 expression was significantly induced by hypoxia in SNU-182 and HUH7 cells.	32670881
1307	Human	NEAT1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2 or Bel7404	sorafenib (Sora) treatment	"lncRNA NEAT1 mediates Sora resistance of HCC cells by suppressing miR-335 expression, and disinhibition on c-Met-Akt signaling pathway"	30937906
1308	Human	NEAT1	lncRNA	histone deacetylase (HDAC)	histone deacetylase resistance in nasopharyngeal cancer (NPC)	CNE1; CNE2; C666¨C1	Histone deacetylase treatment	upregulated	32692721
1309	Human	NEAT1	lncRNA	herpes simplex virus 1 (HSV-1)	herpes simplex virus 1 (HSV-1) infection	HeLa cells	infect with HSV-1	upregulated	27783096
1310	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	osteoblasts inflammation	MG63 cells	lipopolysaccharide (LPS) treatment	downregulated	33416115
1311	Human	NEAT1	lncRNA	Toll-like receptor3-p38 pathway-triggered poly I:C	innate immune response	HeLa TO cells £¬ A549 cells	cells were transfect poly I:C treatment	upregulated	24507715
1312	Human	NEAT1	lncRNA	advanced glycation end product (AGE)	intervertebral disc degeneration (IDD)	human nucleus pulposus cells (HNPC)	advanced glycation end product (AGE) treatment	upregulated	32850952
1313	Human	NEAT1	lncRNA	sepsis	liver damage	liver tissues	sepsis induce treatment	The expression of lncRNA NEAT1 in liver tissue of patients with sepsis-induced liver injury was clearly increased	31344555
1314	Human	NEAT1	lncRNA	particulate matter (PM2.5)	lung cancer	BEAS-2B and HBE cells	particulate matter (PM2.5) treatment	Loss of NEAT1 represses the malignant transformation of BEAS-2B and HBE cells induced by PM25	33829382
1315	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	Human renal mesangial cells (HRMCs)	lipopolysaccharide (LPS) treatment	"NEAT1 accelerated renal mesangial cell injury via directly targeting miR-146b, promoting the expression of TRAF6, and activating the NF-¦ÊB signaling in lupus nephritis."	32710276
1316	Human	NEAT1	lncRNA	dexamethasone (DEX)	multiple myeloma (MM)	MM1R cell lines	dexamethasone (Dex) treatment	NEAT1 was highly expressed in DEX-resistant myeloma cell lines.	29948578
1317	Human	NEAT1	lncRNA	resveratrol	multiple T myeloma	U266 cells; LP1 cells	resveratrol (RS) treatment	"lncRNA NEAT1 was highly expressed in MM cells, which could be significantly inhibited by resveratrol"	30107344
1318	Human	NEAT1	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	NEAT1 and miR-140 are upregulated in hepacytes under the NAFLD conditions. The NEAT1-miR-140 axis play a crucial role in modulation of NAFLD via inactivation of AMPK/SREBP1 signaling.	31239155
1319	Human	NEAT1	lncRNA	free fatty acids (FFA)	nonalcoholic fatty liver disease (NAFLD)	HepG2 cells	free fatty acids (FFA) treatment	upregulated	31484042
1320	Human	NEAT1	lncRNA	bone morphogenetic protein 1 (BMP1)	osteogenesis	human bone marrow-derived mesenchymal stem cells (hBMSCs)	BMP1 treatment	NEAT1 promotes osteogenic differentiation in hBMSCs by regulating miR-29b-3p/BMP1 axis.	30638953
1321	Human	NEAT1	lncRNA	radioactivity iodine (RAI)	papillary thyroid cancer (PTC)	TPC-1 cells; B-CPAP cells	radioactivity iodine (RAI) treatment	upregulated	30596336
1322	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	Human neuroblastoma cell line SH-SY5Y	1-methyl-4-phenylpyridinium (MPP+) treatment	?NEAT1 expression was significantly increased in SH-SY5Y cells after MPP+?treatment in dose- and time- dependent manners.	31228597
1323	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	downregulated of NEAT1 repressed ¦Á-syn-induced activation of NLRP3 inflammasome via inhibiting the expression of GJB1 by targeting miR-1301-3p.	32712773
1324	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29287722
1325	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	29575151
1326	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	32712773
1327	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"Here, the increased lncRNA NEAT1 was discovered in MPP+-induced SH-SY5Y cells."	32712773
1328	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MMP+) treatment	upregulated	33069733
1329	Human	NEAT1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"We demonstrated that, in SH-SY5Y cells treated with MPP+, NEAT1 and PDE4B expression levels were raised, while miR-124-3p expression was repressed"	33522352
1330	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	upregulated	31632562
1331	Human	NEAT1	lncRNA	H2O2	preeclampsia (PE)	HTR-8/SVneo	H2O2 treatment	upregulated of LncRNA NEAT1 induces apoptosis of human placental trophoblasts	32998583
1332	Human	NEAT1	lncRNA	docetaxel (DTX)	prostate cancer	PCa samples; PC3 cells; DU145 cells	docetaxel (DTX) treatment	NEAT1 was upregulated in docetaxel-resistant PCa clinical samples and cell lines.	31672604
1333	Human	NEAT1	lncRNA	Paris forrestii (PCT3)	prostate cancer	PC-3 cells	Paris forrestii (PCT3) treatment	downregulated	31810132
1334	Human	NEAT1	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	upregulated	32475133
1335	Human	NEAT1	lncRNA	hypoxia	reperfusion injury	human iPS-derived cardiomyocytes (iPS-CM)	hypoxia treatment	downregulated	32826883
1336	Human	NEAT1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	upregulated	32326576
1337	Human	NEAT1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	RA-FLS cells	tumor necrosis factor alpha (TNF-¦Á) treatment	"We found that NEAT1 was upregulated, and miR-204-5p was downregulated in the RA patients' synovial tissue and TNF-¦Á treated RA-FLSs"	33394349
1338	Human	NEAT1	lncRNA	anti-microbial peptide LL-37	rosacea	skin tissues	LL37 treatment	?NEAT1 was upregulated in rosacea skin and in LL37-treated HaCaT cells.	33678493
1339	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	THP-1 cells	lipopolysaccharide (LPS) treatment	upregulated	32099901
1340	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	"NEAT1 regulated TRAF6 expression by sponging let-7b-5p in HK-2 cells, which promotes LPS-induced injury and inflammation in HK-2 cells."	32724027
1341	Human	NEAT1	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute lung injury	A549 cells	lipopolysaccharide (LPS) treatment	upregulated	32089649
1342	Human	NEAT1	lncRNA	tuberculosis (MTB)	tuberculosis (TB)	THP-1 cells	Mycobacterium tuberculosis (MTB) infection treatment	upregulated	33271233
1343	Human	NEAT1.1	lncRNA	cisplatin (DDP)	bladder cancer	T24 cells	cisplatin (DPP) treatment	"the RNA level of NEAT1.1, one RNA variant of NEAT1, was reduced in cisplatin-sensitive T24 cells compared to cisplatin-resistant T24 (T24R) cells after both treated with cisplatin modulated through Wnt/¦Â-catenin signaling pathway using RNA-seq."	31933859
1344	Human	NEAT1_2	lncRNA	Solamargine	gastric cancer (GC)	"The GC cell lines AGS, BGC823, SGC7901, HGC27 and MGC803"	Solamargine treatment	upregulated	30864686
1345	Human	NEAT1-1	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	mycobacterium tuberculosis (Mtb) infection	Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro.	30534569
1346	Human	NEAT1-2	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	THP-1 cells	mycobacterium tuberculosis (Mtb) infection	Mycobacterium tuberculosis infection robustly increased the expression of NEAT1-1 and NEAT1-2 in THP-1 macrophages in vitro.	30534569
1347	Human	NFAT5-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
1348	Human	NIFK-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1349	Human	NKILA	lncRNA	active fraction of polyrhachis vicina rogers (AFPR)	breast cancer	MCF-7 cells	active fraction of Polyrhachis vicina Rogers (AFPR) treatment	upregulated	31881485
1350	Human	NKILA	lncRNA	active fraction of Polyrhachis vicina Rogers (AFPR)	breast cancer	MCF-7 cells	active fraction of Polyrhachis vicina Rogers (AFPR) treatment	upregulated	31881485
1351	Human	NKILA	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	MCF 7 cells	TGF-¦Â treatment	lncRNA NKILA was upregulated by TGF-¦Â	29761481
1352	Human	NKILA	lncRNA	TGF-¦Â1	esophageal squamous cell carcinoma (ESCC)	KYSE30 cells	TGF-¦Â1 treatment	LncRNA NKILA is upregulated by TGF-¦Â1	29379981
1353	Human	NKILA	lncRNA	baicalin (BAI)	hepatocellular carcinoma (HCC)	SMMC-7721 cells; HepG2 cells	baicalin (BAI) treatment	downregulated	29481769
1354	Human	NKILA	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	infantile pneumonia (IP)	MRC5 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	NKILA weakens TNF-¦Á-induced inflammation of MRC-5 cells by miR-21 upregulated	32013579
1355	Human	NKILA	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	ischemic neuronal injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGDR induce NKILA upregulation in SH-SY5Y cells	30007440
1356	Human	NKILA	lncRNA	osteogenic differentiation medium	osteogenesis	Mesenchymal stem cells (MSCs)	"osteogenic medium (¦Á-MEM containing 10% FBS, 50 ¦Ìg/ml ascorbic acid, and 5 mM ¦Â-glycerophosphate) treatment"	"NKILA is functionally involved in the regulation of RXFP1/PI3K-AKT and NF-¦ÊB signalling. Knockdown of NKILA dramatically down-regulates the expression of RXFP1 and then reduces the activity of AKT, a downstream regulator of RXFP1 signalling which is widely accepted as an activator of osteogenesis."	31657882
1357	Human	NKILA	lncRNA	hypoxia	retinal pigment epithelium (RPE) cells injuries	ARPE-19 human RPE cells	hypoxia treatment	"Hypoxia induced NKILA expression, NKILA-I¦ÊB¦Á association and NF¦ÊB activation in ARPE-19?cells and primary human RPE cells."	30144973
1358	Human	NKILA	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	31599426
1359	Human	NKX2-5-4	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
1360	Human	NMR	lncRNA	IL-1¦Â and TNF-¦Á	esophageal squamous cell carcinoma (ESCC)	KYSE70 Cells	IL-1¦Â and TNF-¦Á treatment	IL-1¦Â and TNF-¦Á stimulation showed that IL-1¦Â and TNF-¦Á could significantly promote the expression of NMR in ESCC cells.	29763634
1361	Human	NNT-AS1	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	NNT-AS1 played a promoting role in smoking-induced COPD via modulating miR-582-5p/FBXO11 signaling.	32768929
1362	Human	NONHSAG024980	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
1363	Human	NONHSAG048134.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
1364	Human	NONHSAG048135.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
1365	Human	NONHSAG048143.2	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
1366	Human	NONHSAG096479.1	lncRNA	docetaxel (DTX)	breast cancer	MCF7 cells; MDA cells	docetaxel (DTX) treatment	upregulated	29683761
1367	Human	NONHSAT000264	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	upregulated	32391956
1368	Human	NONHSAT057283	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	upregulated	32547604
1369	Human	NONHSAT076891	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	bone marrow (BM)	all-trans retinoic acid (ATRA) treatment	upregulated	29956795
1370	Human	NONHSAT084969.2	lncRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	high-phosphorus (HP) treatment	lncRNAs NONHSAT084969.2 was confirmed to increase significantly in the HP group in comparison with than that in the CON group.	32401115
1371	Human	NONHSAT089447	lncRNA	olanzapine (OLP)	schizophrenia (SZ)	Human neuroblastoma cell lines (SK-N-SH)	olanzapine (OLP) treatment	downregulated	31180069
1372	Human	NONHSAT097797	lncRNA	doxorubicin (DOX)	breast cancer	MCF-7 cells	doxorubicin (ADR) treatment	downregulated	32547604
1373	Human	NONHSAT105177	lncRNA	melittin	pancreatic ductal adenocarcinoma (PDAC)	PATU8988 cells; Panc1 cells; SW1990 cells	melittin treatment	melittin treatment increased NONHSAT105177 expression in PDAC cell lines	30237397
1374	Human	NONHSAT108582.2	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	32689997
1375	Human	NONHSAT141593.2	lncRNA	high glucose (HG)	hyperglycemia-induced vascular endothelial cell damage	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	upregulated	32689997
1376	Human	NONHSAT143692.2	lncRNA	H2O2	age-related cataract (ARC)	human lens epithelial cells (LECs)	oxidative stress	NONHSAT143692.2 is involved in oxidative DNA damage repair in the lens by regulating the miR-4728-5p/OGG1 axis.	33000245
1377	Human	NONHSAT161887	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
1378	Human	NONHSAT172176	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	downregulated	31514003
1379	Human	NONHSAT174696	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
1380	Human	NONHSAT177112.1	lncRNA	lipopolysaccharide (LPS)	inflammation	human cardiomyocytes (HCMs)	lipopolysaccharide (LPS) treatment	NONHSAT177112.1 showed dynamic expression that first increased and then decreased during LPS stimulation.	33641342
1381	Human	NONHSAT179219	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	normal human liver cells L-02	PCB 156 treatment	dysregulated	31514003
1382	Human	NONHSAT187744	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
1383	Human	NONHSAT193411.1	lncRNA	high inorganic phosphate (Pi)	vascular calcification (VC)	vascular smooth muscle cells (VSMCs)	high-phosphorus (HP) treatment	NONHSAT193411.1 was confirmed to increase significantly in the HP group in comparison with than that in the CON group.	32401115
1384	Human	NONHSAT203881	lncRNA	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156)"	nonalcoholic fatty liver disease (NAFLD)	L-02 cells	"2, 3, 3', 4, 4', 5 - hexachlorobiphenyl (PCB 156) treatment"	upregulated	31514003
1385	Human	NONHSAT247851.1	lncRNA	particulate matter (PM2.5)	cerebrovascular disease (CVD)	human umbilical vein endothelial cells (HUVECs)	PM 2.5 treatment	upregulated	32278143
1386	Human	NONMMUT008655.2	lncRNA	resveratrol	hepatic insulin resistance	Hepa cells	resveratrol (Res) treatment	RSV may improve hepatic insulin resistance and control blood glucose levels by downregulating lncRNA NONMMUT0086552	32051733
1387	Human	NONSHAT022487	lncRNA	toxoplasma gondii (T. gondii)	T. gondii infection	human foreskin fibroblast (HFF) cells	toxoplasma gondii (T. gondii) infection treatment	The transcriptional level of NONHSAT022487 was increased by more than 30-fold after T gondii infection	29530077
1388	Human	NONT087634	lncRNA	lipopolysaccharide (LPS)	sepsis	human microvascular endothelial cells	lipopolysaccharide (LPS) treatment	dysregulated	29147069
1389	Human	NONT119666	lncRNA	lipopolysaccharide (LPS)	sepsis	human microvascular endothelial cells	lipopolysaccharide (LPS) treatment	dysregulated	29147069
1390	Human	NORAD	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"lncRNA NORAD attenuates endothelial cell senescence, endothelial cell apoptosis, and atherosclerosis via NF-¦ÊB and p53-p21 signaling pathways and IL-8."	32267831
1391	Human	NORAD	lncRNA	hypoxia	coronary artery disease (CAD)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	Long non-coding RNA NORAD regulates angiogenesis of human umbilical vein endothelial cells via miR-590-3p under hypoxic conditions.	32323787
1392	Human	NORAD	lncRNA	high glucose (HG)	diabetic cardiomyopathy (DCM)	AC16	high glucose (HG) treatment	Overexpression of NORAD protects DCM development via miRNA-150-5p/ZEB1 axis.	33215445
1393	Human	NORAD	lncRNA	particulate matter (PM10)	lung cancer	A549 cells	Particulate matter of 10 ¦Ìm or less in diameter (PM10) treatment	we demonstrated that PM10?treatment increased the expression levels of NORAD	33250223
1394	Human	NORAD	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	H446 cells; A549 cells	cisplatin treatment	downregulated	31894841
1395	Human	NORAD	lncRNA	physcion 8-O-¦Â-glucopyranoside (PG)	ovarian cancer (OC)	SKOV3 cells	physcion 8-O-¦Â-glucopyranoside (PG) treatment	upregulated	31299866
1396	Human	NORAD	lncRNA	hypoxia	pancreatic cancer (PC)	"pancreatic cancer cell lines SW1990, Capan-1, PANC-1, AsPC-1, CFPAC-1, MIAPaCa-2, and BxPC-3"	1% O2	upregulated	29121972
1397	Human	NORAD	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	"MPP?+?induced cytotoxicity, and downregulated lncRNA NORAD in both dose- and time- dependent manners in SH-SY5Y cells."	31421205
1398	Human	NORAD	lncRNA	dexamethasone (DEX)	steroid-induced osteonecrosis of femoral head (ONFH)	human bone marrow-derived mesenchymal stem cells (hBMSCs)	dexamethasone (DEX) treatment	"NORAD expression was downregulated in SONFH tissues, while miR-26a-5p expression was upregulated."	33413642
1399	Human	NPSR1-AS1	lncRNA	hypoxia-inducible factor 1¦Á (HIF-1¦Á)	hepatocellular carcinoma (HCC)	Hep3B cells; Huh7 cells	hypoxia-inducible factor-1¦Á (HIF-1¦Á) treatment	Hypoxia-inducible long noncoding RNA NPSR1-AS1 promotes the proliferation and glycolysis of hepatocellular carcinoma cells by regulating the MAPK/ERK pathway.	33008585
1400	Human	NR_002733	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1401	Human	NR_004845	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	downregulated	29409992
1402	Human	NR_024118	lncRNA	lipopolysaccharide (LPS)	sepsis-induced myocardial injury	AC16 cells	lipopolysaccharide (LPS) treatment	downregulated	33846787
1403	Human	NR_024351	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1404	Human	NR_026763	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1405	Human	NR_028034	lncRNA	lipopolysaccharide (LPS)	inflammation	human macrophages	lipopolysaccharides (LPS) treatment	upregulated	28420462
1406	Human	NR_029399	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
1407	Human	NR_033661	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
1408	Human	NR_038323	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	HK-2 cells	High Glucose (HG) treatment	upregulated	31430717
1409	Human	NR_039985	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1410	Human	NR_109779	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1411	Human	NR_110586	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1412	Human	NR_110801	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1413	Human	NR_120420	lncRNA	oxygen glucose deprivation (OGD)	stroke	SH-SY5Y cells	oxygen and glucose deprivation (OGD) treatment	upregulated	31838253
1414	Human	NR_120420	lncRNA	oxygen glucose deprivation (OGD)	stroke	SH-SY5Y cells	oxygen and glucose deprivation (OGD) treatment	NR_120420 knockdown inhibited apoptosis after cerebral infarction by downregulating the phosphorylation of a subunit of NF-¦ÊB (P65)	31838253
1415	Human	NR_122070	lncRNA	dexamethasone (DEX)	steatosis	HepG6 cells	dexamethasone (Dex) treatment	upregulated	29409992
1416	Human	NR2F1-AS1	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HCC cells	hypoxia treatment	?NR2F1-AS1 level was enhanced in HCC tissues and cells.	33488124
1417	Human	NR2F1-AS1	lncRNA	oxaliplatin	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	oxaliplatin (OXA) treatment	lncRNA NR2F1-AS1 was upregulated in oxaliplatin-resistant HCC tissue and cells	29602203
1418	Human	NRAL	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 and HepG2/CDDP	cisplatin treatment	NRAL was highly expressed in HepG2 cisplatin resistant cell lines compared to their parental counterparts.	30030687
1419	Human	NRAL	lncRNA	cisplatin (DDP)	hepatocellular carcinoma (HCC)	HepG2 cells	cisplatin treatment	upregulated	30030687
1420	Human	NRAV	lncRNA	respiratory syncytial virus (RSV)	respiratory syndrome virus (PRRSV) infection	sputum specimens	respiratory syncytial virus (RSV) infection treatment	lncRNA negative regulator of antiviral response (NRAV) in RSV-positive patients was significantly lower than that in uninfected patients	32102886
1421	Human	NRIR	lncRNA	lipopolysaccharide (LPS)	systemic sclerosis (SSc)	human monocytes	lipopolysaccharide (LPS) treatment	upregulated	30804934
1422	Human	NUTF2P3-001	lncRNA	CoCl2	pancreatic cancer (PC)	pancreatic cancer cell	hypoxia£¬CoCl2 treatment	upregulated	26755660
1423	Human	NUTF2P3-001	lncRNA	hypoxia	pancreatic cancer (PC)	pancreatic cancer cell	hypoxia£¬CoCl2 treatment	upregulated	26755660
1424	Human	NUTM2A-AS1	lncRNA	lipopolysaccharide (LPS)	pulpitis	human dental pulp cells (HDPCs)	lipopolysaccharide (LPS) treatment	LPS exposure upregulated the expression of NUTM2A-AS1 and High-Mobility Group Box 1 (HMGB1) and downregulated the level of let-7c-5p.	33831808
1425	Human	OBFC2A	lncRNA	"1,4-benzoquinone (1,4-BQ)"	benzene-induced hematotoxicity	AHH1 cells	"1,4-Benzoquinone (1,4-BQ) treatment"	upregulated	32087087
1426	Human	OBFC2A	lncRNA	"1,4-benzoquinone (1,4-BQ)"	benzene toxicity	human normal lymphocyte line (AHH-1)	"1,4-Benzoquinone (1,4-BQ) treatment"	upregulated	28388563
1427	Human	OGRU	lncRNA	streptozocin (STZ)	diabetic retinopathy (DR)	M¨¹ller cells	streptozotocin (STZ) treatment	DR patients exhibited significantly increased expression of serum LncRNA-OGRU compared with normal individuals Streptozotocin (STZ)-challenged rats with DR also had higher OGRU expression in retinas	33762162
1428	Human	OIP5-AS1	lncRNA	angiotensin II (Ang II)	aortic dissection (AD)	human aortic endothelial cells (HAECs); human aortic smooth muscle cells (HASMCs)	angiotensin II (Ang II) treatment	"We found that lnc-OIP5-AS1 was upregulated, whereas miR-143-3p was downregulated in cells treated with angiotensin II (AngII) and AD tissues."	33577845
1429	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	OIP5-AS1 knockdown modulated cell progression via regulating miR-320a/LOX1 axis in ox-LDL-treated HUVECs.	32072428
1430	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	Our data showed the significant upregulation of OIP5-AS1 in atherosclerosis serum and ox-LDL-stimulated HUVECs.	33778018
1431	Human	OIP5-AS1	lncRNA	dermatophagoides pteronyssinus peptidase 1 (Der p1)	bronchial asthma	BEAS-2B cells	Dermatophagoides pteronyssinus peptidase 1 (Der p1) treatment	OIP5-AS1 exacerbated Der p1-induced inflammation and apoptosis in BEAS-2B cells by targeting miR-143-3p via HMGB1.	33174035
1432	Human	OIP5-AS1	lncRNA	osteogenic differentiation medium	calcific aortic valve disease (CAVD)	valve interstitial cells (VICs) isolated from human calcific aortic valves	"a-minimal essential medium (Gibco, Carlsbad, CA, USA) containing 0.1% FBS, bioactive recombinant human bone morphogenetic protein-2 (BMP-2; 50 ng/mL), dexamethasone (100 nmol/L), ascorbic acid (50 mg/mL), and b-glycerophosphate (5 mmol/L) treatment"	downregulated	30846207
1433	Human	OIP5-AS1	lncRNA	radiation	colorectal cancer (CRC)	LoVo cells; SW480 cells	radiation treatment	LncRNA OIP5-AS1 and DYRK1A were downregulated in radio-resistant CRC cell lines	29773344
1434	Human	OIP5-AS1	lncRNA	etoposide (VP-16)	DNA damage	human HepG2 cells	etoposide treatment	upregulated	31889167
1435	Human	OIP5-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial cell injury	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"The expression of OIP5-AS1 was upregulated, while miR-98-5p was downregulated in ox-LDL-induced human umbilical vein endothelial cells (HUVECs)."	32990894
1436	Human	OIP5-AS1	lncRNA	mercury II chloride	heavy metal stress	human HepG2 cells	mercury II chloride treatment	upregulated	31889167
1437	Human	OIP5-AS1	lncRNA	KSHV-encoded viral interferon regulatory factor 1 (vIRF1)	kaposi's sarcoma (KS)	endothelial cell	KSHV-encoded viral interferon regulatory factor 1 (vIRF1) treatment	upregulated	30699189
1438	Human	OIP5-AS1	lncRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	OIP5-AS1 was downregulated while miR-29b-3p was upregulated in OA models.	32037864
1439	Human	OIP5-AS1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	MG63 cells; Saos-2 cells	cisplatin treatment	OIP5-AS1 positively modulated FOSL2 expression to decrease CDDP sensitivity in OS by sponging miR-377-3p.	32440152
1440	Human	OIP5-AS1	lncRNA	doxorubicin (DOX)	osteosarcoma (OS)	MG63 cells; KHOS cells; U2OS cells	doxorubicin treatment	upregulated	30204936
1441	Human	OIP5-AS1	lncRNA	oxaliplatin	oxaliplatin (L-OHP) resistance	HCT116; W480 cells	oxaliplatin (L-OHP) treatment	upregulated	32308348
1442	Human	OIP5-AS1	lncRNA	H2O2	oxidative stress	human HepG2 cells	H2O2 treatment	upregulated	31889167
1443	Human	OR13C9	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	GEnCs	high glucose (HG) treatment	LncOR13C9 could regulate ABCA1 by inhibiting the action of miR-23a-5p in the LXR pathway.	33192550
1444	Human	OTUD6B-AS1	lncRNA	arsenic trioxide (ATO)	bladder cancer	T24 cells	arsenic trioxide (As2O3) treatment	lncRNA OTUD6B-AS1 Exacerbates As 2 O 3-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2	32952848
1445	Human	linc-p21	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	BEAS-2B cells	lipopolysaccharide (LPS) treatment	LincRNA-p21 was significantly increased in septic model in vivo and in vitro.	32495896
1446	Human	linc-p21	lncRNA	oleanolic acid (OLA)	arteriosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oleanolic acid (OLA) treatment	upregulated	27900030
1447	Human	linc-p21	lncRNA	ginkgo biloba extract EGb 761	colorectal cancer (CRC)	HT29 cells; HCT116 cells	Ginkgo biloba extract EGb 761 treatment	lincRNA-p21 was upregulated in colon cancer cells after treatment with EGb 761.	30594943
1448	Human	linc-p21	lncRNA	X-rays	colorectal cancer (CRC)	CRC cell lines and tissue	X-ray treatment	upregulation	24573322
1449	Human	linc-p21	lncRNA	arsenite	lung cancer	A549 cells	arsenic (As) exposure	upregulated	32816178
1450	Human	linc-p21	lncRNA	hypoxia	glioblastoma multiforme (GBM)	SMMC7721 hepatoma;U251MG glioma cells	hypoxia treatment	upregulated	28689810
1451	Human	linc-p21	lncRNA	X-rays	glioblastoma multiforme (GBM)	"SMMC7721 hepatoma , U251MG glioma cells"	X-ray irradiation treatment	upregulated	28689810
1452	Human	linc-p21	lncRNA	TGF-¦Â1	liver fibrosis	Human LX-2 cell strain	TGF-¦Â1 treatment	downregulated	27610008
1453	Human	linc-p21	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30671473
1454	Human	linc-p21	lncRNA	methotrexate (MTX)	rheumatoid arthritis (RA)	Human Jurkat T cell;THP-1 monocyte;Peripheral blood mononuclear cells (PBMCs)	methotrexate treatment	"MTX restored lincRNA-p21 expression, in vivo, in RA"	25077978
1455	Human	linc-p21	lncRNA	ultraviolet (UV) irradiation	skin cancer	keratinocytes	UV irradiation treatment	lincRNA-p21 is highly inducible by UVB	25789975
1456	Human	linc-p21	lncRNA	arsenite	toxicity of arsenic	A549 cells	arsenic (As) exposure	upregulated	32816178
1457	Human	PAAN	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	HEK293T cells	influenza A virus (IAV) infection	The level of lncRNA-PAAN increases upon infection of IAV.	29914164
1458	Human	PABPC	lncRNA	androgen deprivation therapies (ADT)	castration-resistant prostate cancer (CRPC)	patients with CRPC	androgen deprivation therapies (ADT) treatment	upregulated	25189356
1459	Human	PAGBC	lncRNA	hydrostatic pressure (HP)	osteogenesis	adipose-derived mesenchymal stem cells (AMSCs)	hydrostatic pressure (HP) treatment	lncRNA-PAGBC was upregulated during osteogenic differentiation of AMSCs.	32661199
1460	Human	PANDAR	lncRNA	arsenite	DNA damage	Peripheral blood lymphocytes	arsenic (As) exposure	arsenic exposure increased PANDAR expression and DNA damage among arsenic smelting plant laborers.	31885278
1461	Human	PANDAR	lncRNA	arsenite	DNA damage	peripheral blood lymphocytes	arsenic (As) exposure	Arsenic exposure increased PANDAR expression.	31885278
1462	Human	PANDAR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	A2780 cells	cisplatin treatment	upregulated	30375398
1463	Human	PANDAR	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
1464	Human	PART1	lncRNA	gefitinib	esophageal squamous cell carcinoma (ESCC)	TE1 cells; KYSE-450 cells	gefitinib treatment	lncRNA PART1 was upregulated in gefitinib-resistant cells when compared to parental ESCC cells.	30049286
1465	Human	PART1	lncRNA	lipopolysaccharide (LPS)	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	lipopolysaccharide (LPS) treatment	"Expression levels of lncRNA PART1 in LPS-treated NP cells were found to be higher compared with those in the control groups.? Collectively, these results suggest that PART1 accelerates the progression of IDD."	33376513
1466	Human	PART-1	lncRNA	IL-1¦Â	osteoarthritis (OA)	The immortalized human chondrocytes cell lines C20/A4	IL-1¦Â treatment	downregulated	31571401
1467	Human	PAX8-AS1-N	lncRNA	baicalin (BAI)	breast cancer	MCF-7 cells; MDA-MB-231 cells	baicalin (BAI) treatment	upregulated	29693272
1468	Human	PCAT-1	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1469	Human	PCAT-1	lncRNA	Paris forrestii (PCT3)	prostate cancer	LNCaP cells	Paris forrestii (PCT3) treatment	upregulated	31810132
1470	Human	PCAT6	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	"Seven CRC cell lines: HCT116, HT©\29, SW620, SW480, DLD©\1, RKO, and LoVo, a normal colon fibroblast cell line CCD©\112CoN"	5-fluorouracil (5-FU) treatment	PCAT6 knockdown attenuated CRC chemoresistance to 5-FU through miR-204/HMGA2/PI3K; miR-204 inhibition could partially reverse the effect of PCAT6 knockdown.	30938104
1471	Human	PCAT6	lncRNA	sevoflurane (SEV)	lung cancer	H446 cells; H1975 cells	sevoflurane (Sev) treatment	downregulated	33987473
1472	Human	PCGEM1	lncRNA	montelukast sodium	asthma	serum	montelukast sodium treatment	PCGEM1 was highly expressed in cough-variant asthma (CVA) children with response to the treatment.	32520202
1473	Human	PCGEM1	lncRNA	hypoxia	gastric cancer (GC)	human gastric cancer cell lines SGC-7901 and BGC-823	hypoxia induce	upregulated	30690667
1474	Human	PCGEM1	lncRNA	doxorubicin (DOX)	prostate cancer	LNCaP cells	doxorubicin (DOX) treatment	PCGEM1 overexpression in LNCaP cell culture model results in the inhibition of apoptosis induced by doxorubicin (DOX)	16569192
1475	Human	PCK1-2:1	lncRNA	C-BaP-Cr-Pb-As	inflammation	Human Bronchial Epithelial Cells 16HBE	C-BaP-Cr-Pb-As treatment	downregulated	30913382
1476	Human	PCK1-2:1	lncRNA	particulate matter (PM2.5)	inflammation	Human Bronchial Epithelial Cells 16HBE	PM2.5-JN particles treatment	downregulated	30913382
1477	Human	PDIA3P1	lncRNA	hypoxia	glioblastoma multiforme (GBM)	U251 cells; U87MG cells; A172 cells	hypoxia treatment	Hypoxia-induced lncRNA PDIA3P1 promotes mesenchymal transition via sponging of miR-124-3p in glioma.	32127518
1478	Human	PDIA3P1	lncRNA	doxorubicin (DOX)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells	doxorubicin (Dox) treatment	Dox induced PDIA3P1 expression in a dose-dependent manner.	31509261
1479	Human	PDIA3P1	lncRNA	etoposide (VP-16)	hepatocellular carcinoma (HCC)	SK-Hep-1 cells	etoposide treatment	Etoposide induced PDIA3P1 expression in a dose-dependent manner.	31509261
1480	Human	PGM5-AS1	lncRNA	p53	esophageal squamous cell carcinoma (ESCC)	ESCC cell lines	?p53 overexpression treatment	upregulated	31185143
1481	Human	PINT	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	rheumatoid arthritis (RA)	Fibroblast-like synoviocytes (FLSs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA LINC-PINT increases SOCS1 expression by sponging miR-155-5p to inhibit the activation of ERK signaling pathway in rheumatoid arthritis synovial fibroblasts induced by TNF-¦Á	32289665
1482	Human	PMS2L2	lncRNA	carboplatin (CBP)	endometrial cancer (EC)	plasma	carboplatin treatment	LncRNA PMS2L2 in endometrial cancer was downregulated during carboplatin treatment and regulates chemosensitivity.	31632150
1483	Human	PNRC2-1	lncRNA	TGF-¦Â1	nasopharyngeal carcinoma (NPC)	CNE1 nasopharyngeal carcinoma cells	TGF-¦Â1 treatment	"Sixty lncRNA genes were clustered in a heatmap, and mRNA expression of 14 dysregulated lncRNAs was consistent with RNA sequencing"	33752469
1484	Human	POIR	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; Hep3B; SNU©\387; SNU©\449 cells	Sorafenib (SOR) treatment	lncRNA-POIR promotes EMT progression and suppresses SOR sensitivity simultaneously by sponging miR-182-5p	32951268
1485	Human	POTEF-AS1	lncRNA	5¦Á©\dihydrotestosterone (DHT)	prostate cancer	LNCaP and VCaP cells	DHT treatment	upregulated	28032932
1486	Human	POU5F1P4	lncRNA	cetuximab	metastatic colorectal cancer (mCRC)	NCI-H508 cells; tumor tissues	cetuximab treatment	POU5F1P4 was also downregulated in acquired cetuximab resistant cells.	29136952
1487	Human	PRINS	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MCF-7 cells; MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1488	Human	PRINS	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
1489	Human	PRLB	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	CAOV3 cells; SKOV3 cells	paclitaxel (Tax) treatment	upregulated	33156701
1490	Human	PRNCR1	lncRNA	cisplatin (DDP)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	cisplatin treatment	downregulated	33647908
1491	Human	PRNCR1	lncRNA	lipopolysaccharide (LPS)	pulmonary vascular endothelial cell (PVEC) injury	Human pulmonary microvascular endothelial cells (HPMECs)	lipopolysaccharide (LPS) treatment	PRNCR1 was upregulated in LPS-induced PVEC and aggravated its injury via modulating the miR-330-5p/TLR4 axis.	33049095
1492	Human	PSMB8-AS1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
1493	Human	PSMG3-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
1494	Human	PSOR1C3	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
1495	Human	PTENP1	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	upregulated	30441874
1496	Human	PTPRG-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1497	Human	PTTG3P	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	downregulated	30619763
1498	Human	PVT	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
1499	Human	PVT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	"PVT1 expression was significantly increased, whereas miR-20a-5p expression was significantly decreased in sepsis model mice and LPS-induced HK-2 cells compared with sham mice and control HK-2 cells"	33576456
1500	Human	PVT1	lncRNA	gemcitabine (GEM)	advanced pancreatic cancer (PC)	BxPC-3 cells; PANC-1 cells	Gemcitabine treatment	"Gemcitabine treatment decreases PVT1 levels and increases its encoded miRNAs, such as the miR-1207 pair (miR-1207-5p/3p)."	30341811
1501	Human	PVT1	lncRNA	"corticosteroid, dexamethasone, and fetal calf serum (FCS)."	airway diseases	primary ASM cells	"corticosteroid, dexamethasone, and fetal calf serum (FCS) treatment"	dysregulated	24886442
1502	Human	PVT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	aortic dissection (AD)	Human aortic smooth muscle cells (HASMCs)	platelet derived growth factor-BB (PDGF-BB) treatment	"In AD, PVT1 expression was upregulated, yet that of miR-27b-3p was downregulated"	33106979
1503	Human	PVT1	lncRNA	platelet activating factor (PAF)	asthma	Human small airway epithelial cells (HSAECs)	platelet activating factor (PAF) treatment	LncRNA PVT1 exacerbates the inflammation and cell-barrier injury during asthma by regulating miR-149	32830409
1504	Human	PVT1	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	human airway smooth muscle cells (ASMCs)	platelet derived growth factor-BB (PDGF-BB)?treatment treatment	upregulated	33825599
1505	Human	PVT1	lncRNA	angiotensin II (Ang II)	atrial fibrosis	human atrial fibroblasts	angiotensin II (Ang II) treatment	"upregulated, PVT1 knockdown attenuated the Ang-II-induced mouse atrial fibrosis."	30894138
1506	Human	PVT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	?high glucose (HG) induce treatment	lncRNA?PVT1 modulates the proliferation and apoptosis of lens epithelial cells in diabetic cataract via miR-214-3p/MMP2 axis	31755246
1507	Human	PVT1	lncRNA	high glucose (HG)	diabetic cataract (DC)	Human lens epithelial (HLE) B-3 cells	high glucose (HG) treatment	lncRNA PVT1 expression was upregulated in the HG-induced HLE B-3 cells	31755246
1508	Human	PVT1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human mesangial cells (MCs)	high glucose (HG) treatment	PVT1 was highly expressed in high glucose (HG)-induced mesangial cells (MCs).	32322310
1509	Human	PVT1	lncRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	AC16 cells	high glucose (HG) treatment	upregulated	33049089
1510	Human	PVT1	lncRNA	high glucose (HG)	dilated cardiomyopathy (DCM)	cardiomyocytes	high-glucose (HG) treatment	We observed that PVT1 and CASP10 were upregulated while miR-23a-3p was downregulated in high glucose-induced cardiomyocytes.	33049089
1511	Human	PVT1	lncRNA	5-fluorouracil (5-Fu)	gastric cancer (GC)	Human GC cell lines SGC-7901	5-fluorouracil (5-FU) treatment	PVT1 can regulate the expression of Bcl2 and enhance drug-resistance of gastric cancer to 5-Fu.	31205469
1512	Human	PVT1	lncRNA	cardamonin	gastric cancer (GC)	"The human gastric cancer cell lines (AGS, MGC-803, BGC-823)"	cardamonin treatment	downregulated	31028131
1513	Human	PVT1	lncRNA	cisplatin (DDP)	gastric cancer (GC)	AGS/DPP; NUGC-3/DPP cells	cisplatin treatment	PVT1 silencing attenuated the DPP resistance in GC by downregulating TBL1XR1 via sponging miR-3619-5p.	32407172
1514	Human	PVT1	lncRNA	paclitaxel (PTX)	glioblastoma multiforme (GBM)	SHG 44 cells	paclitaxel treatment	LncRNA PVT1 was overexpressed in glioma cells SHG-44 RE compared with parent SHG-44 cells	30347597
1515	Human	PVT1	lncRNA	IFN-¦Á	hepatocellular carcinoma (HCC)	SMMC-7721 cells	IFN-¦Á treatment	IFN-¦Á treatment further increases PVT1 expression in HCC cells by enhancing H3K4me3 modification on the promoter.	29715456
1516	Human	PVT1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	AC16 cells	hypoxia/reoxygenation (H/R) treatment	Knockdown of long non-coding RNA PVT1 protects human AC16 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis and autophagy by regulating miR-186/Beclin-1 axis.	32428696
1517	Human	PVT1	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 and H1975 cells	Xiaoji decoction (XJD) treatment	downregulated	31707347
1518	Human	PVT1	lncRNA	xiaoji decoction (XJD)	non-small cell lung cancer (NSCLC)	A549 cells; H1975 cells	xiaoji decoction (XJD) treatment	XJD decreased lncRNA PVT1 expressions.	31707347
1519	Human	PVT1	lncRNA	high glucose (HG)	osteoarthritis (OA)	human osteoarthritis (OA) chondrocytes	high-glucose (HG) treatment	upregulated	31625803
1520	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	30126849
1521	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	upregulated	31863917
1522	Human	PVT1	lncRNA	IL-1¦Â	osteoarthritis (OA)	Human transformed chondrocytes C28/I2	IL-1¦Â treatment	upregulated	31863917
1523	Human	PVT1	lncRNA	pioglitazone	osteoarthritis (OA)	high-glucose (HG) treated human osteoarthritis (OA) chondrocytes	pioglitazone (PGZ) treatment	downregulated	31625803
1524	Human	PVT1	lncRNA	gemcitabine (GEM)	osteosarcoma (OS)	LncRNA PVT1-overexpressed MG63 cells and LncRNA PVT1 knockdown MG63/DOX cells.	gemcitabine treatment	"LncRNA PVT1 overexpression promoted cell proliferation and exhibited the anti-apoptotic property in LncRNA PVT1-overexpressing MG63 cells treated with gemcitabine. While, LncRNA PVT1-depleted MG63/DOX cells treated with gemcitabine exhibited significant lower survival rate and high percentage of apoptosis."	30661902
1525	Human	PVT1	lncRNA	gemcitabine (GEM)	osteosarcoma (OS)	MG63 cells	gemcitabine treatment	lncRNA PVT1 level was upregulated about 3.3 folds in MG63/DOX cells compared to MG63 cells.	30661902
1526	Human	pvt1	lncRNA	carboplatin-docetaxel	ovarian cancer (OC)	3AO cells	carboplatin-docetaxel treatment	carboplatin-docetaxel-induced lncRNA PVT1 which may be a central downstream target of carboplatin plus docetaxel because expression of PVT1 positively correlates with anticancer action of carboplatin plus docetaxel.	26097562
1527	Human	PVT1	lncRNA	ketamine	ovarian cancer (OC)	"human ovarian cancer cell lines OVCAR-3, SKOV3, A2780, 3AO, COC1, OV-90"	ketamine treatment	"We then investigated the effect of ketamine on these lncRNAs, and found that ketamine regulated the expression of lncRNA PVT1."	33763107
1528	Human	PVT1	lncRNA	radiation	radioresistance	C666-1; 5¨C8F cells	radiation exposure treatment	"PVT1 Mediates Cell Proliferation, Apoptosis and Radioresistance in Nasopharyngeal Carcinoma Through Regulating miR-515-5p/PIK3CA Axis"	33116864
1529	Human	PVT1	lncRNA	TGF-¦Â1	renal fibrosis	HK-2 cells	TGF-¦Â1 treatment	PVT1 was upregulated in TGF-¦Â1-treated HK-2 cells	32921988
1530	Human	PVT1	lncRNA	lipopolysaccharide (LPS)	temporomandibular joint osteoarthritis	SW982 cells	lipopolysaccharide (LPS) treatment	upregulated	32171788
1531	Human	R-471B22	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1532	Human	RAB11B-AS1	lncRNA	hypoxia	breast cancer	MDA-MB-231; MDA-MB-468; SUM159; MCF-7; T47D; BT474; ZR-75-1; HCC1954 cells	hypoxia treatment	upregulated	31900259
1533	Human	RAD51-AS1	lncRNA	Corylin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Corylin treatment	upregulated	29749376
1534	Human	RAD51-AS1	lncRNA	melatonin	hepatocellular carcinoma (HCC)	Huh7 and HepG2 cells	Melatonin treatment	upregulated	30201872
1535	Human	RAET1K	lncRNA	hypoxia	hepatocellular carcinoma (HCC)	HCCLM3 cells; HepG2 cells	hypoxia treatment	upregulated	32152275
1536	Human	RALY-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1537	Human	RAXIP-AS2	lncRNA	Paris forrestii (PCT3)	prostate cancer	LNCaP cells	Paris forrestii (PCT3) treatment	downregulated	31810132
1538	Human	RDH10-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
1539	Human	RGMB-AS1	lncRNA	quercetin	chronic high glucose-induced oxidative stress and mitochondrial dysfunction	HepG2 cells	quercetin treatment	Quercetin increased RGMB-AS1 ~35-fold after 6 h in high glucose-treated HepG2 cells	30266680
1540	Human	RHPN1-AS1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	PC9 cells; HCC827 cells	gefitinib treatment	RHPN1-AS1 was observed to be downregulated in gefitinib resistant NSCLC cell lines.	30010468
1541	Human	RMEL3	lncRNA	PD98059	melanoma	"five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)"	PD98059 treatment	downregulated	30457212
1542	Human	RMEL3	lncRNA	vemurafenib/PLX4032	melanoma	"five melanoma cell lines: 4 harboring BRAFV600E mutation (WM1617, A375, Skmel19 and UACC-62) and one BRAF-wt/NRAS-mutant (WM1366)"	Vemurafenib/PLX4032 treatment	downregulated	30457212
1543	Human	RMRP	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	RMRP was upregulated in sera from patients with AKI and in LPS-induced cells.	33635017
1544	Human	RMRP	lncRNA	silica	lung fibrosis	human bronchial epithelial (HBE) cells; BEAS2b cells	treatment treatment	RMRP is upregulated in human bronchial epithelial (HBE) and BEAS2b cells exposed to silica and activated by p53	33297121
1545	Human	RMRP	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	neural ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	30926681
1546	Human	RMST	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HBMEC;bEnd.3 cells	oxygen-glucose deprivation (OGD) treatment	RMST was upregulated in OGD-treated HBMEC and bEnd3 cells	33607153
1547	Human	RMST	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
1548	Human	RNCR3	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	27253412
1549	Human	ROR	lncRNA	apatinib	breast cancer	breast cancer stem cells (BCSCs) were isolated from MDA-MB-231 cells	apatinib treatment	"Apatinib decreased the viability and colony numbers of BCSCs in a concentration-dependent manner, and it also reduced sphere numbers, suppressed migration, invasion and lncRNA ROR expression, and induced apoptosis of BCSCs."	33845750
1550	Human	ROR	lncRNA	homocysteine (Hcy)	atherosclerosis (AS)	human aortic smooth muscle cells (HASMCs)	homocysteine (HCY) treatment	upregulated	31629816
1551	Human	ROR	lncRNA	denovirus type 36 (Ad36)	cell differentiation	human adipose-derived stem cells (hADSCs)	denovirus type 36 (Ad36) treatment	Ad36 may promote the differentiation of hADSCs into brown adipocytes by up-regulating LncRNA ROR.	33189825
1552	Human	ROR	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	TPC-1 cells	TGF-¦Â1 treatment	upregulated	29967342
1553	Human	ROR	lncRNA	adriamycin (ADR) and vincristine (VCR)	gastric cancer (GC)	human gastric cancer tissues	adriamycin (ADR) and vincristine (VCR) treatment	upregulated	32019330
1554	Human	ROR	lncRNA	radiation	hepatocellular carcinoma (HCC)	HepG2 cells; SMMC-7721 cells	radiation treatment	linc-ROR was significantly upregulated in radioresistant HCC cells	29559320
1555	Human	ROR	lncRNA	TGF-¦Â	hepatocellular carcinoma (HCC)	HCC cells	TGF-¦Â treatment	upregulated	24918061
1556	Human	ROR	lncRNA	hypoxia/reoxygenation (H/R)	ischemia/reperfusion (I/R) injury	human cardiomyocytes (HCM)	hypoxia/reoxygenation (H/R) treatment	upregulated	29694511
1557	Human	ROR	lncRNA	arsenic trioxide (ATO)	hepatocellular carcinoma (HCC)	HepG2 cells	arsenic trioxide treatment	Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression.	32017938
1558	Human	ROR	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	The human cardiac myocyte (HCM) cell line	HCMs were exposed to hypoxic conditions for 2?h followed by re-oxygenation (H/R) treatment.	lncRNA ROR were upregulated in both MIRI rat model and H/R treated HCMs.	31768721
1559	Human	ROR	lncRNA	polyphyllin I (PPI)	nasopharyngeal carcinoma (NPC)	"The normal nasopharyngeal cell line NP69 and NPC cell lines (CNE-1, CNE-2, HONE-1, and HNE-1)"	Polyphyllin I (PP I) treatment	A higher level of lncRNA regulator of reprogramming (ROR) expression was detected in NPC cell lines compared with normal nasopharyngeal cell line and PP I must significantly down-regulate the expression level of lncRNA ROR	30601067
1560	Human	ROR	lncRNA	CoCl2	obstructive sleep apnoea-hypopnoea syndrome (OSAHS)	HK-2 cells	CoCl2 treatment	CoCl2?decreased cell viability and increased apoptosis as well as increased the expression of ROR.	31164009
1561	Human	ROR	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"OS tissues, MG63/DDP, and U2OS/DDP cells."	cisplatin treatment	upregulated	31539112
1562	Human	ROR	lncRNA	curcumin (Cur)	prostate cancer	HuPCaSCs	curcumin treatment	downregulated	28843521
1563	Human	ROR	lncRNA	deoxyelephantopin (DOE)	uterine leiomyoma (UL)	UL cells	deoxyelephantopin (DOE) treatment	downregulated	33152917
1564	Human	RP11	lncRNA	artesunate (ART)	epithelial-mesenchymal transition (EMT)	SK-HEP1 and SM7721 hepatocellular carcinoma cell lines	artesunate (ART) treatment	RP11 depresses the inhibitory effect of ART on cancer cell EMT.	30335897
1565	Human	RP11	lncRNA	artesunate (ART)	epithelial-mesenchymal transition (EMT)	SK-HEP1 cells; SM7721 cells; HepG2 cells; Huh7 cells	artesunate (ART) treatment	downregulated	30335897
1566	Human	RP11	lncRNA	artesunate (ART)	hepatocellular carcinoma (HCC)	SK-HEP1 and SM7721 hepatocellular carcinoma cell lines	artesunate (ART) treatment	RP11 depresses the inhibitory effect of ART on cancer cell EMT.	30335897
1567	Human	RP11	lncRNA	radiation	radiation-induced lung injury (RILI)	HFL-1; WI-38	TGF-¦Â1 and radiation treatment	upregulated	33117089
1568	Human	RP11-1055B8.4	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
1569	Human	RP11-120K9.2	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
1570	Human	RP11-121G22.3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1571	Human	RP11-132E11.2	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
1572	Human	RP11-134F2.2	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
1573	Human	RP11-135L22.1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	HO8910 cells	cisplatin treatment	RP11-135L22.1 level in chemotherapy-sensitive group was significantly lower than that of insensitive group.	29509240
1574	Human	RP11-154D6	lncRNA	steroids	osteonecrosis of femoral head (ONFH)	BMSCs of patients	steroid treatment	?the expression of lncRNA RP11-154D6 was significantly decreased in BMSCs of patients with ONFH	31190361
1575	Human	RP11-218C14.5	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
1576	Human	RP11-23P13.6	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
1577	Human	RP11-2C24.6-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1578	Human	RP11-347E10.1	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
1579	Human	RP11-354P11.2	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1580	Human	RP11-354P17.15-001	lncRNA	T cell	acute kidney injury (AKI)	kidney biopsies and urine	T cell treatment	upregulated	26506996
1581	Human	RP11-381N20.2	lncRNA	paclitaxel (PTX)	cervical cancer (CC)	SiHa cells	paclitaxel treatment	The expression of RP11-381N202 was reduced with the increased paclitaxel dose	29863245
1582	Human	RP11-381O7.3	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1583	Human	RP11-388M20.9	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	Cr(VI)-treated 16HBE cells	Cr(VI) exposure	"dysregulated. RP11-388M20.9 to regulate DNA damage by interacting with the target gene after Cr(VI) exposure, and was likely to be a potential biomarker of DNA damage in Cr(VI)-treated 16HBE cells."	30476843
1584	Human	RP11-388M20.9	lncRNA	hexavalent chromium [Cr(VI)]	DNA damage	16HBE cells	hexavalent chromium [Cr(VI)] treatment	upregulated	30476843
1585	Human	RP11-390F4.3	lncRNA	hypoxia	tumor metastasis	FADU cells; MCF7 cells; U2-OS cells	hypoxia treatment	upregulated	32353468
1586	Human	RP11-394l13.1	lncRNA	Vitamins A and D	fungal infection	human monocytes during C.albicans infections	Vitamins A and D treatment	dysregulated	28094339
1587	Human	RP11-395P13.3-001	lncRNA	T cell	acute kidney injury (AKI)	kidney biopsies and urine	T cell treatment	upregulated	26506996
1588	Human	RP1-140K8.5	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	upregulated	30093949
1589	Human	RP11-414H23.3	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1590	Human	RP11-415D17.3	lncRNA	homocysteine (Hcy)	homocysteine (HCY)-induced vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	homocysteine (HCY) treatment	downregulated	30093949
1591	Human	RP11-426C22.6	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
1592	Human	RP11-430L16.1	lncRNA	ginsenoside Rh2	hepatocellular carcinoma (HCC)	HepG2 cells	ginsenoside Rh2 treatment	upregulated	30394104
1593	Human	RP11-442H21.2	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
1594	Human	RP11-445H22.4	lncRNA	lipopolysaccharide (LPS)	osteoarthritis (OA)	human cartilage ATDC5 cells	lipopolysaccharide (LPS) treatment	LPS significantly promoted RP11-445H22.4 expression.	29414810
1595	Human	RP11-474G23.2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1596	Human	RP11-48O20.4	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
1597	Human	RP11-497G19.1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	upregulated	30113217
1598	Human	RP11-504P24.3	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1599	Human	RP11-504P24.3-005	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1600	Human	RP11-543N12.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1601	Human	RP11-553L6.5	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1602	Human	RP11-566E18.3-201	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1603	Human	RP11-588G21.2	lncRNA	Vitamins A and D	fungal infection	human monocytes during C.albicans infections	Vitamins A and D treatment	dysregulated	28094339
1604	Human	RP11-642d21.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1605	Human	RP11-65M17.3	lncRNA	calycosin	breast cancer	MCF-7 and T47D cells	calycosin treatment	"Here we provide evidence for the presence of a positive feedback loop between ER¦Á and long noncoding RNA RP11-65M17.3 in both normal and cancer cells, and calycosin stimulated this feedback loop in ECs but decreased RP11-65M17.3 expression in BCCs."	33647882
1606	Human	RP11-670E13.5	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
1607	Human	RP11-670E13.6	lncRNA	ultraviolet (UV) irradiation	cell senescence	primary human dermal fibroblasts	UVB-irradiated treatment	RP11-670E136?may facilitate DNA damage repair by increasing ATM and ¦ÃH2AX levels	31444317
1608	Human	RP11-670E13.6	lncRNA	ultraviolet (UV) irradiation	skin photodamage	primary human dermal fibroblasts (HDFs)	UVB treatment	upregulated	29143326
1609	Human	RP11-798E3.2	lncRNA	IL-1¦Â	crohn disease (CD)	Caco-2 cells	IL-1¦Â treatment	downregulated	29361088
1610	Human	RP1-179N16.3	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	dysregulated	24379026
1611	Human	RP1-179N16.3	lncRNA	curcumin (Cur)	nasopharyngeal carcinoma (NPC)	nasopharyngeal carcinoma (NPC) cells	curcumin treatment	upregulated	24379026
1612	Human	RP11-820	lncRNA	H2O2	primary open angle glaucoma (POAG)	Human trabecular meshwork cells (HTMCs)	H2O2 induced oxidative stress	lncRNA-RP11-820 was significantly upregulated under oxidative stress in HTMCs.	31495061
1613	Human	RP11-838N2.4	lncRNA	erlotinib	non-small cell lung cancer (NSCLC)	HCC827 cells; HCC4006 cells	erlotinib treatment	lncRNA RP11-838N2.4 was upregulated in erlotinib-resistant cells when compared to normal NSCLC cells.	29845246
1614	Human	RP11-86H7.1	lncRNA	traffic-originated PM2.5 organic component (tPo)	chronic obstructive pulmonary disease (COPD)	human bronchial epithelial cells (HBECs)	Traffic-related air pollution particulate matter 2.5 (TRAPM2.5) treatment	LncRNA RP11-86H71 promotes airway inflammation induced by TRAPM25 by acting as a ceRNA of miRNA-9-5p to regulate NFKB1 in HBECS	32665564
1615	Human	RP1-286D6	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1616	Human	RP1-43E13	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1617	Human	RP1-77H15.1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1618	Human	RP-1-7H24.1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	human lung epithelial A549 cells	influenza A/Puerto Rico/8/34 infection	upregulated	30669933
1619	Human	RP1-93H18.7	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
1620	Human	RP6-65G23.1	lncRNA	"M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M)"	psoriasis	HaCaT cells; primary keratinocytes	"M5 (IL-17A, TNF-¦Á, IL-1¦Á, IL-22, and Oncostatin-M) treatment"	RP6-65G23.1 was significantly upregulated in M5-stimulated keratinocytes.	32065443
1621	Human	RPMS1	lncRNA	epstein-barr virus (EBV)	nasopharyngeal carcinoma (NPC)	NPC C666-1 cells	Epstein-Barr virus (EBV) infection	upregulated	31696060
1622	Human	Rpph1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SK-N-SH cells	amyloid-¦Â (A¦Â) 25-35 treatment	Both lncRNA Rpph1 and miR-122 were upregulated in AD mouse and Rpph1 activated Wnt/¦Â-catenin signaling to ameliorate amyloid-¦Â induced neuronal apoptosis in SK-N-SH cells via direct targeting miR-122.	31718352
1623	Human	RPPH1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	32336203
1624	Human	RPPH1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	A¦Â25-35-induced ERS and apoptosis in SH-SY5Y cells can be attenuated by lncRNA RPPH1 through regulating miR-326/PKM2 axis.	32336203
1625	Human	Rpph1	lncRNA	amyloid-¦Â (A¦Â)	neuronal cell injury	SK-N-SH cells	amyloid-¦Â (A¦Â) treatment	LncRNA Rpph1 protects amyloid-¦Â induced neuronal injury in SK-N-SH cells via miR-122/Wnt1 axis	31718352
1626	Human	RPS27L-1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
1627	Human	RPSAP52	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	ARPE-19 cells	high glucose treatment	"High glucose treatment led to downregulated RPSAP52 and Timp3, but upregulated miR-365 in RPE cells."	33178344
1628	Human	SAF	lncRNA	human immunodeficiency virus (HIV)-1	apoptosis	human monocyte-derived macrophages (MDM)	Human immunodeficiency virus (HIV)-1 infection	upregulated	30918127
1629	Human	SAF	lncRNA	oligo-fucoidan	hepatocellular carcinoma (HCC)	HepG2 cells	oligo-fucoidan treatment	apoptosis and cell cycle pathways could also contribute to the induction of lncRNA-Saf and lncRNA-p21 by oligo-fucoidan.	30632031
1630	Human	SAMD12-AS1	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	HepG2 cells	hepatitis B virus (HBV) infection	upregulated	31406141
1631	Human	SAMD12-AS1	lncRNA	N-retinylidene-N-retinylethanolamine (A2E)	retinitis pigmentosa	human retinal pigment epithelium cells	N-retinylidene-N-retinylethanolamine (A2E) treatment	downregulated	32326576
1632	Human	SARCC	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	Sarcoma Osteogenic-2 (Saos-2) cells	cisplatin treatment	lncRNA-SARCC was significantly downregulated in the cisplatin-resistant OS tissues.	32508321
1633	Human	SARCC	lncRNA	sunitinib (SU)	renal cell carcinoma (RCC)	renal cell carcinoma (RCC)	treat with sunitinib treatment	upregulated	28644440
1634	Human	SBF2-AS1	lncRNA	Vitamins A and D	bacterial infection	human monocytes during A.fumigatus infections	Vitamins A and D treatment	dysregulated	28094339
1635	Human	SBF2-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	"Five human GBM cell lines (U87, LN229, A172, T98, U251)"	temozolomide (TMZ) treatment	"SBF2-AS1 was upregulated in TMZ-resistant GBM cells and tissues, and overexpression of SBF2-AS1 led to the promotion of TMZ resistance, whereas its inhibition sensitized resistant GBM cells to TMZ"	30992025
1636	Human	SBF2-AS1	lncRNA	radiation	non-small cell lung cancer (NSCLC)	NCI-H1299 ; NCI-H1299R cells	radiation treatment	upregulated	31928130
1637	Human	SBF2-AS1	lncRNA	gemcitabine (GEM)	pancreatic cancer (PC)	"Pancreatic cancer cell lines including AsPC-1, HPAC, BxPC-3, and PANC-1"	gemcitabine treatment	knock-down of SBF2-AS1 inhibits the expression of TWF1 by competitively binding with miR-142-3p to induce gemcitabine resistance in pancreatic cancer.	31619579
1638	Human	SBF2-AS1	lncRNA	IFN-¦Ã and lipopolysaccharide (LPS)	pancreatic cancer (PC)	THP-1 cells	lipopolysaccharide; interferon-¦Ã treatment	"lncRNA SBF2-AS1 in M2 macrophage-derived exosomes increases miR-122-5p expression to restrain XIAP expression, which further inhibits PC progression."	32301277
1639	Human	SCA8	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1640	Human	SCAL1	lncRNA	high glucose (HG)	diabetic lung disease	Normal human lung cell line BEAS-2B	high (30 mM) glucose treatment	upregulated	31410144
1641	Human	SCAL1	lncRNA	cigarette smoke (CS)	lung cancer	A549;CL1¨C0; CL1¨C5; H1975; HCC-827; NCI-H292;PC9 cells;Normal human primary bronchial epithelial (NHBE) cells	cigarette smoke (CS) treatment	a novel long noncoding RNA (lncRNA) that is induced by cigarette smoke extract (CSE) bothin vitroandin vivoand is elevated in numerous lung cancer cell lines.	23672216
1642	Human	SCAMP1	lncRNA	H2O2	renal cell carcinoma (RCC)	ACHN and Caki-1 cells	H2O2 treatment	upregulated	31550675
1643	Human	SCARNA2	lncRNA	enterovirus 71 (EV71)	hand-foot-mouth disease (HFMD)	human rhabdomyosarcoma (RD) cells	Enterovirus 71 (EV71) treatment	downregulated	30314355
1644	Human	SCRG1	lncRNA	TGF-¦Â1	liver fibrosis	LX2 cells	TGF-¦Â1 treatment	upregulated	30226813
1645	Human	SDHAP1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 and Hey-8	Paclitaxel (PTX) treatment	SDHAP1 was upregulated in PTX-resistant SKOV3 and Hey-8 ovarian cancer cell lines while the level of miR-4465 was downregulated	32211849
1646	Human	SDHAP2	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	upregulated	29947995
1647	Human	SENCR	lncRNA	rapamycin	vascular endothelial dysfunction	human umbilical vein endothelial cells (HUVECs)	rapamycin (RPM) treatment	RPM treatment downregulates the endogenous expression of lncRNAs MALAT1 and SENCR in HUVECs	29845247
1648	Human	SGCG-5:4	lncRNA	melanin	melanoma	Primary melanocytes	melanin treatment	upregulated	26596215
1649	Human	SIAH1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29217406
1650	Human	SIKIAT1	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	HK-2 cells	lipopolysaccharide (LPS) treatment	upregulated	32342116
1651	Human	SLC7A11-AS1	lncRNA	gemcitabine (GEM)	pancreatic ductal adenocarcinoma (PDAC)	BxPC-3 cells	gemcitabine treatment	upregulated	32036249
1652	Human	SMILR	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	U937 cells	oxidized low-density lipoprotein (ox-LDL) treatment	SMILR was upregulated in ox-LDL-induced AS cell models.	32367412
1653	Human	SMILR	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary arterial smooth muscle cells (hPASMCs)	hypoxia treatment	SMILR is upregulated in vitro PAH model.	32559140
1654	Human	snaR	lncRNA	human papilloma virus (HPV)	human papillomaviruses (HPV)-negative cervical squamous cell carcinoma (CSCC)	plasma	human papillomaviruses (HPV) infection	lncRNA snaR was downregulated in HPV-negative CSCC patients comparing with healthy controls.	30249756
1655	Human	SNHG1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y and human primary neuron (HPN) cells	amyloid-¦Â (A¦Â) 25-35 treatment	"A¦Â25-35 inhibited cell viability, induced cell apoptosis and increased the expression of SNHG1 in SH-SY5Y and human primary neuron (HPN) cells."	31447119
1656	Human	SNHG1	lncRNA	resveratrol	Alzheimer's disease (AD)	SK-N-SH cells; CHP-212 cells	resveratrol (Res) treatment	SNHG1 expression was positively regulated by A¦Â and negatively regulated by resveratrol	32741808
1657	Human	SNHG1	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
1658	Human	SNHG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	32536864
1659	Human	SNHG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	LncRNA SNHG1 regulates vascular endothelial cell proliferation and angiogenesis via miR-196a	32297149
1660	Human	SNHG1	lncRNA	H2O2	cardiomyocyte apoptosis	human cardiomyocytes (HCMs)	Hydrogen peroxide (H2O2) treatment	Hydrogen peroxide (H2O2) treatment suppressed SNHG1 expression in HCMs.	30355909
1661	Human	SNHG1	lncRNA	doxorubicin (DOX)	cardiotoxicity	human AC16 cardiomyocytes	Doxorubicin (DOX)? treatment	"DOX treatment also reduced the expression of SNHG1 in AC16 cells, and overexpression of SNHG1 alleviated the increased apoptosis in DOX-treated AC16 cells."	31300525
1662	Human	SNHG1	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	lncRNA SNHG1 regulates OGD/R-induced cell death through serving as a ceRNA for miR-424 in SH-SY5Y cells	31900069
1663	Human	SNHG1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Human HCC HepG2 and Huh7 cells, and SR-HCC cells"	sorafenib treatment	upregulated	31053148
1664	Human	SNHG1	lncRNA	hypoxia	hypoxic brain injury	SH-SY5Y cells	hypoxia treatment	"LncRNA SNHG1-modulated miR-140-5p inhibition regulates Bcl-XL expression, thereby reducing cell apoptosis and recovering cell viability of SH-SY5Y cells."	32186226
1665	Human	SNHG1	lncRNA	oxygen glucose deprivation (OGD)	hypoxic brain injury	SH-SY5Y cells	Oxygen glucose deprivation (OGD) treatment	Oxygen glucose deprivation (OGD) treatment inhibited SNHG1 and Bcl-XL expression and enhanced miR-140-5p expression	32186226
1666	Human	SNHG1	lncRNA	oxygen glucose deprivation (OGD)	ischemic stroke (IS)	HCMEC/D3 cells	Oxygen-glucose deprivation (OGD) treatment	LncRNA SNHG1 depressed apoptosis and inflammation of IS cell model via inhibiting miR-376a and upregulating CBS/H2S signal	32532171
1667	Human	SNHG1	lncRNA	hypoxia/reoxygenation (H/R)	myocardial ischemia/reperfusion (I/R) injury (MIRI)	human umbilical vein endothelial cells (HUVECs)	hypoxia/reoxygenation (H/R) induce	upregulated	31792649
1668	Human	SNHG1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H1299)	cisplatin treatment	upregulated	31288529
1669	Human	SNHG1	lncRNA	IL-1¦Â	osteoarthritis (OA)	human articular chondrocytes-knee cells	IL-1¦Â treatment	SNHG1 alleviates the inflammation of IL-1¦Â-induced OA through the activation of miR-16-5p-mediated p38MAPK and NF-¦ÊB signaling pathway.	31383786
1670	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	human SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated lncRNA SNHG1 promotes MPP+ -induced cytotoxicity and ROS production through the miR-15b-5p/GSK3¦Â axis in human dopaminergic SH-SY5Y cells	30302821
1671	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	SNHG1 aggravates MPP+-induced cellular toxicity in SH-SY5Y cells by regulating PTEN/AKT/mTOR signaling via sponging miR-153-3p.	31907031
1672	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	29217406
1673	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH5Y-SY cells	N-methyl-4-phenylpyridinium (MPP +) treatment	upregulated	30031125
1674	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	N-methyl-4-phenylpyridinium (MPP +) treatment	Upregulation of SNHG1 enhanced MPP + -induced cellular toxicity in SH-SY5Y cells.	30302821
1675	Human	SNHG1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells; SK-N- AS cessl	1-methyl-4-phenylpyridinium (MPP+) treatment	"We discovered that SNHG1 was significantly elevated, while miR-181a-5p was decreased in N-methyl-4-phenylpyridinium (MPP+)-treated neuroblastoma cells in dose-dependent manners."	33389428
1676	Human	SNHG12	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32339345
1677	Human	SNHG12	lncRNA	radiation	cervical cancer (CC)	SiHa cells; Hela cells	radiation treatment	LncRNA SNHG12 promoted CDK1 expression to regulate the sensitivity of CC cells to radiation through sponging miR-148a	33292254
1678	Human	SNHG12	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	Pri GBM; Rec GBM; N3S; N3T3rd; U251; U251T3rd; glioblastoma (GBM) tissues	temozolomide (TMZ) treatment	SNHG12 was upregulated in TMZ-resistant cells and tissues.	32039732
1679	Human	SNHG12	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	vascular endothelial dysfunction	SH-SY5Y cell	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	upregulated	31056262
1680	Human	SNHG12	lncRNA	angiotensin II (Ang II)	vascular endothelial injury	human umbilical vein endothelial cells (HUVECs)	angiotensin II (Ang II) treatment	"As a result, LncRNA SNHG12 was downregulated in aortic primary ECs isolated from Ang II-induced hypertensive mice and 1 kidney/deoxycorticosterone acetate/salt-induced hypertensive mice."	33464650
1681	Human	SNHG14	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	"SNHG14 was boosted in renal tissues of I/R-stimulated rats and H/R-induced HK-2 cells, while miR-124-3p was diminished in H/R-stimulated HK-2 cells."	33490282
1682	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	Increased expression of SNHG14 was observed in LPS-induced HK-2 cells.	33505213
1683	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	lipopolysaccharide (LPS) treatment	upregulated	33856026
1684	Human	SNHG14	lncRNA	lipopolysaccharide (LPS)	acute lung injury (ALI)	A549 cells	lipopolysaccharide (LPS) treatment	"LPS induced A549 cells apoptosis and inflammation, wherein SNHG14 was upregulated and miR-124-3p was downregulated."	33652176
1685	Human	SNHG14	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	he current study revealed that SNHG14 level was high in the serum of AS patients and oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines.	32735135
1686	Human	SNHG14	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Vascular smooth muscle cells (VSMCs); human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	SNHG14 level was high in oxidized low-density lipoprotein (ox-LDL)-induced AS cell lines.	32876518
1687	Human	SNHG14	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	lncRNA-small nucleolar RNA host gene 14 (SNHG14) was upregulated in trastuzumab-resistant cells when compared with parental breast cancer cells	30015837
1688	Human	SNHG14	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	SNHG14 was upregulated in resistant cell lines in contrast to their parental cell lines	30063126
1689	Human	SNHG14	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33071725
1690	Human	SNHG15	lncRNA	high glucose (HG)	diabetes mellitus (DM)	human umbilical vein endothelial cells (HUVECs)	high glucose (HG) treatment	downregulated	33636173
1691	Human	SNHG15	lncRNA	hypoxia	cardiomyocyte apoptosis	AC16 cells	hypoxia treatment	upregulated	32970504
1692	Human	SNHG15	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	SNHG15 knockdown protected against cerebral I/R injury via targeting miR-183-5p/FOXO1 axis	33194027
1693	Human	SNHG15	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human glomerular mesangial cells (HGMCs)	high glucose (HG) treatment	The results showed that SNHG15 was remarkably upregulated in pediatric DN tissues and HG-induced HGMCs.	33506255
1694	Human	SNHG15	lncRNA	palbociclib	glioblastoma multiforme (GBM)	"HMC3 cells, temozolomide-resistant (TMZ-R) cells"	palbociclib treatment	SNHG15-silenced TMZ-R cells became significantly sensitive towards TMZ treatment and less capable of promoting M2-phenotype in the HMC3 microglial cells	31462285
1695	Human	SNHG15	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-1¦Â treatment	Long non-coding RNA SNHG15 is a competing endogenous RNA of miR-141-3p that prevents osteoarthritis progression by upregulating BCL2L13 expression	32247266
1696	Human	SNHG16	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 macrophage-derived foam cells	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31646601
1697	Human	SNHG16	lncRNA	platelet derived growth factor-BB (PDGF-BB)	cell proliferation	human aortic smooth muscle cell (HASMC)	platelet-derived growth factor (PDGF)-BB treatment	upregulated	31441592
1698	Human	SNHG16	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	OGD/R itreatment downregulated LncRNA SNHG16 in SH-SY5Y cells	32407850
1699	Human	SNHG16	lncRNA	H2O2	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HMRECs)	H2O2 treatment	We confirmed that over-expression of SNGH16 attenuated H2O2-induced angiogenesis by HMRECs.	33530902
1700	Human	SNHG16	lncRNA	ropivacaine	glioblastoma multiforme (GBM)	T98G cells; LN229 cells	ropivacaine treatment	ropivacaine impeded SNHG16 expression in glioma cells.	33817285
1701	Human	SNHG16	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	HepG2/SOR cell line	sorafenib treatment	"SNHG16 is upregulated in HepG2/SOR cells, whereas knockdown of SNHG16 increases the sensitivity of HepG2/SOR cells to sorafenib in vitro and in vivo"	30655679
1702	Human	SNHG16	lncRNA	ketamine	ketamine-induced neurotoxicity	human embryonic stem cell (hESC)	ketamine treatment	"48-h in vitro treatment of ketamine induced significant neurotoxicity, and downregulated SNHG16 among hESC-derived neurons."	30171995
1703	Human	SNHG16	lncRNA	oxidized low density lipoprotein (ox-LDL)	myocardial infarction (MI)	HUVECs	oxidized low-density lipoprotein (ox-LDL) treatment	downregulated	31355606
1704	Human	SNHG16	lncRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS cells; SK-N-SH cells	cisplatin treatment	upregulated	32365562
1705	Human	SNHG16	lncRNA	liposomal bupivacaine (BUP)	neurotoxicity	SH-SY5Y cells	liposomal bupivacaine (BUP) treatment	BUP induced dose-dependent cell death and SNHG16 downregulated in SH-SY5Y cells.	32335807
1706	Human	SNHG16	lncRNA	IL-1¦Â	osteoarthritis (OA)	CHON-001 cells	IL-1¦Â treatment	lncRNA SNHG16 knockdown significantly limited the progression of OA by sponging miR-373-3p in vitro	33300061
1707	Human	SNHG16	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (SAOS2, U2OS)"	cisplatin (DPP) treatment	SNHG16 enhanced the cisplatin resistance in osteosarcoma cell lines.	31427084
1708	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	human lung fibroblasts cell WI-38	lipopolysaccharide (LPS) treatment	SNHG16 regulated LPS-induced inflammation injury in WI-38 cells through competitively binding miR-146a-5p with CCL5 further mediating JNK and NF-¦ÊB pathways	31071307
1709	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	LPS treatment	"SNHG16 impeded cell viability and promoted apoptosis, inflammatory injury by targeting IGF2 mediated by miR-370-3p in LPS-induced A549 cells."	31841752
1710	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"SNHG16 and sushi domain containing 2 (SUSD2) were upregulated, and miRNA (miR)-141-3p was downregulated in the serum of acute pneumonia patients and lipopolysaccharide (LPS)-challenged human lung fibroblasts WI-38."	33836533
1711	Human	SNHG16	lncRNA	lipopolysaccharide (LPS)	pneumonia	A549 cells	lipopolysaccharides (LPS) treatment	upregulated	31841752
1712	Human	SNHG22	lncRNA	cisplatin (DDP)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	cisplatin treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel.	31581131
1713	Human	SNHG22	lncRNA	paclitaxel (PTX)	epithelial ovarian cancer (EOC)	"Eight EOC cell lines (Hey, OAW28, COV-362, OVCAR-3, CAOV3, SKOV3, A2780, and A2780/CP)"	paclitaxel treatment	Knockdown of SNHG22 expression increased the sensitivity of EOC cells to cisplatin and paclitaxel	31581131
1714	Human	SNHG29	lncRNA	¦Â-glycerophosphate (¦Â-GP)	vascular calcification (VC)	human aortic smooth muscle cells (HASMCs)	¦Â-glycerophosphate (¦Â-GP) treatment	downregulated	32818704
1715	Human	SNHG3	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	"Seven HCC cell lines PLC/PRF/5, Hep3B, HepG2, MHCC97L, Huh7, SMMC©\7721, and HCCLM3"	sorafenib treatment	"forced expression of SNHG3 promoted cell invasion, epithelial-mesenchymal transition (EMT), and sorafenib resistance in HCC"	30132868
1716	Human	SNHG4	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	retinal pigment epithelial cells (ARPE-19)	high glucose (HG) treatment	We found that SNHG4 was downregulated in DR.	33822671
1717	Human	SNHG5	lncRNA	yin yang 1 (YY1)	acute myeloid leukemia (AML)	"Human AML cells U937, KG-1, THP-1, and HL-60"	yin yang 1 (YY1) treatment	upregulated	33318617
1718	Human	SNHG5	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	AML cell lines	adriamycin (ADR) treatment	upregulated	31884339
1719	Human	SNHG5	lncRNA	lipopolysaccharide (LPS)	acute respiratory distress syndrome (ARDS)	A549 cells	lipopolysaccharide (LPS) treatment	"SNHG5 was downregulated, while miR-205 was upregulated in the serum of ARDS patients and lung tissues of LPS-induced mice."	33170429
1720	Human	SNHG5	lncRNA	gemcitabine (GEM)	ancreatic cancer (PC)	SW1990 cells	gemcitabine (GEM) treatment	downregulated	30113217
1721	Human	SNHG5	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	16HBE cells	cigarette smoke extract (CSE) treatment	LncRNA SNHG5 regulates cell apoptosis and inflammation by miR-132/PTEN axis in COPD	32145584
1722	Human	SNHG5	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	upregulated	32269710
1723	Human	SNHG5	lncRNA	high glucose (HG) and high fat diet (HFD)	type 2 diabetes mellitus (T2DM)	NCM460 cells; DLD-1 cells	high-glucose and high-fat treatment	upregulated	32242546
1724	Human	SNHG5	lncRNA	TGF-¦Â1	intrauterine adhesion (IUA)	primary human endometrial stromal cells (HESCs)	TGF-¦Â1 treatment	upregulated	33176855
1725	Human	SNHG5	lncRNA	gefitinib	lung adenocarcinoma (LUAD)	PC9 cells; A549 cells	gefitinib treatment	downregulated	29592872
1726	Human	SNHG5	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocytes	IL-0¦Â treatment	LncRNA SNHG5 promotes chondrocyte proliferation and inhibits apoptosis in osteoarthritis by regulating miR-10a-5p/H3F3B axis	32967481
1727	Human	SNHG6	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	The levels of SNHG6 was increased in oxidized low-density lipoprotein (ox-LDL)-treated HUVECs.	31921409
1728	Human	SNHG6	lncRNA	propofol (PPF)	heart failure (HF)	Human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs)	Propofol (PPF) treatment	"PPF induced significant cytotoxicity, as well as SNHG6 upregulation in HiPSC-CMs"	32968636
1729	Human	SNHG6	lncRNA	5-fluorouracil (5-Fu)	colorectal cancer (CRC)	RKO cells	5-fluorouracil (5-FU) treatment	SNHG6 enhanced CRC cell resistance to 5-fluorouracil (5-FU).	31516391
1730	Human	SNHG7	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA SNHG7 was remarkedly upregulated in ox-LDL exposed HUVECs.	32603818
1731	Human	SNHG7	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal endothelial cells (hRECs)	high glucose (HG) treatment	SNHG7 was decreased in hRECs under HG stimuli.	31056258
1732	Human	SNHG7	lncRNA	cisplatin (DDP)	neuroblastoma (NB)	SK-N-AS;  LAN-6 cells	cisplatin (DPP) treatment	LncRNA SNHG7 enhances chemoresistance in neuroblastoma through cisplatin-induced autophagy by regulating miR-329-3p/MYO10 axis.	32329857
1733	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary human chondrocytes	IL-1¦Â treatment	"SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1"	32066502
1734	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	human primary chondrocytes	IL-1¦Â treatment	"The results showed that SNHG7 was distinctly downregulated, while miR-214-5p was significantly upregulated in OA patients and primary chondrocytes treated with IL-1¦Â."	33296783
1735	Human	SNHG7	lncRNA	IL-1¦Â	osteoarthritis (OA)	primary chondrocytes	IL-1¦Â treatment	SNHG7 prevents IL-1¦Â induced OA by inhibiting NLRP3 inflammasome and apoptosis through miR-214-5p/PPARGC1B axis.	33296783
1736	Human	SNHG7-003	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	"SNHG7-003 may inhibit the proliferation, migration and invasion of VSMCs via the miR-1306-5p/SIRT7 signaling pathway."	33416100
1737	Human	SNHG8	lncRNA	human papilloma virus (HPV)	cervical cancer (CC)	HeLa cells; SiHa cells; MS751 cells; CaSki cells	human papillomaviruses (HPVs) treatment	SNHG8 was upregulated in HPV-induced CC cells was found compared with HPV-negative CC cells.	31961005
1738	Human	SOX21-AS1	lncRNA	amyloid-¦Â (A¦Â) 1-42	Alzheimer's disease (AD)	SH-SY5Y;SK-N-SH cells	amyloid ¦Â1-42?(A¦Â) treatment	SOX21-AS1 silencing could attenuate A¦Â1-42-induced neuronal damage by sponging miR-107	32124921
1739	Human	SOX2OT	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1740	Human	SOX2OT	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocytes cells (HPCs)	high glucose (HG) treatment	SOX2OT overexpression alleviates the HG-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis.	31301307
1741	Human	SOX2OT	lncRNA	all-trans retinoic acid (ATRA)	glioblastoma multiforme (GBM)	U87 glioblastoma cells	all-trans retinoic acid (ATRA) treatment	downregulated	31186810
1742	Human	SOX2OT	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
1743	Human	SOX2OT	lncRNA	H2O2	thoracic aortic aneurysm (TAA)	mouse aortic smooth muscle cells (SMCs)	H2O2 treatment	long noncoding RNA (lncRNA) Sox2ot modulates the progression of TAA by regulating miR-330-5p/Myh11 axis.	32578852
1744	Human	SOX2OT	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte primary cells (HCM)	hypoxia treatment	lncRNA SOX2-OT expression was upregulated in hypoxic HCMs.	32528555
1745	Human	SOX2OT variant 7	lncRNA	epigallocatechin-3-gallate (EGCG)	osteosarcoma (OS)	U2OS and SaoS2 cell lines	epigallocatechin-3-gallate (EGCG) treatment	downregulated	29475441
1746	Human	SPAG5-AS1	lncRNA	high glucose (HG)	podocyte injury	human podocytes (HPCs)	high glucose (HG) treatment	upregulated	31957155
1747	Human	SPRY4-IT1	lncRNA	ketamine	neurotoxicity	human embryonic stem cells (hESCs)	ketamine treatment	"Ketamine-induced dose-dependent apoptosis, neurite degeneration, and SPRY4-IT1 upregulation in hESC-induced neurons."	33827085
1748	Human	SRA	lncRNA	resveratrol	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	resveratrol (RSV) treatment	RSV suppressed the production of SRA	30272285
1749	Human	SRA1	lncRNA	X-rays	radiation-induced injury	human lymphoblast cell line TK6	irradiat a RAD Source 2000 X-ray Biological irradiator treatment	upregulated	24502193
1750	Human	SRAs	lncRNA	high glucose (HG)	type 1 diabetes mellitus (T1DM)	CD4+ MOLT4 Tregs	high glucose (HG) treatment	upregulated	33572095
1751	Human	SRLR	lncRNA	sorafenib (SOR)	renal cell carcinoma (RCC)	RCC cells	sorafenib treatment	upregulated	27841868
1752	Human	STAiRs15	lncRNA	IL-6	multiple myeloma (MM)	human multiple myeloma cell lines INA-6 and JK-6E	interleukin-6 (IL-6) treatment	upregulated	28801664
1753	Human	STAiRs18	lncRNA	IL-6	multiple myeloma (MM)	human multiple myeloma cell lines INA-6;JK-6E	interleukin-6 (IL-6) treatment	upregulated	28801664
1754	Human	T199678	lncRNA	¦Á-synuclein (¦Á-Syn)	parkinson's disease (PD)	SH-SY5Y cells	¦Á-synuclein (¦Á-Syn) treatment	Xogenous ¦Á-Syn induced the downregulated of lncRNA-T199678 in SH-SY5Y cells	33328976
1755	Human	TALC	lncRNA	temozolomide (TMZ)	temozolomide (TMZ) resistance in glioblastoma (GBM)	"LN229, U251, 551 W, and HG7 cells"	temozolomide (TMZ) treatment	Lnc-TALC is highly expressed in TMZ-resistant GBM cells	31053733
1756	Human	TapSAKI	lncRNA	lipopolysaccharide (LPS)	sepsis	HK-2 cells	lipopolysaccharide (LPS) treatment	TapSAKI was upregulated and miR-205 was downregulated in LPS-induced HK-2 cells.	33869780
1757	Human	TapSAKI	lncRNA	lipopolysaccharide (LPS)	sepsis-induced acute kidney injury	HK-2 cells	lipopolysaccharide (LPS) treatment	"TapSAKI was elevated in urine derived sepsis-induced kidney injury, and promoted HK-2 cell apoptosis and inflammatory response through miR-22/PTEN/TLR4/NF-¦ÊB pathway."	30666657
1758	Human	TATDN1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	NSCLC tissues and cell lines	cisplatin treatment	"?TATDN1 and TRIM66 was significantly upregulated while miR-451 was downregulated in NSCLC tissues and cell lines, especially in DDP-resistant tumor tissues and cells."	30481109
1759	Human	TATDN1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells; H157 cells	cisplatin treatment	upregulated	30481109
1760	Human	TBILA	lncRNA	TGF-¦Â1	non-small cell lung cancer (NSCLC)	A549 cells; H226 cells	TGF-¦Â1 treatment	lncRNA TBILA is upregulated in response to TGF-¦Â1 treatment	29908210
1761	Human	TBULC	lncRNA	TGF-¦Â	non-small cell lung cancer (NSCLC)	NSCLC cell lines (A549 and H226)	TGF¦Â treatment	upregulated	31921623
1762	Human	TBX2-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	downregulated	31925944
1763	Human	TC0101441	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
1764	Human	TC0101441	lncRNA	oestrogen (E2)	epithelial ovarian cancer (EOC)	The human EOC cell lines SKOV3 and A2780	oestrogen(E2) treatment	E2 modulates lncRNA expression in ER?-positive EOC cells and that this regulation is sometimes ER¦Á-mediate	24380700
1765	Human	TC0101441	lncRNA	oestrogen (E2)	ovarian cancer (OC)	The human EOC cell lines SKOV3 and A2780	the cells were ed for 24 h with 10-8 M E2 treatment	dysregulated	24380700
1766	Human	TC0101686	lncRNA	estrogen (ES)	epithelial ovarian cancer (EOC)	E2 receptor (ER) ¦Á-positive EOC cells	Estrogen (E2) treatment	dysregulated	24481591
1767	Human	TC0101686	lncRNA	oestrogen (E2)	ovarian cancer (OC)	The human EOC cell lines SKOV3 and A2780	the cells were ed for 24 h with 10-8 M E2 treatment	dysregulated	24380700
1768	Human	TCF7	lncRNA	platelet derived growth factor-BB (PDGF-BB)	asthma	airway smooth muscle cells (ASMCs)	platelet-derived growth factor (PDGF)-BB treatment	PDGF-BB treated ASMCs exhibited elevated levels of lncTCF7	30528236
1769	Human	TCONS_00001266	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
1770	Human	TCONS_00006019	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	sorafenib treatment	upregulated	32149026
1771	Human	TCONS_00015544	lncRNA	sub-lethal heat	hepatocellular carcinoma (HCC)	"human SMMC-7721, HepG2, and MHCC97-H HCC cells"	treat with sub-lethal heat treatment	upregulated	28732507
1772	Human	TCONS_00022632-XLOC_010933	lncRNA	all-trans retinoic acid (ATRA)	acute promyelocytic leukemia (APL)	bone marrow (BM)	all-trans retinoic acid (ATRA) treatment	downregulated	29956795
1773	Human	TCONS_00024652	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	acute coronary syndrome (ACS)	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	TCONS_00024652 is highly expressed in TNF-¦Á-induced HUVECs	30233677
1774	Human	TCONS_00284048	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Huh7 cells; HepG2 cells	sorafenib treatment	upregulated	32149026
1775	Human	TCONS-00010875	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	upregulated	28487500
1776	Human	TCONS-00018436	lncRNA	X-rays	hypopharyngeal cancer	RS-FaDu cells	4 Gy radiation	downregulated	28487500
1777	Human	TCTN2	lncRNA	oxygen glucose deprivation (OGD)	spinal cord injury (SCI)	human SY-SH-5Y cells	oxygen-glucose deprivation treatment	"TCTN2 was downregulated in the spinal cord tissues of a rat model of SCI and in oxygen-glucose deprivation-induced hypoxic SY-SH-5Y cells, while microRNA-216b (miR-216b) was upregulated"	31050183
1778	Human	TDRG1	lncRNA	hypoxia	cervical cancer (CC)	HeLa and C-33A cells	hypoxia induce	We found Lnc-TDRG1 was highly expressed in CC tissues and cells and it was upregulated in response to hypoxia.	33394293
1779	Human	TDRG1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal microvascular endothelial cells (HRECs)	high glucose (HG) treatment	upregulated	32082175
1780	Human	TERRA	lncRNA	H2O2	oxidative stress	HEK-293T cells	H2O2 treatment	TERRA levels significantly increased upon incubation of cells with 500 ¦ÌM H2O2.	31917282
1781	Human	TERRA	lncRNA	compound C	subtelomeric DNA methylation	HeLa and HCT116 cells	AMPK inhibitor (compound C) treatment	upregulated	31181625
1782	Human	TERRAs	lncRNA	etoposide (VP-16)	DNA damage	HeLa cells	etoposide treatment	upregulated	31756221
1783	Human	TFDP2-001	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1784	Human	TGFB2-AS1	lncRNA	TGF-¦Â	epithelial-mesenchymal transition (EMT)	Human immortalized male keratinocytes (HaCaT)	TGF-¦Â treatment	upregulated	31533040
1785	Human	TGF¦Â2-AS1	lncRNA	H2O2	open-angle glaucoma (OAG)	human trabecular meshwork cells (HTMCs)	H2O2 treatment	lnc-TGF¦Â2-AS1 promotes ECM production via TGF-¦Â2 in HTMC.	32423825
1786	Human	TGS-1	lncRNA	mycobacterium tuberculosis (Mtb)	tuberculosis (TB)	whole blood samples	Mycobacterium tuberculosis (MTB) infection	downregulated	31028876
1787	Human	THAP9-AS1	lncRNA	helicobacter pylori (H. pylori)	gastric cancer (GC)	"The human GC cell lines AGS, BGC-823, HGC-27, MGC803 and SGC-7901"	H. pylori infection	upregulated	32021238
1788	Human	THOR	lncRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	HONE-1 cells	triptolide (TPL) treatment	"THOR (¡°Lnc-THOR¡±), was significantly decreased in TN-treated cells"	30503558
1789	Human	THOR	lncRNA	triptolide (TPL)	nasopharyngeal carcinoma (NPC)	"The established human NPC cell lines, HONE-1, CNE1, CNE-2, 5¨C8F, 6¨C10B and primary culture of human NPC cells"	triptolide (TPL) treatment	downregulated	30503558
1790	Human	THRIL	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	THRIL was upregulated in both?in vitro?and?in vivo?models of brain ischemia-reperfusion injury	33675584
1791	Human	THRIL	lncRNA	lipopolysaccharide (LPS)	sepsis	human bronchial epithelial cells (HBEpCs)	lipopolysaccharide (LPS) treatment	"THRIL is upregulated in sepsis and may sponge miR-19a to upregulate TNF-¦Á, thereby promoting lung cell apoptosis."	32944003
1792	Human	THRIL	lncRNA	lipopolysaccharide (LPS)	systemic lupus erythematosus (SLE)	HK2 cells	lipopolysaccharide (LPS) treatment	LncRNA THRIL was highly expressed in the LPS-stimulated cells.	30414207
1793	Human	THUMPD3-AS1	lncRNA	calcium oxalate monohydrate (COM)	renal injury	HK-2?cells	calcium oxalate monohydrate treatment	downregulated	29947995
1794	Human	TINCR	lncRNA	trastuzumab	breast cancer	SKBR-3-TR and BT474-TR cell lines	Trastuzumab treatment	upregulated	30621694
1795	Human	TINCR	lncRNA	high glucose (HG)	cardiac hypertrophy	human cardiomyocyte cells	high glucose (HG) treatment	upregulated	30453794
1796	Human	TINCR	lncRNA	X-rays	colorectal cancer (CRC)	radioresistant CRC cell line (SW620R)	2 Gy of X-ray irradiation (120 kV and 3.5 mA for 4 min with a 0.5-mm A1 filter) treatment	upregulated	31540772
1797	Human	TINCR	lncRNA	photodynamic therapy using 5©\aminolevulinic acid (ALA-PDT)	cutaneous squamous cell carcinoma (CSCC)	CSCC cell lines A431	ALA©\PDT treatment	"ALA-PDT treatment at 32?mmol/L for 120?minutes significantly promoted TINCR expression in CSCC A431 cells, and TINCR promoted ALA-PDT-induced apoptosis and cell autophagy"	30993776
1798	Human	TLINC	lncRNA	TGF-¦Â	intrahepatic cholangiocarcinoma (iCCA)	HuCCT1 cells; Huh28 cells	TGF¦Â treatment	upregulated	29916183
1799	Human	TM1P3	lncRNA	IL-1	osteoarthritis (OA)	primary cultured chondrocytes	?IL-1 treatment	The lncRNA-TM1P3 significantly upregulated in patients with OA	30887601
1800	Human	TMPO-AS1	lncRNA	propofol (PPF)	esophageal cancer (EC)	EC109; KYSE70 cells	Propofol treatment	"Propofol suppresses hypoxia-induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO-AS1/miR-498 axis"	32643321
1801	Human	TNK2-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	human aortic smooth muscle cells (HASMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31468685
1802	Human	TOCN_00011820	lncRNA	coal tar pitch extracts (CTPE)	lung cancer	malignant-transformed Human bronchial epithelial (BEAS-2B) cells	coal tar pitch extracts (CTPE) treatment	downregulated	32470693
1803	Human	tp53inp1	lncRNA	polyunsaturated fatty acids (PUFAs)	glioblastoma multiforme (GBM)	Glioblastoma cells (U373; GBM2;GBM5)	polyunsaturated fatty acids (PUFAs) treatment	downregulated	21961478
1804	Human	TP53TG1	lncRNA	glucose deprivation (GD)	cell proliferation and migration	U87 and LN18 cells	glucose deprivation treatment	upregulated	28569381
1805	Human	TP53TG1	lncRNA	ultraviolet (UV) irradiation	DNA damage	CD4 cells	ultraviolet-C (UVC) treatment	upregulated	32258156
1806	Human	TP53TG1	lncRNA	covalent inhibitor of CDK7 (THZ1)	nasopharyngeal carcinoma (NPC)	"HK1,S18, S26, SUNE1, and SUNE2 cells"	THZ1 treatment	upregulated	28951465
1807	Human	TP73-AS1	lncRNA	bisphosphonates (BPs)	bisphosphonate-induced osteonecrosis of the jaw (BONJ)	lymphomonocytes	bisphosphonates (BPs) treatment	upregulated	32714991
1808	Human	TP73-AS1	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	GBM cancer stem cells (gCSC)	temozolomide (TMZ) treatment	"Using CRISPRi to downregulate our candidate lncRNA in gCSC, we demonstrate that TP73-AS1 promotes TMZ resistance in gCSC and is linked to regulation of the expression of metabolism- related genes and ALDH1A1, a protein known to be expressed in cancer stem cell markers and protects gCSC from TMZ treatment."	30867410
1809	Human	TPTEP1	lncRNA	cisplatinum	hepatocellular carcinoma (HCC)	"The human HCC cell lines, including HepG2, SMMC-7721, QGY-7703, Huh-7, MHCC97h, SNU-449 and Sk-hep1, and L02 human normal liver cell line"	cisplatinum treatment	upregulated	31072375
1810	Human	TRERNA1	lncRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HCC cells	?hepatitis B virus-encoded X (HBx) protein treatment	we found that translation regulatory lncRNA 1 (TRERNA1) upregulation by HBx not only promoted HCC cell proliferation by regulating the cell cycle in vitro and in vivo but also correlated positively with poor prognosis in HCC	33839325
1811	Human	TRIM58	lncRNA	progesterone (P4)	lung cancer	A549 cells	progesterone (P4) treatment	downregulated	32391956
1812	Human	TRINGS	lncRNA	glucose starvation	glucose homeostasis	human tumor cells	glucose starvation condition	upregulated	29046333
1813	Human	TSI	lncRNA	TGF-¦Â1	renal fibrosis	HK2 and HKC8 cells	TGF-¦Â1 treatment	upregulated	30305452
1814	Human	TSPEAR-AS2	lncRNA	CoCl2	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	CoCl2 treatment	upregulated	32391042
1815	Human	TSPOAP1-AS1	lncRNA	influenza A virus (IAV)	influenza A virus (IAV) infection	"A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells"	influenza A virus (IAV) infection	upregulated	30968963
1816	Human	TSPOAP1-AS1	lncRNA	polyinosinic-polycytidilic acid (Poly(I:C))	influenza A virus (IAV) infection	"A549 and THP-1 cell lines, MDCK, A172, Caco-2, and SH-SY5Y cells"	poly (I:C) treatment	upregulated	30968963
1817	Human	TTN-AS1	lncRNA	sorafenib (SOR)	hepatocellular carcinoma (HCC)	Bel7404; HepG2 cells	sorafenib treatment	LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1	33378944
1818	Human	TTN-AS1	lncRNA	X-rays	large intestine cancer	SW620 cells; HT29 cells	X-ray radiation treatment	upregulated	32749739
1819	Human	TTTY14	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
1820	Human	TTTY15	lncRNA	H2O2	acute myocardial infarction (AMI)	Human myocardial cell line (AC16)	H2O2 treatment	upregulated	32888161
1821	Human	TTTY15	lncRNA	hypoxia	acute myocardial infarction (AMI)	AC16	hypoxia treatment	upregulated	32922590
1822	Human	TTTY15	lncRNA	hypoxia	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	hypoxia treatment	downregulated of TTTY15 ameliorated hypoxia-induced cell injury by targeting miR-186-5p in HUVECs.	32271447
1823	Human	TTTY15	lncRNA	human papilloma virus (HPV)	head and neck squamous cell carcinoma (HNSCC)	primary tumors resected from HNSCC patients	human papillomavirus (HPV) infection	upregulated	32998396
1824	Human	TTTY15	lncRNA	hypoxia	myocardial infarction (MI)	human cardiomyocyte	hypoxia induce	Suppression of long noncoding RNA TTTY15 attenuates hypoxia-induced cardiomyocytes injury by targeting miR-455-5p.	30898696
1825	Human	TTTY15	lncRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	upregulated	32926961
1826	Human	TUC339	lncRNA	IL-4	hepatocellular carcinoma (HCC)	THP-1 cells	IL-4 treatment	upregulated	30274167
1827	Human	TUG1	lncRNA	hypoxia/reoxygenation (H/R)	acute kidney injury (AKI)	Human renal proximal tubular cell line HK-2	hypoxia/reoxygenation (H/R) treatment	lncRNA TUG1 was decreased while miR-494-3p was elevated in vivo and in vitro.	33663500
1828	Human	TUG1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	Human bone marrow stromal cell line HS-5 and human AML cell line HL60	adriamycin (ADR) treatment	upregulated	30551433
1829	Human	TUG1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	TUG1 was upregulated in ADR-resistant AML tissues and cells.	30551433
1830	Human	TUG1	lncRNA	rapamycin	angiogenesis	human umbilical vein endothelial cells (HUVECs)	rapamycin treatment	upregulated	30186415
1831	Human	TUG1	lncRNA	metformin (Met)	atherosclerosis (AS)	Blood Samples; HUVECs	Metformin treatment	Metformin prevent AS by activating the AMPK/mTOR pathway via lncRNA TUG1.	32099330
1832	Human	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human VSMC; human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 knockdown attenuated ox-LDL-induced injury through regulating proliferation and apoptosis of VSMC and HUVEC by miR-148b/IGF2 axis	31926240
1833	Human	TUG1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (HA-VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	TUG1 enhanced the progression of AS in vitro by regulating the miR-141-3p/ROR2 axis.	32565910
1834	Human	TUG1	lncRNA	X-rays	bladder cancer	"SW780,HT1376,BIU87, T24"	X-ray treatment	upregulated	28376901
1835	Human	TUG1	lncRNA	pterostilbene	breast cancer	MCF 7 cells	pterostilbene treatment	upregulated	30619763
1836	Human	TUG1	lncRNA	doxorubicin (DOX)	cellular defense against genotoxic agents	human glioma cell lines	doxorubicin (DOX) treatment	downregulated	25645334
1837	Human	TUG1	lncRNA	cigarette smoke extract (CSE)	chronic obstructive pulmonary disease (COPD)	BEAS-2B cells	cigarette smoke extract (CSE) treatment	LncRNA TUG1 knockdown mitigates inflammatory injury induced by cigarette smoke extract in chronic obstructive pulmonary disease via miR-34c/BRD4 axis	32812639
1838	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	cirrhosis	liver sinusoidal endothelial cells (LSECs)	lipopolysaccharide (LPS) treatment	LPS treatment enhanced autophagy and promoted EndMT of LSECs by upregulating TUG1.	32269710
1839	Human	TUG1	lncRNA	methotrexate (MTX)	colorectal cancer (CRC)	human colorectal cancer cell lines HT-29-P/HT-29-R cell and HCT-8 cells	methotrexate treatment	upregulated	28805722
1840	Human	TUG1	lncRNA	high glucose (HG)	diabetic atherosclerosis	human umbilical vein endothelial cells (HUVECs)	high glucose treatment	upregulated	30402858
1841	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	diabetic atherosclerosis	human umbilical vein endothelial cells (HUVECs)	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	30402858
1842	Human	TUG1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	human podocyte cell line (CIHP) cells	high glucose (HG) treatment	upregulated	30671964
1843	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	dysfunction of vascular endothelial cells	human umbilical vein endothelial cells (HUVECs)	lipopolysaccharide (LPS) treatment	"TUG1 could repress cell apoptosis, autophagy, and inflammatory response in LPS-treated HUVECs by sponging miR-27a-3p to target SLIT2."	32738556
1844	Human	TUG1	lncRNA	endothelial growth medium©\2 (EGM©\2) plus VEGF	endothelial dysfunction	Adipose-derived stem cells (ADSCs)	endothelial growth medium©\2 (EGM©\2) supplemented with 15 ng/mL VEGF innduce	upregulated	31264280
1845	Human	TUG1	lncRNA	hypoxia	hypoxia-induced cardiac dysfunctions	AC16 cells	hypoxia treatment	upregulated	31926162
1846	Human	TUG1	lncRNA	baicalin (BAI)	inflammation	LPS stimulated human normal liver L-02 and THLE2 cells	baicalin (BAI) treatment	upregulated	31396818
1847	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	inflammation	human normal liver L-02; THLE2 cells	lipopolysaccharide (LPS) treatment	downregulated	31396818
1848	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	intervertebral disc degeneration (IDD)	human nucleus pulposus (NP) cells	tumor necrosis factor alpha (TNF-¦Á) treatment	upregulated	28756222
1849	Human	TUG1	lncRNA	TGF-¦Â1	intrauterine adhesion (IUA)	human embryonic stem cells (hESCs)	TGF-¦Â1 treatment	lncRNA TUG1 promotes endometrial fibrosis and inflammation by sponging miR-590-5p to regulate Fasl in intrauterine adhesions	32599321
1850	Human	TUG1	lncRNA	TGF-¦Â	liver fibrosis	LX-2 cells	TGF-¦Â treatment	upregulated	29904430
1851	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	lupus nephritis (LN)	HK2 cells	lipopolysaccharide (LPS) treatment	TUG1 was downregulated and related with LPS-induced HK-2 cell inflammatory response.	29800915
1852	Human	TUG1	lncRNA	ultraviolet (UV) irradiation	melanogenesis	PIG1 cells	UVB irradiation exposure treatment	upregulated	30924963
1853	Human	TUG1	lncRNA	hypoxia	myocardial ischaemic injury	AC16 cells	hypoxia treatment	upregulated	33165134
1854	Human	TUG1	lncRNA	IL-1¦Â	osteoarthritis (OA)	Human chondrocytes	IL-1¦Â treatment	TUG1 was elevated in OA cartilage tissues and interleukin (IL)-1¦Â-induced chondrocytes.	33093892
1855	Human	TUG1	lncRNA	IL-1¦Â and TNF-¦Á	osteoarthritis (OA)	primary chondrocytes	interleukin-1 beta (IL-1¦Â) and tumor necrosis factor-alpha (TNF-¦Á) treatment	"After chondrocytes were induced by IL-1¦Â and TNF-¦Á, the expression of lncRNA-TUG1 increased."	30575896
1856	Human	TUG1	lncRNA	ionizing radiation (IR)	osteogenesis	bone marrow mesenchymal stem cells (BM-MSCs)	"For the radiation treatment, when cultured cells reached 80 % confluence, they were irradiated with Co-60 for 13min at a rate of 0.69 Gy/min"	upregulated	31149038
1857	Human	TUG1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	"osteosarcoma cell lines (Saos-2/DDP, MG-63/DDP)"	cisplatin treatment	upregulated	31305159
1858	Human	TUG1	lncRNA	cisplatin (DDP)	osteosarcoma (OS)	Saos-2 cells; MG-63 cells	cisplatin treatment	upregulated	31305159
1859	Human	TUG1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	A2780 cells; SK-OV-3 cells	Paclitaxel (PTX) treatment	TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells	32189969
1860	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (hPDLCs)	lipopolysaccharide (LPS) treatment	?TUG1 was downregulated upon LPS stimulation in hPDLCs.	32762066
1861	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	periodontitis	human periodontal ligament cells (PDLCs)	lipopolysaccharide (LPS) treatment	"TUG1 had a decreased expression in both periodontal ligament (PDL) tissues with periodontitis and PDLCs under a LPS-induced inflammatory condition, and TUG1 expression was negatively correlated with miR-132 expression in periodontitis-affected PDL tissues."	31735958
1862	Human	TUG1	lncRNA	lipopolysaccharide (LPS)	pneumonia	MRC-5 cells	lipopolysaccharide (LPS) treatment	TUG1 lightened LPS-evoked pro-inflammatory response in MRC-5 cells.	31017717
1863	Human	TUG1	lncRNA	X-rays	prostate cancer	PC-3 cells; DU145 cells	X-ray radiation treatment	Knockdown of lncRNA TUG1 enhanced radiosensitivity in PCa via the TUG1/miR-139-5p/SMC1A axis	32256083
1864	Human	TUG1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	hypoxia induce	upregulated	31679623
1865	Human	TUG1	lncRNA	IL-6	pulmonary arterial hypertension (PAH)	human pulmonary smooth muscle cell (HPASMC)	IL-6 treatment	upregulated	31679623
1866	Human	TUG1	lncRNA	TGF-¦Â1	renal interstitial fibrosis (RIF)	HK-2 cells	transforming growth factor (TGF)-¦Â1 treatment	upregulated	33135476
1867	Human	TUG1	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	ulcerative colitis (UC)	HT-29 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	TUG1 negatively regulated inflammation in ulcerative colitis through miR-142-5p/SOCS1 axis	32173492
1868	Human	TUSC7	lncRNA	temozolomide (TMZ)	glioblastoma multiforme (GBM)	U87 cells	temozolomide (TMZ) treatment	low expression of TUSC7 in GBM cells and tissues resistant to TMZ	29397407
1869	Human	uc.173	lncRNA	lead (Pb)	lead-induced nephrotoxicity	Human proximal tubular epithelial cell line (HK-2) cells; human kidney proximal tubular epithelial cell line (HKC)	lead (Pb) exposure	Lead exposure inhibited the expression of lncRNA UC.173 in renal tubular epithelial cells.	29425744
1870	Human	uc.173	lncRNA	lead (Pb)	nerve injury	serum	lead treatment	downregulated	26683706
1871	Human	uc.187	lncRNA	lipopolysaccharide (LPS)	preeclampsia (PE)	HTR-8/SVneo cells	lipopolysaccharide (LPS) treatment	Overexpression of uc.187 could induce PE-like symptoms in a pregnant rat model by affecting the distribution of ¦Â-catenin in the cytoplasm and nucleus.	31950140
1872	Human	uc.333	lncRNA	IL-6	insulin resistance (IR)	HepG2 cells	IL-6 treatment	downregulated	32303004
1873	Human	uc.333	lncRNA	tumor necrosis factor alpha (TNF-¦Á) 	insulin resistance (IR)	HepG2 cells	tumor necrosis factor alpha (TNF-¦Á) treatment	downregulated	32303004
1874	Human	uc.477	lncRNA	herbal formula HQT	rheumatoid arthritis (RA)	fibroblast-like synoviocytes	herbal formula HQT treatment	upregulated	32696503
1875	Human	uc.477	lncRNA	Tongbi formula (HQT)	rheumatoid arthritis (RA)	RA-derived human fibroblast-like synoviocytes (HFLS-RA)	Tongbi formula (HQT) treatment	upregulated	32696503
1876	Human	uc001.dgp.1	lncRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-3B"	particulate matter 2.5 (PM2.5) exosure treatment	upregulated	31864925
1877	Human	uc001.dgp.1	lncRNA	particulate matter (PM2.5)	airway inflammation	"human bronchial epithelial cell line, BEAS-2B"	particulate matter 2.5 (PM2.5) exposure treatment	upregulated	31864925
1878	Human	uc002mbe.2	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	hepatocellular carcinoma (HCC)	Huh7;Bel7402; Bel7721; HepG2	"histone deacetylase inhibitor (Trichostatin A, TSA) treatment"	TSA-induced apoptosis of HCC cells is uc002mbe.2 dependent and reduced expression of uc002mbe.2 may be associated with liver carcinogenesis	23643933
1879	Human	uc007keu.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
1880	Human	uc010vei.1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
1881	Human	UCA1	lncRNA	5-fluorouracil (5-Fu)	retinoblastoma (RB)	retinoblastoma cells	5-fluorouracil (5-Fu) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
1882	Human	UCA1	lncRNA	carboplatin (CBP)	retinoblastoma (RB)	retinoblastoma cells	carboplatin (CBP) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
1883	Human	UCA1	lncRNA	cisplatin (DDP)	retinoblastoma (RB)	retinoblastoma cells	cisplatin treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
1884	Human	UCA1	lncRNA	vincristine (VCR)	retinoblastoma (RB)	retinoblastoma cells	vincristine (VCR) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
1885	Human	UCA1	lncRNA	etoposide (VP-16)	retinoblastoma (RB)	retinoblastoma cells	Etoposide (VP-16) treatment	knockdown of UCA1 remarkably inhibited proliferation and sensitized retinoblastoma cells to multiple chemotherapy drugs	31264280
1886	Human	UCA1	lncRNA	adriamycin (ADR)	acute myeloid leukemia (AML)	HL60 cells	adriamycin (ADR) treatment	UCA1 expression was upregul.ated following adr-based chemotherapy	29663500
1887	Human	UCA1	lncRNA	arsenite	arsenic (As) toxicities	HepG2 cells	arsenic (As) exposure	lncRNA UCA1 was markedly induced by As treatment in human hepatocytes.	29248574
1888	Human	UCA1	lncRNA	arsenite	arsenic (As) toxicities	HepG2 cells	arsenic (As) exposure	UCA1 facilitates the ubiquitination of EZH2 to upregulate NFATc2 and further antagonizes As-induced cell cycle arrest.	32537408
1889	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cell line	oxidized low-density lipoprotein (ox-LDL) treatment	ox-LDL increased UCA1 expression greatly in THP-1 cells.	30633352
1890	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human vascular smooth muscle cell line (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	Dysregulation of the Urothelial Cancer Associated 1 Long Noncoding RNA Promotes Proliferation of Vascular Smooth Muscle Cells by Modulating Expression of P27KIP1/CDK2.	32213082
1891	Human	UCA1	lncRNA	arsenite	autophagy	human hepatocytes	arsenic (As) exposure	upregulated	29248574
1892	Human	UCA1	lncRNA	cisplatin (DDP)	bladder cancer	patients with bladder and cancer.cisplatin-resistant bladder cancer cells	cisplatin treatment	upregulated	24495014
1893	Human	UCA1	lncRNA	metformin (Met)	bladder cancer	bladder cancer 5637 cells	metformin	downregulated	28641488
1894	Human	UCA1	lncRNA	transcription factor CCAAT/enhancer binding protein ¦Á (C/EBP¦Á)	bladder cancer	human bladder cancer cell lines 5637 and T24	C/EBP¦Á treatment	upregulated	24648007
1895	Human	UCA1	lncRNA	aurora kinase inhibitor (CCT137690)	breast cancer	MDA-MB-231 cells	aurora kinase inhibitor (CCT137690) treatment	downregulated	31319040
1896	Human	UCA1	lncRNA	paclitaxel (PTX)	breast cancer	MCF-7 cells	paclitaxel (PTX) treatment	Long Non-Coding RNA UCA1 Modulates Paclitaxel Resistance in Breast Cancer via miR-613/CDK12 Axis	32425595
1897	Human	UCA1	lncRNA	tamoxifen (TAM)	breast cancer	breast cancer cells (LCC2 and LCC9)	tamoxifen treatment	upregulated	30628639
1898	Human	UCA1	lncRNA	TGF-¦Â	breast cancer	MCF-7 cells	TGF-¦Â treatment	"TGF-¦Â induced genome-wide changes in lncRNA levels in breast cancer cells, among which AC0269041 and UCA1 were highly expressed in metastatic breast cancer and closely associated with poor prognosis"	29774079
1899	Human	UCA1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells	trastuzumab treatment	upregulated	29408336
1900	Human	UCA1	lncRNA	ionizing radiation (IR)	cervical cancer (CC)	SiHa cells; HeLa cells	irradiation treatment	upregulated	30015920
1901	Human	UCA1	lncRNA	5-fluorouracil (5-Fu)	chemoresistance of 5-fluorouracil (5-FU)	SW480 and SW620	5-fluorouracil (5-FU) treatment	UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro.	32801774
1902	Human	UCA1	lncRNA	X-rays	colorectal cancer (CRC)	CCL244 cells	X-ray irradiation treatment	UCA1 was significantly higher in CRC tissues after chemoradiotherapy	30015983
1903	Human	UCA1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose (HG) treatment	downregulated	31608712
1904	Human	UCA1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
1905	Human	UCA1	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	human umbilical vein endothelial cells (HUVECs)	TGF-¦Â1 treatment	UCA1 exerted its role via regulating the UCA1/miR-455/ZEB1 regulatory axis in HUVECs treated with TGF-¦Â1	32584608
1906	Human	UCA1	lncRNA	hypoxia	hypoxic pulmonary hypertension (HPH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia induce	upregulated	30353369
1907	Human	UCA1	lncRNA	curcumin (Cur)	lung cancer	A549 cells	curcumin treatment	curcumin inhibited the expression of UCA1.	30001775
1908	Human	UCA1	lncRNA	cetuximab	metastatic colorectal cancer (mCRC)	Caco2 cells	cetuximab treatment	upregulated	30377411
1909	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	UCA1 inhibition protected WI-38 cells against LPS-managed inflammatory injury and apoptosis process via miR-499b-5p/TLR4 crosstalk.	33368965
1910	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	neonatal pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	?We displayed that UCA1 was elevated in LPS-injured WI-38 cells.	33368965
1911	Human	UCA1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin treatment	upregulated	30652341
1912	Human	UCA1	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	A549 cells	cisplatin (DPP) treatment	The cisplatin-R group exhibited lower levels of UCA1 and NRF2 expression but a higher level of miR-495 expression than the cisplatin-S group.	31583720
1913	Human	UCA1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	The NSCLC cell lines (HCC827 and PC9)	gefitinib treatment	UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes.	31951852
1914	Human	UCA1	lncRNA	gefitinib	non-small cell lung cancer (NSCLC)	HCC827 cells; PC9 cells	gefitinib treatment	UCA1 was increased in both gefitinib-resistant NSCLC cells and their secreted exosomes.	31951852
1915	Human	UCA1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	Human ovarian cancer cell lines (A2780 and SKOV-3) and normal ovarian epithelial cell line (IOSE-80)	cisplatin treatment	upregulated	31234009
1916	Human	UCA1	lncRNA	cisplatin (DDP)	ovarian cancer (OC)	ES2 cells	cisplatin treatment	upregulated	32901049
1917	Human	UCA1	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells; HeyA8 cells	paclitaxel (PTX) treatment	UCA1 was markedly upregulated in PTX-resistant OC cells	32016960
1918	Human	UCA1	lncRNA	hypoxia	pancreatic cancer (PC)	human umbilical vein endothelial cells (HUVECs)	hypoxia exposure	hypoxic exosomal UCA1 could promote angiogenesis and tumor growth through the miR-96-5p/AMOTL2/ERK1/2 axis	32942233
1919	Human	UCA1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4- phenylpyridinium iodide(MPP +) treatment	upregulated	30536337
1920	Human	UCA1	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SK-N-SH cells	1-methyl-4-phenylpyridinium (MPP+) treatment	Our data showed that MPP+?induced UCA1 expression in SK-N-SH cells.	33464446
1921	Human	UCA1	lncRNA	metformin (Met)	preeclampsia (PE)	HUVEC and HPASMC cells	Metformin treatment	downregulated	31582211
1922	Human	UCA1	lncRNA	oxidized low density lipoprotein (ox-LDL)	cell proliferation and migration	vascular smooth muscle cells (VSMCs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	32346422
1923	Human	UCA1	lncRNA	artesunate (ART)	prostate cancer	"DU145,LNCaP cells"	artesunate (ART) treatment	upregulated	28209917
1924	Human	UCA1	lncRNA	¦Ã-rays	prostate cancer	22RV1; DU145 cells	Gy radiation treatement	LncRNA UCA1 deletion suppressed the radioresistance to PCa by suppressing EIF4G1 expression via miR-331-3p.	32943997
1925	Human	UCA1	lncRNA	hypoxia	pulmonary arterial hypertension (PAH)	human pulmonary artery smooth muscle cells (HPASMCs)	hypoxia treatment	UCA1 was confirmed to be highly expressed under hypoxia compared with normoxia.	30353369
1926	Human	UCA1	lncRNA	carboplatin (CBP)	retinoblastoma (RB)	SO-RB50 cells	carboplatin (CBP) treatment	upregulated	31702387
1927	Human	UCA1	lncRNA	vincristine (VCR)	retinoblastoma (RB)	SO-RB50 cells	vincristine (VCR) treatment	upregulated	31702387
1928	Human	UCA1	lncRNA	lipopolysaccharide (LPS)	sepsis	human dermal microvascular endothelial cells (HMECs)	lipopolysaccharide (LPS) treatment	upregulated	31231228
1929	Human	UCA1	lncRNA	TGF-¦Â1	tongue squamous cell carcinoma (TSCC)	"Human tongue cancer cell lines, CAL©\27 and SCC©\9"	TGF¦Â1 treatment	LncRNA?UCA1/miR-124 axis modulates TGFbeta1-induced?epithelial-mesenchymal transition and invasion of tongue cancer cells through JAG1/Notch signaling	30635938
1930	Human	UIHTC	lncRNA	H2O2	myocardial infarction (MI)	AC16 cells	H2O2 treatment	upregulated	29887450
1931	Human	UIHTC	lncRNA	hypothermia	myocardial infarction (MI)	AC16 cells	hypothermia (28 ¡ãC) treatment	upregulated	29887450
1932	Human	Unigene56159	lncRNA	hepatitis B virus (HBV)	hepatocellular carcinoma (HCC)	Huh7 cells	hepatitis B virus (HBV) infection	Unigene56159 significantly promoted cell migration/invasion and epithelial-mesenchymal transition (EMT) in HCC.	27597739
1933	Human	UPK1A-AS1	lncRNA	hypoxia	lung cancer	A549 cells;NCI-H460 cells	hypoxia treatment	upregulated	33273139
1934	Human	VCAN-AS1	lncRNA	hypoxia and TGF¦Â1	idiopathic pulmonary fibrosis (IPF)	human pulmonary fibroblasts (HPFs)	hypoxia and TGF¦Â1 treatment	upregulated	31925944
1935	Human	VIM-AS1	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial cells (RPEs)	high glucose treatment	downregulated	32447557
1936	Human	VLDLR	lncRNA	adriamycin (ADR)	esophageal squamous cell carcinoma (ESCC)	Eca109 cell line	adriamycin (ADR) treatment	upregulated	30606658
1937	Human	VLDLR	lncRNA	"anticancer agents£¨sorafenib, camptothecin, and doxorubicin£©"	hepatocellular carcinoma (HCC)	malignant hepatocytes	anticancer agents treatment	upregulated	24874432
1938	Human	VNN3	lncRNA	benzene	benzene-induced hematotoxicity	serum	low-dose benzene exposure	upregulated	31541949
1939	Human	VPS9D1-AS1	lncRNA	histone deacetylase inhibitor chidamide	acute myeloid leukemia (AML)	SKM-1 cells; THP-1 cells	histone deacetylase inhibitor Chidamide treatment	Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 downregulated via MEK/ERK Signaling Pathway	33192510
1940	Human	WAKMAR2	lncRNA	TGF-¦Â	chronic wounds	cultured keratinocytes	TGF-¦Â treatment	upregulated	30594489
1941	Human	WDR86-AS1	lncRNA	hypoxia	preeclampsia (PE)	human trophoblast HTR-8/SVneo cells	hypoxia induce	upregulated	30552989
1942	Human	WISP1-AS1	lncRNA	carcinogenic nephrotoxin ochratoxin A	carcinogenic nephrotoxin ochratoxin A. toxicity	HK-2 cells	carcinogenic nephrotoxin ochratoxin A. treatment	upregulated	29282485
1943	Human	WT1-AS	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	"Overexpression of WT1-AS can inhibit the miR-375/SIX4 axis, OSI and neuronal apoptosis in AD by inhibiting WT1 expression."	33234729
1944	Human	WWC2-AS1	lncRNA	ionizing radiation (IR)	radiation-induced intestinal fibrosis (RIF)	human intestinal CCD-18Co fibroblasts cell lines;subepithelial SEMFs	"Ionizing radiation (IR) was done with 6 MV photons, 8 Gy/min by a linear accelerator (Varian, America) at room temperature."	upregulated	31262262
1945	Human	X72487	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
1946	Human	X85157	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	downregulated	29633064
1947	Human	XIST	lncRNA	CoCl2	acute kidney injury (AKI)	HK-2 cells	CoCl2 treatment	downregulated of XIST ameliorates acute kidney injury by sponging miR-142-5p and targeting PDCD4.	32347551
1948	Human	XIST	lncRNA	ethanol (EtOH)	alcoholic liver fibrosis (ALF)	Human HSC cells (LX-2)	ethanol treatment	upregulated	31418997
1949	Human	XIST	lncRNA	hypoxia	angiogenesis	Human Brain Microvascular Endothelial Cells (HBMEC)	hypoxia induce	upregulated	31737200
1950	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA XIST (X-inactive specific transcript) was upregulated in human umbilical vein endothelial cells (HUVECs) stimulated by ox-LDL.	29902461
1951	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human THP-1 macrophages	oxidized low-density lipoprotein (ox-LDL) treatment	dysregulated	31804889
1952	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	"silence of XIST displayed a protective role in ox-LDL-induced injury in HUVECs by regulating miR-204-5p/TLR4 axis, providing a novel mechanism for understanding the pathogenesis of atherosclerosis."	32345778
1953	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33542956
1954	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	vascular smooth muscle cells (VSMCs) and human mononuclear cells (U937)	oxidized low-density lipoprotein (ox-LDL) treatment	"n this research, we uncovered that the XIST level was elevated in the serum of AS patients and ox-LDL-treated AS cell models."	33566259
1955	Human	XIST	lncRNA	platycodin D (PD)	bladder cancer	T24; RT4	Platycodin D (PD) treatment	"PD inhibited LncRNA-XIST expressions, while increased miR-335 expression levels in bladder cancer cells"	32919956
1956	Human	XIST	lncRNA	cyclosporine A (CsA)	cell proliferation and invasion	HT cells	cyclosporine A treatment	upregulated	28059474
1957	Human	XIST	lncRNA	oxygen-glucose deprivation and reoxygenation (OGD/R)	cerebral ischemia/reperfusion (I/R) injury	SH-SY5Y cells	oxygen-glucose deprivation and reoxygenation (OGD/R) treatment	"XIST and GAB2 were significantly highly expressed, while miR-486-5p was low expressed in SH-SY5Y cells under I/R"	33660813
1958	Human	XIST	lncRNA	IL-1¦Â	chondrocyte apoptosis	CHON-001 cells	IL-1¦Â treatment	downregulated	32517436
1959	Human	XIST	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	?human renal tubular epithelial HK-2 cells	?high glucose (HG) induce	silenced XIST inducing miR-93-5p-dependent CDKN1A inhibition was beneficial for preventing renal interstitial fibrosis in DN	31545928
1960	Human	XIST	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	podocytes	high glucose (HG) treatment	HG could inhibit the expression of XIST.	33332155
1961	Human	XIST	lncRNA	high glucose (HG)	diabetic retinopathy (DR)	human retinal pigment epithelial ARPE-19 cells	high-glucose (HG) treatment	"XIST, likely through competitive binding of hsa-miR-21-5p, provides protection against hyperglycemia-associated injury in human retinal pigment epithelial cells."	32106367
1962	Human	XIST	lncRNA	TGF-¦Â1	epithelial-mesenchymal transition (EMT)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	"Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT"	31013436
1963	Human	XIST	lncRNA	cisplatin (DDP)	gastric cancer (GC)	SGC 7901cells; AGC cells	cisplatin treatment	upregulated	33009035
1964	Human	XIST	lncRNA	X-rays	glioblastoma multiforme (GBM)	U251 cells	X-ray radiation treatment	"XIST accelerates cell proliferation, invasion and inhibits cell apoptosis by repressing radio-sensitivity of glioma via enhancing CREB1 expression through sponging miR-329-3p"	32271437
1965	Human	XIST	lncRNA	gonadotropin-releasing hormone agonist (GnRHa; Buserelin)	infertility	Infertility patients testicular biopsies	treat with GnRHa for 6 months	upregulated	28505621
1966	Human	XIST	lncRNA	IL-1¦Â	intervertebral disc degeneration (IDD)	nucleus pulposus (NP) cell	?IL-1¦Â treatment	"XIST expression was upregulated in the NP tissues of patients with IDD, and IL-1¦Â treatment resulted in a degradation of NPCs"	33722663
1967	Human	XIST	lncRNA	estradiol-17¦Â (E2)	leiomyoma	leiomyoma smooth muscle cells (LSMC)	estradiol-17¦Â (E2) treatment	"XIST levels was reduced in leiomyoma smooth muscle cells (LSMC) after treatment with 17¦Â-estradiol, progesterone."	33070965
1968	Human	XIST	lncRNA	IL-4	macrophage polarization	THP-1-differentiated macrophages	IL-4 treatment	upregulated	31632059
1969	Human	XIST	lncRNA	angiotensin II (Ang II)	membranous nephropathy (MN)	Conditionally immortalized human podocyte cell line AB8/13	angiotensin II (Ang II) treatment	upregulated	30414341
1970	Human	XIST	lncRNA	ionizing radiation (IR)	nasopharyngeal carcinoma (NPC)	human NPC cell lines CNE-1 and CNE-2	ionizing radiation	downregulated	28985197
1971	Human	XIST	lncRNA	Hypoxia	nasopharyngeal carcinoma (NPC)	HK-1 and C666-1	hypoxia treatment	"XIST knockdown inhibited glycolysis and metastasis in hypoxia-induced NPC cells through regulating miR-381-3p/NEK5 axis, providing new insights into the pathogenesis of NPC."	32196601
1972	Human	XIST	lncRNA	cisplatin (DDP)	non-small cell lung cancer (NSCLC)	non-small cell lung cancer (NSCLC) tumors; A549 cells; SPC A1 cells; H2279 cells; H1875 cells; HC827 cells	cisplatin treatment	"XIST is upregulated in human NSCLC specimens, and is especially overexpressed in tumors previously treated with cisplatin (cis-diamminedichloroplatinum(II); DDP)."	32209729
1973	Human	XIST	lncRNA	cisplatin (DDP)	oral squamous cell carcinoma (OSCC)	oral squamous cell carcinoma (OSCC) cells	cisplatin treatment	upregulated	33191714
1974	Human	XIST	lncRNA	IL-1¦Â	osteoarthritis (OA)	chondrocyte	IL-1¦Â treatment	upregulated	30005876
1975	Human	XIST	lncRNA	IL-1¦Â	osteoarthritis (OA)	articular chondrocytes (ACs)	IL-1¦Â treatment	upregulated	31198977
1976	Human	XIST	lncRNA	paclitaxel (PTX)	ovarian cancer (OC)	SKOV3 cells	paclitaxel treatment	XIST promoted the sensitivity of ovarian cancer stem cells to paclitaxel in a KMT2C-dependent manner	32943985
1977	Human	XIST	lncRNA	TGF-¦Â1	pancreatic cancer (PC)	"Five PC cell lines (AsPC-1, MIAPaCa-2, PATU8988T, PANC-1 and SW1990)"	transforming growth factor (TGF)-¦Â1 treatment	"Silencing XIST reduced the expression of YAP and suppressed transforming growth factor (TGF)-¦Â1-induced EMT, while over-expression of XIST increased the expression of YAP and promoted EMT"	31013436
1978	Human	XIST	lncRNA	1-methyl-4-phenylpyridinium (MPP+)	parkinson's disease (PD)	SH-SY5Y cells	1-methyl-4-phenylpyridinium (MPP+) treatment	upregulated	33494069
1979	Human	XIST	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 human lung fibroblasts cells	lipopolysaccharide (LPS) treatment	upregulated	31066476
1980	Human	XIST	lncRNA	lipopolysaccharide (LPS)	pneumonia	WI-38 cells	lipopolysaccharide (LPS) treatment	"Expression of XIST and CCL16 was upregulated in the serum of patients with pneumonia and LPS-induced WI-38 cells, respectively"	33817304
1981	Human	XIST	lncRNA	oxidized low density lipoprotein (ox-LDL)	inflammation	HUVEC	oxidized low-density lipoprotein (ox-LDL) treatment	"PTEN was a target of miR-30c-5p, and its interference led to great inhibition of cell apoptosis and inflammatory response induced by ox-LDL in HUVEC, while this effect was attenuated by miR-30c-5p deficiency or XIST overexpression."	31539155
1982	Human	XLOC_000620	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
1983	Human	XLOC_004122	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
1984	Human	XLOC_004562	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
1985	Human	XLOC_005912	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
1986	Human	XLOC_014388	lncRNA	helicobacter pylori (H. pylori)	H. pylori infection	gastric epithelial cells	H. pylori-infected treatment	dysregulated	25420666
1987	Human	XLOC_032768	lncRNA	cisplatin (DDP)	cisplatin (DDP)-induced nephrotoxicity	human renal proximal tubular epithelial cells (HK-2)	cisplatin treatment	lncRNA XLOC_032768 expression was significantly repressed by cisplatin treatment.	32278129
1988	Human	XLOC-006390	lncRNA	silver nanoparticles (AgNPs)	breast cancer	"MCF7, T47D and MDA-MB-231 cells"	silver nanoparticles (AgNPs)?treatment treatment	"we found that a long noncoding RNA, XLOC_006390, was decreased in AgNPs-treated breast cancer cells"	33613979
1989	Human	Z74666	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	cell differentiation	human umbilical cord derived mesenchymal stem cells (hUCMSCs)	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	29633064
1990	Human	ZBTB20-AS1	lncRNA	amyloid-¦Â (A¦Â) 25-35	Alzheimer's disease (AD)	SH-SY5Y cells	amyloid-¦Â (A¦Â) 25-35 treatment	upregulated	29956723
1991	Human	ZEB1-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	carotid artery atherosclerosis	HCtAEC | Human Carotid Artery Endothelial Cells; THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	LncRNA ZEB1-AS1 contributed to ox-LDL-mediated injury and apoptosis of HCtAEC cells and the oxidative stress and inflammation of THP-1 cells through up-regulating HMGB1 via sponging miR-942.	31962131
1992	Human	ZEB1-AS1	lncRNA	cisplatin (DDP)	cisplatin (DDP) resistance	MCF-7 and MDA-MB-231 cells	cisplatin treatment	lncRNA ZEB1-AS1 silencing protects against drug resistance in breast cancer by promoting miR-129-5p-dependent ZEB1 downregulated.	33430826
1993	Human	ZEB1-AS1	lncRNA	high glucose (HG)	diabetic lung disease	BEAS©\2B cells	high glucose (HG) treatment	ZEB1-AS1 in lung cells was downregulated by high glucose treatment.	33193839
1994	Human	ZEB1-AS1	lncRNA	high glucose (HG)	diabetic nephropathy (DN)	HK2 cells	high glucose treatment	ZEB1-AS1 suppressed HG-induced EMT and fibrogenesis by regulating miR-216a-5p and BMP-7.	32294702
1995	Human	ZEB1-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	endothelial dysfunction	Human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	31040785
1996	Human	ZEB1-AS1	lncRNA	high glucose (HG)	renal fibrosis	HK-2 cells	high glucose (HG) treatment	The expression of lnc ZEB1-AS1 was significantly suppressed by high glucose.	30121551
1997	Human	ZEB2-AS1	lncRNA	hepatitis B virus X protein (HBx)	hepatocellular carcinoma (HCC)	HepG2	?hepatitis B virus-encoded X (HBx) protein treatment	upregulated	29258558
1998	Human	ZEB2-AS1	lncRNA	IL-6	non-small cell lung cancer (NSCLC)	A549 cells	IL-6 treatment	upregulated	32329850
1999	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	THP-1 cells	oxidized low-density lipoprotein (ox-LDL) treatment	The expression of ZFAS1 was significantly upregulated in in-vitro cell model of atherosclerosis at a dose- and time-dependent manner.	32349937
2000	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	upregulated	33278458
2001	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	lncRNA ZFAS1 promotes ox-LDL induced EndMT through miR-150-5p/Notch3 signaling axis	33278458
2002	Human	ZFAS1	lncRNA	cisplatin (DDP)	cervical cancer (CC)	cervical cancer CaSki;the HeLa cell lines	cisplatin treatment	"Silencing ZFAS1 may inhibit cell proliferation, migration and invasion and enhance cisplatin chemosensitivity."	30738960
2003	Human	ZFAS1	lncRNA	cisplatin (DDP)	high-grade serous ovarian carcinomas (HGSOC)	"A2008, HeyA8, and HeyC2 cell lines"	cisplatin treatment	upregulated	28154416
2004	Human	ZFAS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	We found that ZFAS1 and Notch3 were upregulated while miR-150-5p was downregulated in atherosclerosis mice and ox-LDL-treated HUVECs.	33278458
2005	Human	Zfhx2as	lncRNA	radiation	head and neck squamous cell carcinoma (HNSCC)	HNSCC cell lines	radiation treatment	downregulated	30441874
2006	Human	ZNF295-AS1	lncRNA	oxidized low density lipoprotein (ox-LDL)	atherosclerosis (AS)	human umbilical vein endothelial cells (HUVECs)	oxidized low-density lipoprotein (ox-LDL) treatment	ZNF295-AS1 inhibits autophagy via the ZNF295-AS1/miR-508-5p/ATG7 axis in AS	32633396
2007	Human	ZNF593-AS	lncRNA	phenylephrine (PE)	dilated cardiomyopathy (DCM)	cardiomyocytes	phenylephrine treatment	"ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes"	33550812
2008	Human	ZNF649-AS1	lncRNA	trastuzumab	breast cancer	SKBR-3 cells; BT474 cells	trastuzumab treatment	ZNF649-AS1 was more highly expressed in trastuzumab-resistant cells compared to sensitive cells	32735773
2009	Human	ZNF667-AS1	lncRNA	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine)"	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)"	"5-Aza-2'-deoxycytidine (5-Aza-dC, decitabine) treatment"	upregulated	31804468
2010	Human	ZNF667-AS1	lncRNA	histone deacetylase inhibitor trichostatin A (TSA)	esophageal squamous cell carcinoma (ESCC)	"Human esophageal cancer cell lines (Kyse170, Eca109, TE1, and TE13)"	histone deacetylase inhibitor TSA treatment	upregulated	31804468
2011	Human	ZNRD1-AS1	lncRNA	cold atmospheric plasma (CAP)	cancer treatment	MCF-7 breast cancer cells	Cold atmospheric plasma (CAP) treatment	ZNRD1 and Its Antisense Long Noncoding RNA ZNRD1-AS1 Are Oppositely Regulated by Cold Atmospheric Plasma in Breast Cancer Cells.	32454947
2012	Human	ZXF1	lncRNA	cisplatin (DDP)	lung cancer	A549 cells	cisplatin treatment	Enhanced expression of lncRNA ZXF1 promotes cisplatin resistance in lung cancer cell via MAPK axis.	32533982
